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Abstract 
Persistent pain post-total knee replacement (TKR) surgery may be due to 
either a pre-existing pain condition or ‘new’ pain after TKR. This may be the 
reason why the prevalence of persistent pain post-TKR surgery has been 
shown to range from 13% to 44%. Even though multiple risk factors for 
developing persistent pain post-TKR surgery have been considered, there is 
currently no standardised method of accurately predicting who will develop 
this condition. A series of three studies were conducted to investigate the 
issue of persistent pain post-total knee replacement.  
The first study evaluated the differences in health status, clinical presentation 
(pain quality, neuropathic pain symptoms) and quantitative sensory testing 
responses (heat, cold, pressure) between 2 groups of patients at least one 
year after their TKR surgery. The patients were divided into “no pain” and 
“moderate to severe pain” groups based on the Knee Society Score recorded 
independently by Joint Replacement Assessment Clinic staff one year post 
surgery. The results of the first study demonstrated that the “moderate to 
severe pain” group reported significantly higher levels of neuropathic-type 
pain and exhibited widespread mechanical and cold hyperalgesia as 
compared to the “no pain” group. 
The second study evaluated whether the response of healthy participants to 
two different sustained cold stimuli remained stable between 2 separate test 
occasions. The results of the second study demonstrated the excellent 
reliability of the two alternative ways of testing cold response, and the 
positive correlations between the standard way of testing for cold pain 
response and the two alternative cold tests. Due to its relative ease of use, 
the sustained cold response test was utilised as a quantitative sensory test in 
the final study. 
The third study evaluated the predictive value of pre- and post-operative 
psychological (depression, pain catastrophising), clinical (pain quality, 
neuropathic pain symptoms, sleep disturbances), quantitative sensory testing 
(heat, cold, pressure) and intra-operative data (surgical approach, 
anaesthesia) in identifying the likelihood of developing persistent pain post-
TKR.    
 v 
Multiple linear regression was used to determine the predictive value of a 
range of key measures (quantitative sensory testing, PainDETECT score, 
functional level, quality of life and psychological distress) in determining 
persistent pain post-TKR. In addition, receiver operating characteristic curve 
analysis was used to determine the sensitivity and specificity of any 
measures identified in the multiple linear regression model in terms of their 
capacity to identify those who do or do not have persistent pain post-surgery.  
The results of the third study demonstrated that there were significant pre-
operative differences in TKR patients who reported higher pain levels at 3 
and 6 months after surgery. Further analysis revealed that there were several 
pre-operative measures which were found to be predictive of higher pain 
levels and poor outcome at 3 and 6 months respectively. Several of these 
measures are of interest since they are potentially modifiable and can be 
grouped into 4 risk factor categories: psychological distress, neuropathic-type 
pain, impaired physical function and reduced sleep quality. 
The findings of this clinical doctorate research provide the basis for the 
development of a standardised protocol for predicting the type of patients 
who are likely to develop persistent post-operative pain prior to undertaking 
total knee replacement. This creates the opportunity to develop pre-surgical 
preparation programmes aimed at reducing the individual risk of developing 
significant post-surgical pain. 
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Chapter 1 
Literature Review 
1.1. Introduction 
The purpose of this study was to establish the basis for a standardised 
protocol for pre-operative identification of patients who will develop persistent 
post-operative pain following total knee replacement surgery. This literature 
review chapter will explore: 
• The current understanding of osteoarthritis (OA) 
• The complexity of OA pain  
• The different factors that influence OA pain 
• Current management of OA pain 
• Persistent pain post-total knee replacement    
 
1.2. Background 
1.2.1. Osteoarthritis 
1.2.1.1. Definition of Osteoarthritis 
The Osteoarthritis Research Society International (OARSI) defines OA as “a 
disorder involving movable joints characterized by cell stress and 
extracellular matrix degradation initiated by micro- and macro-injury that 
activates maladaptive repair responses including pro-inflammatory pathways 
of innate immunity. The disease manifests first as a molecular derangement 
(abnormal joint tissue metabolism) followed by anatomic, and/or physiologic 
derangements (characterized by cartilage degradation, bone remodeling, 
osteophyte formation, joint inflammation and loss of normal joint function), 
that can culminate in illness.” (Kraus et al., 2015). 
 
1.2.1.2. Prevalence 
The 2011-2012 Australian Health Survey showed that 14.8% (around 3.3 
million) of Australians suffer from arthritis, with a higher prevalence in 
females (17.7%) compared to males (11.8%) (Australian Bureau of Statistics 
[ABS], 2012). 55.9% of Australians who had arthritis reported that they 
suffered from OA (Australian Institute of Health and Welfare [AIHW], 2011). 
  2 
For the financial year 2008-2009 in Australia, $1637 million was spent on the 
care of osteoarthritis sufferers (AIHW, 2014). 
 
1.2.1.3. OA pain 
Nociception 
OA is characterized by articular cartilage degeneration, the subsequent 
breakdown of the joint surface and hypertrophic bone changes (Martel-
Pelletier, 2004). 
Articular cartilage does not have any innervation, blood and lymphatic 
vessels, therefore articular cartilage degeneration is not considered to be the 
cause of nociceptive pain in OA (Fox et al., 2009). However, the joint 
surfaces (periosteum and subchondral bone) are richly innervated and 
together with the surrounding structures (i.e. synovial membrane, joint 
capsule, periarticular ligaments, bone) form the sources of nociceptive pain in 
OA (Hunter et al., 2008).  
 
Pain presentation 
The presentation of pain in knee OA varies greatly, from localised activity-
related pain to referred pain and even widespread pain at sites distant from 
the knee (Arendt-Nielsen et al., 2010; Bajaj et al., 2001; Graven-Nielsen et 
al., 2012; Kidd, 2006). Pain intensity levels also vary widely, without 
necessarily being linked to extent of OA changes. Several studies into knee 
OA have found that there is a poor correlation between degree of OA 
damage on imaging and self-reported pain intensity (Bedson & Croft, 2008; 
Creamer et al., 1999; Davis et al., 1992), although a relationship between the 
development of bone marrow lesions in the underlying bone and the 
magnitude of knee pain has been demonstrated (Felson et al., 2001). 
 
Due to this variability in pain presentation, independent of physical signs of 
OA, it has been hypothesized that both peripheral and central pain processes 
may be active to varying degrees in patients with knee OA (Arendt-Nielsen et 
al., 2010).  
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Pain processes 
Peripheral sensitisation is likely to be driven by inflammation of the damaged 
structures in the OA joint, whereas central sensitisation may be driven by the 
continuous intense nociceptive input from the OA joint (Arendt-Nielsen et al., 
2010). In central sensitisation there is a change in the properties of the 
central nervous system neurons, such that pain may no longer be coupled to 
the presence or intensity of noxious peripheral stimuli (Latremoliere & Woolf, 
2009). Gwilym et al. (2009) used quantitative sensory testing and functional 
brain imaging to investigate the presence of central sensitization in hip OA 
patients with referred pain. The investigators reported that functional brain 
imaging demonstrated significant activation of the periaqueductal grey (PAG) 
area in the hip OA patients as compared to healthy controls (Gwilym et al., 
2009). Based on the scores for the PainDETECT questionnaire (a validated 
self-report screening tool that identifies features of neuropathic pain), the hip 
OA group was split into a high and low PainDETECT score group. During 
punctate stimulation of the referred pain area in the hip OA patients, the high 
PainDETECT group showed significantly greater PAG activation as 
compared to the low PainDETECT group (Gwilym et al., 2009).  The results 
of this study demonstrate the involvement of the PAG in neuroplastic 
changes associated with central sensitization in a sample of hip OA patients 
(Gwilym et al., 2009). 
 
Neuroplastic changes 
A study investigating brain gray matter volume changes in OA pain found that 
patients with painful hip OA exhibited significantly decreased thalamic gray 
matter volume as compared to healthy controls (Gwilym et al., 2010). 
Following total hip replacement (THR) surgery, the investigators found that 
there was a significant increase in the thalamic gray matter volume in the 
patients compared to pre-surgery. This increase in the patients’ post-surgery 
thalamic gray matter volume showed no significant difference when 
compared against the healthy controls (Gwilym et al., 2010). Rodriguez-
Raecke et al. (2009) also investigated brain gray matter volume changes in 
patients with chronic hip OA pain. The investigators reported that pre-
operative brain imaging revealed that the hip OA patients had significantly 
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decreased brain gray matter in the anterior cingulate cortex (ACC), right 
insular cortex and operculum, dorsolateral prefrontal cortex (DLPFC), 
amygdala and brainstem as compared to the control group (Rodriguez-
Raecke et al., 2009). A subgroup of the hip OA patients was followed through 
to 4 months post-THR surgery, where brain imaging revealed a significant 
increase in brain gray matter in the ACC, right insular cortex, DLPFC, 
amygdala and the brainstem (Rodriguez-Raecke et al., 2009). The results of 
the 2 above studies suggest that chronic OA pain leads to changes in brain 
morphology which is reversible following removal of the source of 
nociception. 
A recent brain imaging study on pain sensitization in patients with knee OA 
reported that pain sensitization secondary to knee OA was common, and that 
it was associated with neuroplastic changes extending beyond the normal 
pain-processing brain regions, with increased activity in the posterior 
sensory, non-nociceptive brain areas (Pujol et al., 2017).  
Functional brain imaging studies in patients with OA have demonstrated an 
important role of the affective and motivational aspects of pain (Neogi, 2013). 
Parks et al. (2011) investigated brain activity in chronic knee OA and 
reported that in spontaneous OA pain the brain regions activated were the 
medial prefrontal cortex and limbic areas. The prefrontal and limbic areas are 
brain structures that are implicated in emotional processing and conditioning 
of fear, hence this suggests that spontaneous OA pain has a strong 
emotional component (Parks et al., 2011).The spontaneous knee OA pain-
related brain activation pattern shows close resemblance to the spontaneous 
pain-related brain activation patterns for chronic back pain and post-herpetic 
neuralgia (Parks et al., 2011).In another study, positron emission tomography 
(PET) of the brain was performed on knee OA patients during 3 different pain 
states: arthritic knee pain, experimental knee pain and pain-free (Kulkarni et 
al., 2007). The results of the study revealed that during PET scans of the 
brain in the arthritic pain state there was significantly greater activation of the 
cingulate cortex, thalamus and amygdala (Kulkarni et al., 2007). These brain 
structures are implicated in fear and emotional processing as well as 
aversive conditioning, also indicating that there is a strong emotional aspect 
in arthritic pain (Kulkarni et al., 2007).    
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Neuropathic pain 
The presence of neuropathic pain symptoms in OA has been shown in 
several types of studies. Basic science studies of OA pain have identified a 
neuropathic pain component in animal models of OA pain (Harvey & 
Dickenson, 2009; Im et al., 2010; Ivanavicius et al., 2007).  
Pharmacological studies on OA pain in humans revealed that some 
neuropathic pain medications (e.g. pregabalin, duloxetine, tanezumab) are 
effective in the control of OA pain.  
Pregabalin is an anticonvulsant that has analgesic and anxiolytic properties, 
and has been shown to be effective in the treatment of neuropathic pain 
(Freynhagen et al., 2005; Rosenstock et al., 2004; Sabatowski et al., 2004). 
Wright et al. (2017) investigated the use of pregabalin in individuals with knee 
OA who presented with neuropathic pain, and reported that the intervention 
group demonstrated significant reductions in pain levels, neuropathic pain 
features and tenderness in the affected knee as compared to a control group 
taking paracetamol.  
Duloxetine is a serotonin-norepinephrine reuptake inhibitor and has been 
proven to be effective in the treatment of polyneuropathies (Baron et al., 
2010). The efficacy of duloxetine in the treatment of OA pain has been 
investigated in several pharmacological studies. The results of these studies 
have shown that duloxetine significantly reduces pain intensity and improves 
function in OA patients (Chappell et al., 2011; Chappell et al., 2009; Sullivan 
et al., 2009; Wise, 2010).  
Nerve growth factor (NGF) has been implicated as a major mediator of 
neuropathic pain, and suppression of NGF activity have been shown to lead 
to the reduction of the hyperalgesic state commonly associated with 
neuropathic pain (Watson et al., 2008). Tanezumab is a drug that acts by 
inhibiting the binding of NGF to its receptors, and when used in knee OA 
patients it has resulted in significant reductions in pain, stiffness and 
limitations in functional capabilities (Brown et al., 2012; Lane  et al., 2010).  
Cedraschi et al. (2013), Hawker et al. (2008) and Hochman et al. (2010) 
evaluated the pain quality of focus group participants with OA pain and found 
that a proportion of participants used characteristic neuropathic pain 
descriptors when describing their pain. Using patient report questionnaires, 
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several studies have demonstrated the presence of neuropathic pain 
symptoms in people with OA pain (Hochman et al., 2013; Hochman et al., 
2011; Moreton et al., 2015; Moss et al., 2017; Ohtori et al., 2012; Oteo-Álvaro 
et al., 2015; Shigemura et al., 2011; Wright et al., 2017). 
 
Psychosocial factors 
A systematic review on the influences of psychosocial factors in OA pain 
reported that “pain catastrophizing and self-efficacy show consistent links to 
pain and pain-related outcomes” (Somers et al., 2009).  
Pain catastrophizing is described as an excessive negative focus on pain, 
magnification of the pain sensation and a sense of helplessness in the 
individual’s capability to deal with the pain (Sullivan et al., 2001). Scott et al. 
(2016) conducted a longitudinal study which investigated the effects of 
psychological distress in a cohort of patients with chronic musculoskeletal 
pain. The investigators reported that depression and pain catastrophizing 
were identified as strong predictors of increased pain. A prospective study on 
the predictive value of psychological factors in determining poor outcomes 
post-TKR revealed that pre-operative pain catastrophizing was a unique 
predictor of pain at 6-week follow-up (Sullivan et al., 2009). Pain 
catastrophizing has also been reported as a significant predictor of increased 
sensitivity to physical activities in a cohort of individuals with knee OA 
(Wideman et al., 2014). Keefe et al. (2000) investigated the role of 
catastrophizing in the relationship of gender to pain in OA patients, and found 
that women had significantly higher levels of pain and catastrophizing as 
compared to men. Using meditational analyses, the investigators also 
reported that pain catastrophizing had a significant positive association 
(x2=5.70, P=0.46; NFI=0.97; CFI=1.00) with pain-related outcomes (pain 
levels and physical disability) regardless of gender (Keefe et al., 2000). 
Self-efficacy has been defined as an individual’s belief in his or her capability 
to engage in a course of action to achieve a desired outcome (e.g. control of 
their pain) (Bandura, 1978). A study of overweight/obese individuals with 
knee OA found that pain catastrophizing led to higher levels of pain and 
disability through lowered self-efficacy, meaning that high self-efficacy will 
lead to lesser pain and disability (Shelby et al., 2008). OA patients who had 
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higher self-efficacy in communicating pain to their partners, had significantly 
lower levels of catastrophizing, caregiver strain (in their partners), pain, 
physical and psychological disability (Porter et al., 2008). A randomized 
controlled study on the effects of spouse-assisted coping skills training and 
exercise training in patients with chronic OA knee pain demonstrated that the 
combined coping skills and exercise training group reported significant 
improvements in self-efficacy and reductions in psychological disability 
(Keefe et al., 2004).  
Cremeans-Smith et al. (2003) examined agreement between OA patients 
and two role partners (spouses and rheumatologists) on the patient’s pain 
severity and well-being. Patients who had dyadic agreement with their 
spouses had consistently better psychological well-being, whereas patients 
had better psychological well-being when their rheumatologist 
underestimated their pain severity (Cremeans-Smith et al., 2003). 
Apart from the psychosocial factors listed above, educational level has also 
been identified as a significant factor for self-reported pain and physical 
function in OA; with higher education levels reflecting lower pain levels 
(Cimmino et al., 2005; Juhakoski et al., 2008; Thumboo et al., 2002). 
 
Sleep disturbance 
Sleep disturbance is a common problem, with up to 70% of knee OA 
sufferers having poor sleep quality (Hawker et al., 2010). In normal and 
healthy subjects, sleep deprivation has been shown to cause thermal 
hyperalgesia, and increased sensitivity to mechanical pain stimuli (Schuh-
Hofer et al., 2013). Another experimental sleep model study in healthy 
participants reported that chronic exposure to insufficient sleep reduced the 
body’s ability to habituate to experimental cold pain, and the authors 
concluded that chronic insufficient sleep could potentially increase an 
individual’s vulnerability to chronic pain (Simpson et al., 2017). In knee OA 
sufferers, greater sleep disturbance has been correlated to more arthritic 
joints (r=0.15, P<0.01), increased knee pain (r=0.13, P<0.01) and poorer 
physical functioning (FAST Functional Performance Inventory: r=0.25, 
P<0.001; 6-minute walk test: r=-0.1 P<0.01) (Wilcox et al., 2000). 
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Summary 
In summary, there are multiple mechanisms (nociceptive pain, neuroplastic 
pain and neuropathic pain), pain processes (peripheral sensitisation, central 
sensitisation), sleep disturbance and psychological/social factors that 
contribute to the generation of OA pain. To further complicate the nature of 
OA pain: the mechanisms, pain processes and factors that mediate OA pain 
vary substantially among individuals (Kidd, 2006; Suokas et al., 2012). 
 
1.2.1.4. Assessment of widespread sensitisation and neuropathic pain 
In the last 10-15 years, there has been an increased emphasis on using a 
combination of quantitative sensory testing and neuropathic pain 
questionnaires as a way of assessing both widespread sensitisation and 
neuropathic pain (Arendt-Nielsen & Yarnitsky, 2009; Backonja et al., 2013; 
Bennett et al., 2007; Bennett et al., 2005; Cruz-Almeida & Fillingim, 2014; 
Felix & Widerström-Noga, 2009; Freynhagen & Baron, 2006; Gwilym et al., 
2011; Hochman et al., 2013; Hochman et al., 2011; Jespersen et al., 2010; 
Krumova, 2010; Ohtori et al., 2012; Pavlaković & Petzke, 2010; Rommel et 
al., 2001; Shigemura et al., 2011; Shy et al., 2003; Uddin & MacDermid, 
2016; Walk et al., 2009; Wylde et al., 2012). 
 
1.2.1.4.1. Quantitative sensory testing 
Quantitative sensory testing (QST) has been widely used to explore local and 
widespread pain in OA. QST been defined as “the determination of 
thresholds or stimulus response curves for sensory processing under normal 
and pathophysiological conditions” (Arendt-Nielsen & Yarnitsky, 2009). QST 
uses a psychophysical testing approach to quantify somatosensory function 
in individuals (Backonja et al., 2013). This psychophysical approach means 
that QST is semi-subjective as it assesses an individual’s subjective 
responses to a controlled stimulus (Uddin & MacDermid, 2016). QST 
assesses the functional status of the entire somatosensory system, and 
threshold detection testing can be used to quantify / monitor the presence of 
both negative (e.g. hypoalgesia) and positive (e.g. hyperalgesia) sensory 
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phenomena (Backonja et al., 2013; Uddin & MacDermid, 2016). Threshold 
determination is indicative of basal sensitivity (of the somatosensory system), 
and is easily defined and identifiable (Arendt-Nielsen & Yarnitsky, 2009; 
Uddin & MacDermid, 2016). Table 1.1 lists some QST stimuli and the 
somatosensory channels assessed. 
 
Table 1.1: QST Stimuli and somatosensory channels 
Stimulus Sensation 
Elicited 
Peripheral Sensory 
Channel 
Central Pathway 
Blunt Pressure Sharp Pain A, C Spinothalamic 
Vibration Vibration A Lemniscal 
Heat Detection Heat C Spinothalamic 
Heat Pain Painful Heat A, C Spinothalamic 
Cold Detection Cold A, C Spinothalamic 
Cold Pain Painful Cold A, C Spinothalamic 
Based on Backonja et al. (2013) and Uddin and MacDermid (2016) 
 
There are 2 general testing algorithms for QST, the method of limits and the 
method of levels (Backonja et al., 2013; Shy et al., 2003; Uddin & 
MacDermid, 2016). In the method of limits, a stimulus of increasing or 
decreasing intensity is applied to the test site and the subject is required to 
press a control switch/button when they perceive or feel a stimulus as being 
present or being painful (Shy et al., 2003; Uddin & MacDermid, 2016). In the 
method of levels, a series of stimuli of predetermined intensity are applied to 
the test site and the subject must choose whether the stimulus is felt or not, 
or whether the stimulus is painful or not (Shy et al., 2003; Uddin & 
MacDermid, 2016). Backonja et al. (2013) stated that “the method of limits is 
less time consuming and therefore more commonly used for both clinical and 
research”. 
Due to the complex pathophysiology of OA pain, QST is a useful approach 
that can be used to evaluate mechanism-based phenotyping of OA pain 
(Cruz-Almeida & Fillingim, 2014; Suokas et al., 2012; Wylde, et al., 2011).  
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1.2.1.4.2. Widespread sensitisation 
Due to inflammation and tissue damage, changes in the processing 
(increased responsiveness) of peripheral and central nociceptor pathways 
can lead to pain sensitisation in OA (Neogi, 2013).  
A number of studies have shown the presence of sensitisation in knee OA. 
Arendt-Nielsen et al. (2010) reported that knee OA patients with high levels 
of pain exhibited widespread pressure pain sensitisation as compared to 
healthy controls.  
Wright et al. (2017) investigated the extent of multi-modality (thermal and 
pressure) hyperalgesia experienced by patients with knee OA and found that 
the knee OA group exhibited widespread cold hyperalgesia as compared to 
healthy controls. 43.75% of the knee OA group were classified as cold 
hyperalgesic and this sub-group exhibited widespread multi-modality 
sensitisation as compared to the remaining cohort of OA sufferers (Wright et 
al., 2017). 
A study investigating sensitization in patients after revision TKR found that 
patients with chronic pain after revision TKR had significantly more pain sites, 
lower cuff pressure pain thresholds and tolerance at the calf, as well as lower 
pressure pain thresholds at the index knee, tibialis anterior muscle and 
forearm (Skou et al., 2013). 
Wylde et al. (2013) reported that TKR patients with lower pre-operative 
pressure pain thresholds at their forearm had higher pain levels in their 
operated knee at 1 year post-TKR surgery. It was not reported whether this 
group of TKR patients had higher levels of pain pre-operatively. 
Similarly, Graven-Nielsen et al. (2012) also found that knee OA patients 
exhibited widespread pressure pain sensitivity as compared to healthy 
controls. Normalization of the pressure pain thresholds occurred following 
TKR surgery for this group of patients (Graven-Nielsen et al., 2012). It must 
be noted that the patients in the above study also reported significant 
reductions in their pain following TKR. 
Petersen et al. (2016) investigated the relationship between pre-operative 
pain mechanisms in knee OA patients and pain levels at 1 year post-TKR 
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surgery. The investigators reported that the presence of pre-operative 
widespread pain sensitisation was associated with higher pain levels at 1 
year post-TKR. 
Based on the current evidence, there is an association between widespread 
pain sensitivity and OA pain.  
 
1.2.1.4.3. Neuropathic pain 
Neuropathic pain is defined by the International Association for the Study of 
Pain (IASP) as “pain caused by a lesion or disease of the somatosensory 
system” (http://www.iasp-pain.org/Taxonomy#Neuropathicpain)(Jensen et al., 
2011).  
 
1.2.1.4.3.1. Identification of neuropathic pain – use of PainDETECT 
questionnaire 
Patients with neuropathic pain exhibit both negative and positive sensory 
signs and symptoms (Baron et al., 2010). Persistent or paroxysmal pain are 
also hallmarks of neuropathic pain syndromes (Woolf & Mannion, 1999). 
Diagnosis of neuropathic pain is based on the patient’s self-reported pain 
characteristics, the presence of somatosensory abnormalities and laboratory 
studies (Dworkin et al., 2003; Hochman et al., 2011; Jensen et al., 2001; 
Treede et al., 2008).  
Pain characteristics can be measured by self-report pain questionnaires such 
as the PainDETECT questionnaire (Appendix 1). The PainDETECT 
questionnaire is a reliable screening tool with good internal consistency 
(Cronbach’s Alpha: 0.83), high sensitivity (85%), specificity (80%) and 
positive predictive accuracy (83%) of a neuropathic pain component being 
present in chronic low back pain sufferers (Freynhagen & Baron, 2006). It 
has also been used in a number of studies looking at the presence of 
neuropathic pain features in other musculoskeletal conditions including 
osteoarthritis (Gwilym et al., 2011; Hochman et al., 2013; Hochman et al., 
2011; Jespersen et al., 2010; Ohtori et al., 2012; Shigemura et al., 2011). 
Other neuropathic pain questionnaires (e.g. S-LANSS, DN4) have also been 
used to evaluate features of neuropathic pain in the OA population (Moreton 
et al., 2015; Oteo-Álvaro et al., 2015). 
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1.2.1.4.3.2. Prevalence of neuropathic pain in OA 
A number of studies using the PainDETECT questionnaire found that the 
prevalence of neuropathic-type pain symptoms in OA ranges from 18.5% to 
34% (Hochman et al., 2011; Moss et al., 2017; Ohtori et al., 2012; Shigemura 
et al., 2011; Valdes et al., 2014). Shigemura et al. (2011) investigated the 
relationship between neuropathic pain and hip OA pain, and found that 
18.5% of their study sample had features of neuropathic pain. In another 
study, investigators using the PainDETECT questionnaire found that 20.6% 
of knee OA patients reported components of neuropathic pain (Ohtori et al., 
2012). Using a modified version of the PainDETECT questionnaire, Hochman 
et al. (2011) found that 28% of individuals in a community cohort of 
symptomatic knee OA sufferers had symptoms of neuropathic pain. Valdes et 
al. (2014) reported that up to 34% of patients with severe painful knee OA 
had PainDETECT questionnaire scores corresponding to having possible 
neuropathic pain. They also found that a history of past knee surgery was 
strongly associated with possible neuropathic pain (Valdes et al., 2014).  
 
1.2.1.4.3.3. Prevalence of neuropathic pain post-TKR 
The prevalence of neuropathic pain post-TKR ranges from 5.2% to 41% 
(Albayrak et al., 2016; Buvanendran et al., 2010; Fuzier et al., 2015; Harden 
et al., 2003; Haroutiunian et al., 2013). Albayrak et al. (2016) investigated risk 
factors for persistent pain following TKR and found that patients with 
persistent pain post-TKR scored higher in the PainDETECT questionnaire as 
compared to TKR patients without persistent pain. The investigators reported 
the prevalence of neuropathic pain after TKR (mean time of 22.8 ± 12.3 
months) to be 15.3%. 
A randomized controlled trial of perioperative oral pregabalin before TKR 
reported that in their control group, the incidence of neuropathic pain was 
8.7% at 3 months and 5.2% at 6 months post-TKR (Buvanendran et al., 
2010). 
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Fuzier et al. (2015) investigated the incidence of persistent pain 3 months 
following orthopaedic surgery, their results showed that the prevalence of 
neuropathic pain at 3 months after orthopaedic surgery was 20%. Closer 
analysis of the results revealed that the prevalence of neuropathic pain at 3 
months after TKR was 41%. 
A prospective study on the predictive utility of emotional distress and pain 
intensity on the occurrence of complex regional pain syndrome reported that 
the prevalence of neuropathic pain was 21% at 1 month, 13% at 3 months 
and 12.7% at 6 months post-TKR (Harden et al., 2003). 
A systematic review reported that the prevalence of probable/definitive 
neuropathic pain in total knee arthroplasty/total hip arthroplasty patients with 
persistent post-surgical pain is about 5.7% (Haroutiunian et al., 2013). 
 
1.2.1.4.3.4. Cold hyperalgesia as an indicator of neuropathic pain  
Cold hyperalgesia is a clinical feature commonly exhibited in individuals with 
neuropathic pain (Baron et al., 2010), and has been documented in the 
literature to be a prognostic factor for the development of chronic pain and 
disability in some musculoskeletal conditions such as whiplash associated 
disorder (Goldsmith et al., 2012; Maxwell & Sterling, 2013) and lateral 
epicondylalgia (Coombes et al., 2012). It has been proposed that the 
presence of widespread cold hyperalgesia alongside self-reported 
neuropathic pain may particularly reflect widespread central sensitisation in 
OA (Gwilym et al., 2009; Hochman et al., 2013).  
 
1.2.1.4.3.5. Cold hyperalgesia in OA – Evidence  
Several studies have reported the presence of cold hyperalgesia in knee OA. 
Wright et al. (2017) aimed to establish the extent of multi-modality 
hyperalgesia in a cohort of knee OA patients. The investigators reported that 
the knee OA patients had widespread cold hyperalgesia as compared to 
controls, they also identified a sub-group of patients with knee OA with high 
global cold pain threshold that exhibited multi-modality hyperalgesia as 
compared to the rest of the OA group. King et al. (2013) investigated 
experimental pain sensitivity in symptomatic knee OA and reported that 
individuals with higher pain levels were significantly more sensitive to cold 
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stimuli as compared to controls and the low symptom knee OA group. 
Another study investigated the presence of widespread mechanical and 
thermal hyperalgesia in knee OA patients and reported that the knee the OA 
group demonstrated significantly increased widespread sensitivity to both 
pressure and cold stimuli as compared to controls (Moss et al., 2016). 
 
1.2.1.4.3.6. Cold hyperalgesia as a predictor of persistent pain 
In whiplash associated disorders, the presence of cold hyperalgesia has 
been demonstrated to be a significant predictor of poor outcome at short and 
long term follow-up (Goldsmith et al., 2012; Sterling et al., 2012; Sterling et 
al., 2006; Sterling et al., 2003; Sterling et al., 2005). Sterling et al. (2011) 
investigated the developmental trajectories for neck disability and post-
traumatic stress disorder (PTSD) following whiplash injury. The investigators 
reported that the same baseline factors of cold hyperalgesia, high initial pain 
levels and older age predicted both chronic/severe neck disability and 
chronic moderate/severe PTSD trajectory. 
Coombes et al. (2012) investigated sensory, motor and psychological factors 
in patients with varying severity of lateral epicondylalgia (LE), and reported 
that patients with severe LE had bilateral cold hyperalgesia as compared to 
controls. Based on the findings of the above study, the same investigators 
conducted a prognostic study of physical and psychological factors in LE and 
reported that cold hyperalgesia was the only consistent predictor of poor 
prognosis in LE (Coombes et al., 2015). 
Currently, cold hyperalgesia has not been extensively investigated as a 
predictor of persistent pain post-TKR.   
 
1.2.1.4.3.7. Clinical measurement of cold hyperalgesia 
Assessment of cold hyperalgesia is relatively complex. Metal rollers, test 
tubes filled with ice/chilled water, ice or coolants and simple ice cubes are 
some of the methods used to assess cold hyperalgesia in the clinical setting 
(Baron et al., 2010; Maxwell & Sterling, 2013; Uddin & MacDermid, 2016; 
Walk et al., 2009). These methods are imprecise and prone to errors, as 
there is no way of controlling the temperature of the cold stimulus and the 
patient response.  
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Testing of cold hyperalgesia in the research setting is usually performed with 
a computer-controlled peltier thermode (Cruz-Almeida & Fillingim, 2014; 
Geber et al., 2011; Hagander et al., 2000; Heldestad et al., 2010; Krumova, 
2010; Shy et al., 2003; Walk et al., 2009). These devices can generate 
precise repeatable stimuli but their complexity and the high cost of these 
devices are major barriers to their widespread use in the clinical setting. 
There is potential value in developing new clinical methods to assess cold 
hyperalgesia. 
 
1.2.1.5. Management of OA pain 
There are multiple guidelines available on the management of knee OA pain 
(Hochberg et al., 2012; Larmer et al., 2014; McAlindon et al., 2014; Nelson et 
al., 2014). The consensus on the management of knee OA pain is that it is 
based on symptom severity, and the treatment options available are 
classified under non-pharmacological, pharmacological, complementary and 
lastly, surgical interventions. Optimal conservative management of knee OA 
pain must be individualized and requires a combination of both non-
pharmacological and pharmacological interventions (Taruc-Uy & Lynch, 
2013; Zhang et al., 2008).  
The recent Osteoarthritis Research Society International (OARSI) guidelines 
for the non-surgical management of knee OA recommended treatments 
based on 4 clinical knee OA sub-phenotypes (McAlindon et al., 2014) (Figure 
1.1).  
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Fig. 1.1  
OARSI guidelines for the non-surgical management of knee OA 
 
Surgical interventions are used as a last resort for management of knee OA. 
Knee arthroscopy is a minimally invasive procedure used for removal of 
loose bodies and debridement of loose articular cartilage (Kirkley et al., 
Core Treatments 
Appropriate for all 
individuals
Land-based exercise
Water-based exercise
Weight management
Strength training
Self-management and 
education
Multi-joint OA
Biomechanical 
interventions
Duloxetine
Intra-articular 
corticosteroids
Oral NSAIDs
Paracetamol
Knee-only OA 
with co-
morbidities
Biomechanical 
interventions
Intra-articular 
corticosteroids
Topical NSAIDs
Walking cane
Multi-joint OA with 
co-morbidities
Balneotherapy
Biomechanical 
interventions
Duloxetine
Intra-articular 
corticosteroid
Oral COX-2 inhibitors
Knee-only OA
Biomechanical 
interventions
Duloxetine
Intra-articular 
corticosteroids
Oral NSAIDs
Paracetamol
Topical 
NSAIDs
Walking cane
  17 
2008). A recent systematic review on the effectiveness of knee arthroscopy 
versus conservative management of patients with degenerative knee disease 
reported that patients who underwent knee arthroscopy reported very small 
reductions in pain in the short term, but had no additional benefit as 
compared to conservative management in the long term (Brignardello-
Petersen et al., 2017). 
 
TKR is the recommended treatment for end-stage knee OA in patients who 
are not getting adequate pain relief and functional improvement from 
conservative treatment (Nelson et al., 2014; Zhang et al., 2008). However, 
dissatisfaction with TKR ranges from 18.6% to 25% (Baker et al., 2007; 
Beswick et al., 2012; Bourne et al., 2010; Gandhi et al., 2008; Scott et al., 
2010). Dissatisfaction after TKR could be due to patient expectations not 
being met and, continued pain and limitation in physical function after joint 
replacement (Wylde et al., 2007). 
 
1.2.2. Persistent post-surgical pain 
Persistent post-surgical pain (PPSP) has been defined by the IASP to be 
pain that has developed after surgery, has been present for at least 2 to 3 
months, and is independent of any pre-existing pain condition (IASP, 1986; 
Macrae & Davies, 1999; Merskey & Bogduk, 1994). 
PPSP has been reported in a proportion of patients following several 
common surgical operations, such as thoracotomy, mastectomy, amputation, 
coronary artery bypass surgery, inguinal hernia repair, hysterectomy, 
caesarean section and total hip/knee replacements (Hickey et al., 2011; 
Kehlet et al., 2006; Recker & Perry, 2011; Vilardo & Shah, 2011).  
The incidence of PPSP varies across different surgeries due to the different 
patient populations and surgical techniques. For example, performing a 
thoracotomy usually involves the separation of ribs or the resection of part of 
a rib which can then lead to injury to the intercostal nerves (Kehlet et al., 
2006). Another example is breast surgery, where persistent post-mastectomy 
pain is commonly attributed to axillary node dissection, intercostobrachial 
nerve injury, or nerve injury as a result of chemotherapy and/or radiotherapy 
(Macrae, 2008; Perkins & Kehlet, 2000). A systematic review reported the 
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incidence of persistent pain after thoracotomy as 47%, persistent pain after 
breast surgery ranges from 11-57%, persistent pain after amputation ranges 
from 30-81%, persistent pain after cholecystectomy ranges from 3-56%, and 
persistent pain after inguinal hernia surgery as 11.5% (Perkins & Kehlet, 
2000). Macrae (2008) estimated the incidence of persistent post-surgical pain 
for mastectomy to range from 20-50%, caesarean section at 6%, amputation 
from 50-85%, cardiac surgery from 30-55%, hernia repair from 5-35%, 
cholecystectomy from 5-50%, hip replacement at 12% and thoracotomy from 
5-65%. 
Several studies have investigated factors that predict development of PPSP. 
In a prospective study of risk factors for PPSP following hysterectomy, Pinto 
et al. (2012) reported that preoperative anxiety, pain catastrophizing and 
emotional illness representations (emotions in response to the illness 
underlying the need for surgery) as being the most significant predictive 
factors for the development of PPSP 4 months after hysterectomy. Poleshuck 
et al. (2006) investigated predictive risk factors for development of PPSP 
following breast cancer surgery. They reported that younger age was a 
significant predictor of developing PPSP 3 months after surgery. Predictive 
factors for higher pain levels for PPSP following breast cancer surgery were 
more invasive surgery, higher acute postoperative pain and radiation therapy 
after surgery (Poleshuck et al., 2006). In persistent post-thoracotomy pain, 
female gender and higher pain levels at first postoperative day were the most 
significant predictors of persistent pain (Gotoda et al., 2001).  
Table 1.2 lists the risk factors for development of persistent post-surgical 
pain. 
 
Table 1.2: Risk factors for persistent post-surgical pain. 
Risk factors for persistent post-surgical pain  
Pre-Operative Intra-Operative Post-Operative 
• Age  
• Chemoradiotherapy 
• Genetic 
predisposition 
• Anaesthetic 
technique 
• Surgical technique 
• High levels of acute 
post-operative pain 
• Anxiety 
• Depression 
  19 
• Female gender 
• Depression 
• Anxiety 
• Pain catastrophising 
• High levels of pain 
• Chronic pain 
• Fear related to 
surgery 
• Neuropathic pain 
• Workers’ 
compensation 
• Repeat surgery 
• Excessive tissue 
damage (e.g. Nerves, 
muscles, soft tissues)  
 
• Pain catastrophising 
• Chemoradiotherapy 
• Ongoing inflammatory 
response 
Based on Bruce and Quinlan (2011); Cregg et al. (2013); Kehlet et al. (2006) 
and Macrae and Davies (1999) 
 
1.2.2.1. Total knee replacement 
Total knee replacement (TKR) is a surgical procedure commonly used to 
manage chronic knee pain and improve physical function in those with knee 
OA, with 41,810 surgeries performed in Australia in 2012 (Australian 
Orthopaedic Association National Joint Replacement Registry [AOANJRR], 
2013) at a cost ranging from $18,874 to $23,702 per surgery in a public 
hospital (Independent Hospital Pricing Authority, 2013). Although many 
patients report good outcomes, (Brander et al. (2003) reported that 86.9% did 
not report significant pain at 1 year post-TKR surgery; Puolakka et al. (2010) 
reported that 65% did not report significant pain at a minimum of 4 months 
(maximum of 22 months) after TKR surgery; Wylde et al. (2011) reported that 
56% did not have any pain at 3-4 years following TKR surgery), a proportion 
of patients continue to report significant and persistent pain following TKR 
(Baker et al., 2007; Beswick et al., 2012; Brander et al., 2003; Puolakka et 
al., 2010; Wylde et al., 2007; Wylde et al., 2011).  
 
1.2.2.2. Prevalence of persistent pain post-TKR 
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The prevalence of persistent pain post-TKR has been shown to range from 
13.1% to 44% (Baker et al., 2007; Brander et al., 2003; Puolakka et al., 2010; 
Wylde et al., 2011). The reason for this wide variance is due to the different 
levels of pain reported in the studies. For example, in the study by Brander et 
al. (2003), they reported that in a study of 116 TKR subjects 13.1% reported 
significant (Visual Analogue Scale >40) pain at 12 months post-operatively; 
Wylde et al. (2011) found that 44% of TKR patients reported having 
persistent post-surgical pain of any severity (mild to severe-extreme), with 
15% reporting severe-extreme persistent post-surgical pain at between 3 to 4 
years post-operatively. 
 
1.2.2.3. Causes of pain post-TKR 
Mandalia et al. (2008) suggested that the causes of pain post-TKR could be 
broadly divided into intrinsic and extrinsic factors, with the common causes of 
pain being infection, haemarthrosis, instability, and patellofemoral problems.  
• Infection 
Infection following TKR is very rare and the incidence rate ranges from 0.4% 
to 2% (Austin et al., 2004; Blom et al., 2004; Mahomed et al., 2005; Namba 
et al., 2013; Wilson et al., 1990; Windsor & Bono, 1994).  
• Haemarthrosis  
Haemarthrosis after TKR ranges from 0.3% to 1.6% (Kindsfater & Scott, 
1995; Ohdera et al., 2004; Oishi et al., 1995; Worland & Jessup, 1996).  
• Instability  
Knee prosthesis instability accounts for up to 22% of revision TKR surgery 
(Parratte & Pagnano, 2008; Rodriguez-Merchan, 2011). Instability may be 
due to several factors such as improper intra-operative ligamentous 
balancing, malalignment of prosthesis, loosening of the components and 
collapse (Toms et al., 2009). 
• Patellofemoral Pain Syndrome (PFPS) 
The incidence rate of PFPS has been reported to range from 2% to 7% 
(Scuderi et al., 1994).  
 
A prospective study of persistent pain post-TKR demonstrated that 13.1% of 
TKR patients reported unexplained pain at 1 year post-TKR (Brander et al., 
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2003). Hence, it appears that in a certain proportion of TKR patients there is 
no clear, structural cause for their persistent post-surgical pain. 
 
1.2.2.4. Proposed risk factors / predictors 
A number of other studies have identified pre-operative, intra-operative and 
post-operative risk factors that can lead to the development of persistent pain 
post TKR (Table 1.3).  
A prospective study investigating predictors of poor outcome after TKR 
reported that at 5 years following surgery, the incidence of unexplained 
moderate to severe pain was 6% (Elson & Brenkel, 2006). The investigators 
reported that younger age (below 60 years), performing a lateral release and 
posterior cruciate ligament sacrifice were significant predictors of poor 
outcomes at 5 years following TKR. 
Lingard et al. (2004) examined the preoperative predictors of persistent pain 
and functional outcome following TKR, and reported that higher levels of pre-
operative pain and functional limitation were the strongest predictors of poor 
outcomes at 1 and 2 years following TKR. The investigators also reported 
that a higher number of comorbid medical conditions and a low mental health 
score pre-operatively were significantly associated with poor outcomes. 
Abeloff et al. (2000) defines psychological distress as, “the general concept 
of maladaptive psychological functioning in the face of stressful life events”. 
In the scientific literature, psychological distress can include post-traumatic 
stress disorder, depression, anxiety, pain catastrophisation and stress (Belfer 
et al., 2013; Masselin-Dubois et al., 2013; Ross et al., 2015; Skogstad et al., 
2014; Vilardo & Shah, 2011; Vincent et al., 2015). Psychological distress is a 
frequent feature of patients afflicted with persistent post-surgical pain (Belfer 
et al., 2013; Jeffery et al., 2011; Masselin-Dubois et al., 2013; Vilardo & 
Shah, 2011; Wylde et al., 2011).  
Pre-operative depression has been found to be a significant predictor of 
higher post-operative resting and movement pain in TKR (Rakel et al., 2012). 
Depression has also been associated with higher non-steroidal anti-
inflammatory drug use after primary TKR (Singh & Lewallen, 2012). A study 
on patients with anxiety and depressive symptoms prior to having a total hip 
or knee replacement found that they had worse patient reported outcomes 
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and were less satisfied than controls at 3 and 6 months post-operatively 
(Duivenvoorden et al., 2013). 
Brander et al. (2003) conducted a prospective study to assess the predictive 
value of clinical and radiographic variables in the development of persistent 
pain post-TKR. They reported that pre-operative depression and anxiety 
were significant predictors of poor pain outcomes at 1 year post-TKR. The 
results of the study also demonstrated that high levels of pre-operative pain 
predicted poorer function at 1 year post-TKR. 
Another prospective cohort study on the predictors of outcome following TKR 
reported that high levels of pre-operative pain and functional limitations 
predicted poor outcomes, with pre-operative depression and anxiety also 
being significant predictors of persistent pain at 6 months post-TKR (Judge et 
al., 2012). Of interest is the report that increased age, female gender and a 
higher body mass index predicted poor functional outcomes but not pain. 
Riddle et al. (2010) investigated the influence of psychological factors in 
predicting persistent pain post-TKR. The investigators reported that pain 
catastrophizing was the only consistent predictor of pain at 6 months after 
TKR. 
Masselin-Dubois et al. (2013) investigated the psychological predictors of 
persistent postsurgical pain in 2 surgical models (TKR and breast surgery for 
cancer), the results demonstrated that regardless of surgical model; older 
age, high levels of post-operative pain, state anxiety and pain magnification 
predicted presence of persistent pain at 3 months following surgery. 
A study which investigated acute post-operative pain at rest after hip and 
knee arthroplasty found that 44-57% of TKR patients woke up because of 
pain over the study period (post-operative days 1 – 3) (Wylde et al., 2011). 
The same study found that TKR patients who were woken by pain had 
significantly higher overnight pain scores as compared to those not woken by 
their pain each night (Wylde et al., 2011). 
Cremeans-Smith et al. (2006) investigated sleep disruptions in patients 
undergoing TKR and found that patients who reported more post-operative 
sleep disruptions had more pain at 1 month post-TKR and more functional 
limitations at 3 months post-TKR.  
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Based on the current research, psychological distress, functional limitation 
and pre-operative pain levels appear to be the most important predictors of 
persistent pain post-TKR. There is also ample evidence to indicate that sleep 
and pain are related. However, the mechanisms are still not fully understood. 
Hence more research is needed on the influence of sleep disturbance in the 
development of persistent post-surgical pain. 
 
Table 1.3: Risk factors for persistent post-surgical pain after TKR. 
Risk factors for persistent post-surgical pain after TKR 
Pre-Operative Intra-Operative Post-Operative 
• Age 
• Female gender 
• Depression 
• Anxiety 
• Pain catastrophising 
• High levels of pain 
• Lower functional 
capacity 
• Pain sensitivity 
• Presence of comorbid 
medical conditions 
• Excessive tissue 
damage (e.g. Nerves, 
muscles, soft tissues)  
• Surgical approach 
(eg PCL sacrifice, 
lateral release) 
 
• High levels of acute 
post-operative pain 
• Anxiety 
• Depression 
• Pain catastrophising 
• Sleep quality 
Based on Brander et al. (2003); Cremeans-Smith et al. (2006); Elson and 
Brenkel (2006); Fortin et al. (1999); Hawker et al. (2010); Judge et al. (2012); 
Lingard et al. (2004); Riddle et al. (2010); Vilardo and Shah (2011); Wilcox et 
al. (2000) and Wylde et al. (2011) 
 
Pre-existing pain conditions 
A systematic review identified pre-operative pain in the operating field and 
chronic pre-operative pain elsewhere as being predictors of persistent pain 
post-surgery (Althaus et al., 2012). The presence of previous pain has also 
been shown to be strongly associated with the development of chronic 
neuropathic pain (Kehlet et al., 2006). Widespread pain sensitisation in OA 
patients has been found to be associated with the development of persistent 
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pain post-TKR (Lundblad et al., 2008; Wylde et al., 2013). Presence of 
widespread pain sensitisation has also been documented in individuals 
suffering from persistent pain post-TKR (Skou et al., 2013). 
 
‘New’ pain after TKR 
Several groups have attempted to categorize persistent post-TKR pain in 
order to better manage poor outcomes. The UK-based Support and 
Treatment After Replacement (STAR) Expert Group 
(http://www.bristol.ac.uk/clinical-
sciences/research/musculoskeletal/orthopaedic/research/star), based at the 
University of Bristol involves pain researchers from across Europe, Canada 
and Australia and has proposed 5 relatively distinct post-operative 
presentations (personal communication from Prof Anthony Wright, advisory 
group member). These are neuropathic pain, painful instability, proximal tibial 
tenderness, patellofemoral pain and chronic pain syndromes (i.e. widespread 
pain sensitisation and complex regional pain syndrome).  
• Neuropathic pain 
A number of studies support the presence of neuropathic-type symptoms. 
The prevalence of probable/definitive neuropathic pain in total knee 
arthroplasty/total hip arthroplasty patients with persistent post-surgical pain is 
about 5.7% (Haroutiunian et al., 2013). Two recent studies have found that 
close to 20% of knee OA sufferers reported components of neuropathic pain, 
using the PainDETECT questionnaire (Hochman et al., 2011; Ohtori et al., 
2012). Albayrak et al. (2016) investigated risk factors for persistent pain 
following TKR and found that patients with persistent pain post-TKR scored 
higher in the PainDETECT questionnaire as compared to TKR patients 
without persistent pain. Cold hyperalgesia is a clinical feature commonly 
exhibited in neuropathic pain (Baron et al., 2010), and has been documented 
in the literature to be a prognostic factor for the development of chronic pain 
and disability in some musculoskeletal conditions such as whiplash 
associated disorder (Goldsmith et al., 2012; Maxwell & Sterling, 2013) and 
lateral epicondylalgia (Coombes et al., 2012). It has been proposed that the 
presence of widespread cold hyperalgesia alongside self-reported 
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neuropathic pain may particularly reflect excessive central sensitisation in OA 
(Gwilym et al., 2009; Hochman et al., 2013).  
• Proximal tibial tenderness 
Proximal tibial tenderness affects patients who have had a uni-
compartmental knee replacement (Simpson et al., 2009), although this 
usually resolves within 12 months post-operatively due to bone remodeling 
(Simpson et al., 2009).  
• Patellofemoral pain 
The causes of patellofemoral pain following TKR are still largely unknown, 
however patellar mal-tracking and femoral component mal-rotation are 
believed to be the key causes (Dennis et al., 2011; Motsis et al., 2009; 
Muñoz-mahamud et al., 2011). 
• Chronic pain syndromes 
Chronic pain syndromes that have been reported post-TKR include complex 
regional pain syndrome and widespread pain sensitisation. Complex regional 
pain syndrome (CRPS) is characterized by pain in combination with sensory, 
autonomic, trophic and motor abnormalities (Marinus et al., 2011). Aberrant 
inflammatory mechanisms, vasomotor dysfunction and maladaptive 
neuroplasticity have been identified as the three major pathophysiological 
pathways of CRPS (Marinus et al., 2011). The incidence rate for CRPS after 
TKR has been stated to be 0.8% (Burns et al., 2006). Skou et al. (2013) 
found that patients with chronic pain after revision TKR surgery have 
significantly more pain sites, reduced mechanical pain thresholds and 
tolerance, as well as impaired conditioned pain modulation as compared to 
controls.  
 
1.3. Conclusion 
A recent knee OA study that compared QST measures of central 
sensitisation in 20 participants before and after TKR reported that these 
measures ‘normalised’ approximately 20 weeks post-surgery. The authors 
hypothesized that this return to normal values after removal of damaged 
tissue supports the notion that central pain processes in knee OA are 
maintained by peripheral nociceptive input (Graven-Nielsen et al., 2012). 
However, this should mean that knee OA pain should always be eliminated 
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with TKR surgery, provided that they have no other pre-existing chronic pain 
conditions. Yet, the prevalence of persistent pain post-TKR has been shown 
to range from 13.1% to 44% (Baker et al., 2007; Brander et al., 2003; 
Puolakka et al., 2010; Wylde et al., 2011).  
 
Suokas et al. (2012) stated “the complexity of OA pain means that treatments 
targeting one specific mechanism may have low efficacy if offered to people 
whose pain is largely mediated by other mechanisms”. This could possibly 
explain the seemingly high rates of persistent pain post-TKR.  
 
Persistent pain post-TKR: Pre-existing versus ‘new’ pain  
Looking at all the available literature on persistent pain post-TKR, it is 
possible that persistent pain post-TKR may reflect ‘new’ pain resulting from 
the surgical intervention or may reflect lack of success in the detection or 
resolution of pre-existing, ‘old’ pain conditions. Development of a screening 
protocol that identifies patients who will not gain maximal benefit from 
undergoing a TKR will enable clinicians to (i) use suitable interventions that 
could help resolve the pre-existing pain conditions before TKR, hence 
reducing the risk of developing persistent pain post-TKR, or (ii) try a different 
approach to conservative management. The research reported in this thesis 
has used a range of measures to comprehensively screen patients to 
determine which measures are most strongly linked to the development of 
persistent pain post-TKR. 
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Chapter 2 
Study 1 
Quantitative Sensory Testing identifies patients with 
poor outcomes one year following Total Knee 
Replacement 
 
2.1. Abstract 
Background and Aims 
Total knee replacement (TKR) is a standard intervention for individuals with 
painful osteoarthritis. Yet up to 15% of patients report severe persistent 
postsurgical pain. Poor outcomes following TKR may be attributed to various 
causes including infection or prosthetic instability, however it has been 
suggested that the presence of widespread pain/hyperalgesia and/or report 
of neuropathic-type pain may also be important predictors of ongoing pain. 
This study aimed to determine whether patients with persistent pain post 
TKR exhibit widespread hyperalgesia, sensory deficits and/or features of 
neuropathic pain. 
Method 
A cross sectional design was used. Fifty-three participants, 12-36 months 
following TKR surgery were divided into ‘good outcome’ and ‘poor outcome’ 
groups, based on Knee Society Score one year post surgery. Group 
differences in mechanical and thermal detection and pain thresholds at local 
and distant test sites and self-report of neuropathic-type pain, pain quality, 
comorbid conditions, health status and function were investigated. 
Results 
At the knee, significant group differences were found for pressure pain 
threshold (PPT) (p=0.024), heat detection threshold (HDT) (p=0.009) and 
cold pain threshold (CPT) (p=0.008). At the elbow, significant differences 
were similarly found for PPT (p=0.002), HDT (p=0.01), CPT (p=0.01), heat 
pain threshold (HPT) (p=0.034) and cold detection threshold (CDT) (p=0.034) 
There were also significant group differences for self-reported neuropathic 
pain (PainDETECT (p=0.001)), pain quality (PQAS subscores: paroxysmal 
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(p=0.008), superficial (p=0.025), deep (p<0.001)), health status (EQ-5D 
(p=0.018), EQ-5D Health Score (p=0.03)) and disease specific questionnaire 
scores (WOMAC total (p<0.001), pain (p<0.001), stiffness (p<0.001) and 
function (p<0.001)).  
Conclusion 
Individuals with poor outcomes exhibited widespread mechanical and cold 
hyperalgesia, sensory deficits and higher levels of neuropathic-type pain. 
These findings may indicate that neuropathic pain and/or persistent central 
sensitization may be an important driver of persistent pain following joint 
replacement surgery. 
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2.2. Overview, Aims and Objectives 
Knee arthroplasty is a widely-applied intervention which aims to relieve the 
pain and disability of osteoarthritis by replacing the weight-bearing surfaces 
of the knee joint. In 2009-2010, a total of 97,213 total knee replacement 
(TKR) surgeries were performed in Australia (AIHW, 2011). 719,000 in the 
United States of America (Centers for Disease Control and Prevention, 2011) 
and 76,497 in England and Wales in 2012 (National Joint Registry, 2013). 
Although most patients achieve substantial pain relief and improved function 
following TKR a proportion continue to experience significant persistent pain 
many years post-surgery. Persistent postsurgical pain is defined by the 
International Association of the Study of Pain as pain that develops after 
surgical intervention and lasts at least 2 months, with other causes of pain 
being excluded, particularly pain from a condition preceding the surgery 
(Macrae & Davies, 1999). A recent UK study (Wylde et al., 2011) reported 
that 44% of patients may be affected by persistent postsurgical pain at 3 to 4 
years, although much of the pain was mild in severity, infrequent and an 
improvement from preoperative pain. Of concern, though is the 15% of TKR 
patients in this study who reported severe to extreme persistent postsurgical 
pain (Wylde et al., 2011). Such poor outcomes could be attributed to factors 
such as post-operative infection or prosthesis instability, but may also be 
influenced by preoperative factors such as presence of neuropathic-type pain 
or presence of widespread pain sensitivity. These latter factors suggest pre-
existing altered central pain processing, which in some patients creates the 
potential for persistent post-operative pain. 
The presence of neuropathic-type pain or widespread hyperalgesia has been 
reported in patients with knee OA in several recent studies. Hochman et al 
(2011) reported that more than 19% of an unselected community based 
sample of individuals with chronic OA had features of neuropathic pain 
according to the PainDETECT questionnaire. A more recent study confirmed 
this finding; with 43% of participants with knee OA reporting significantly 
higher scores on PainDETECT (Wright et al., 2017). This group also 
exhibited widespread cold hyperalgesia and increased sensitivity to pressure 
pain, which are clinical features often associated with neuropathic pain states 
  30 
(Wright et al., 2017). King et al. (2013) presented similar findings, reporting 
that high symptom severity knee OA sufferers demonstrated reduced heat 
pain thresholds as compared to low symptom severity knee OA sufferers and 
controls. The investigators also reported that after controlling for the 
temperature for heat pain threshold and heat pain tolerance, high symptom 
severity knee OA sufferers had greater pain with experimental heat pain 
threshold and heat pain tolerance at a distant site (forearm), and greater pain 
with experimental heat pain threshold at the affected knee as compared to a 
low symptom severity knee OA group and controls. High symptom severity 
knee OA sufferers also demonstrated reduced mechanical pain thresholds at 
both distant sites (forearm, trapezius muscle and quadriceps muscle) and the 
affected knee as compared to controls (King et al., 2013). Similarly, Wylde et 
al. (2012) found that 71% of knee OA patients in their study had at least one 
sensory abnormality (hypoesthesia or hyperalgesia) as compared to normal 
controls.   
Widespread hyperalgesia has been shown to occur in patients with painful 
knee OA in a number of studies, with a significant moderate to large 
correlation found between widespread mechanical hyperalgesia and self-
reported pain (Arendt-Nielsen et al., 2010; King et al., 2013; Wright et al., 
2017).  It therefore appears that some patients with OA exhibit features 
potentially associated with a neuropathic pain phenotype and it is possible 
that they may be predisposed to ongoing post-operative pain.  
Treede et al. (2008) proposed a grading system with 4 criteria in the 
evaluation of neuropathic pain in individuals (Table 2.1). 
 
Table 2.1: Grading system for neuropathic pain 
Grading system for neuropathic pain 
1 Pain with a distinct neuroanatomically plausible distribution 
2 A history suggestive of a relevant lesion or disease affecting the 
peripheral or central somatosensory system 
3 Demonstration of the distinct neuroanatomically plausible distribution 
by at least one confirmatory test 
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4 Demonstration of the relevant lesion or disease by at least one 
confirmatory test 
 
The levels of certainty of presence of neuropathic pain is determined by the 
number of fulfilled criteria in an individual (Treede et al., 2008):  
• Possible neuropathic pain 
o Criteria 1 and 2 fulfilled 
• Probable neuropathic pain  
o Criteria 1 and 2, plus either 3 or 4 fulfilled 
• Definite presence of neuropathic pain. 
o All 4 criteria fulfilled  
Based on the current research, it can be postulated that a proportion of knee 
OA sufferers fit the criteria for probable neuropathic pain. 
The aim of this study was to determine whether patients with persistent pain 
post-TKR exhibit widespread hyperalgesia, sensory deficits and/or features 
of neuropathic pain. 
 
The objective of this study was: 
1. To investigate whether there is a difference between measures of pain, 
function, health status and quantitative sensory testing (QST) between 
the ‘no pain (good outcome)’ and ‘moderate to severe pain (poor 
outcome)’ groups. 
 
2.3. Research Hypotheses 
2.3.1. Primary Hypothesis: 
1. There will be a difference in measures of pressure pain threshold (PPT), 
thermal (heat and cold) pain and detection thresholds (heat and cold), 
and self-reported pain (neuropathic pain and pain quality) between 
participants categorized as having a good outcome following TKR surgery 
versus those classified as having a poor outcome. 
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2.3.2. Secondary Hypotheses: 
1. There will be a difference in self-reported health status, comorbid 
conditions and function between participants categorized as good 
outcome versus the poor outcome group. 
2. There will be a difference in self-reported pre-operative pain and function 
between participants categorized as good outcome versus the poor 
outcome group. 
 
2.4. Methods 
2.4.1. Participants 
All participants were recruited as volunteers within 12-36 months of their TKR 
surgery from patients listed on the Joint Replacement Assessment Clinic 
(JRAC) registry at Royal Perth Hospital in Western Australia. Suitable 
patients were identified by JRAC staff but no RPH staff were involved in 
direct recruitment of participants. 
 
Volunteers with numbness around the knee, haemophilia or previous history 
of stroke were excluded from the study because those factors can possibly 
influence the perception of thermal and pressure stimuli. Volunteers with 
limited understanding of English were also excluded. Inclusion and exclusion 
criteria were as in Table 2.2.   
 
Table 2.2: Inclusion / Exclusion criteria 
Inclusion Criteria • Above 50 years old 
• Underwent primary uni-lateral TKR because of 
OA, at least 12 months ago 
• Indicated either no pain (none) or moderate to 
severe pain (moderate-occasional, moderate-
continuous, or severe) during the previous 4 
weeks on the pain component of the Knee 
Society Score 
• Good comprehension of English language 
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Exclusion Criteria • Recent surgery (<6 months) in the contralateral 
knee and/or ipsilateral elbow 
• Indicated mild pain during the previous 4 weeks 
on the pain component of the Knee Society Score 
• Any cognitive impairment 
• Any neurological conditions (i.e. previous stroke) 
• Numbness around the knee and/or ipsilateral 
elbow 
• Haemophilia 
All participants were advised to continue with their usual medications prior to 
attending the assessment session.  
All participants provided written informed consent before participating in the 
study. Ethical approval was granted by Royal Perth Hospital Medical 
Research Ethics Committee (Approval Number 2012/117) and Curtin 
University Human Research Ethics Committee (Approval Number 
PT217/2012). 
 
2.4.2. Study Design and Procedure 
This study used a cross-sectional design. All participants were asked to 
attend a single assessment session. Once informed consent was obtained, 
each participant completed five self-report questionnaires and then 
underwent the quantitative sensory tests in standardised order. Additional 
pre-operative WOMAC data were collected for each participant from their 
JRAC documentation. 
The research assessment was conducted at a single time for each 
participant, between 12 and 36 months after their TKR surgery, although their 
categorization was based on the pain component of the Knee Society Score 
(KSS) at the 12 month JRAC follow-up. The pain component of the KSS is 
categorized as no pain (none), mild or occasional pain (stairs only, walking 
and stairs), moderate pain (occasional, continual), and severe pain (Insall et 
al., 1989). Participants who had no pain were allocated to the good outcome 
group, and those with moderate to severe pain were allocated to the poor 
outcome group. Individuals reporting mild or occasional pain were not 
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included in the study. No pre-operative assessment was performed in this 
cross-sectional study.  
 
2.4.3. Outcome Measures  
Self-Reported Measures: 
All participants completed a paper version of the questionnaires on the day of 
their research assessment. The questionnaires were as stated below. 
Disease-specific 
1. Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) is a disease-specific self-report measure designed for 
standardised reporting of pain and function in individuals with knee or 
hip osteoarthritis (Bellamy, 1989). It consists of 24 items divided over 
3 subscales: pain, joint stiffness and physical function. The WOMAC 
index has demonstrated good internal validity (Cronbach’s Alpha: 0.92 
for pain subscale; 0.90 for stiffness subscale; 0.98 for physical 
function subscale) (Jinks et al., 2002), good test-retest reliability 
(ICC2,1: 0.88; 95% CI: -0.40 to 1.81 for pain subscale, ICC2,1: 0.69; 
95% CI: -0.84 to 0.55 for stiffness subscale, ICC2,1: 0.85; 95% CI: -
1.47 to 6.3 for physical function subscale) (Jinks et al., 2002), 
responsiveness to change (RE: 0.98; 95% CI: -37.0 to -26.2 for pain 
subscale, RE: 0.66; 95% CI: -31.5 to -20.6 for stiffness subscale, RE: 
1.00; 95% CI: -34.1 to -24.2 for physical function subscale) (Ackerman 
et al., 2006), and acceptable construct validity (McConnell et al., 
2001).  
Health status 
2. European Quality of Life Questionnaire (EQ-5D) represents an 
estimation of the patient’s perceived quality of life and state of health 
(Busschbach et al., 1999). The EQ-5D demonstrated moderate test-
retest reliability (EQ-5Dvas ICC: 0.70; 95% CI: 0.60-0.80; EQ-5Dutility 
ICC: 0.73; 95% CI: 0.63-0.83) and acceptable validity (Hurst et al., 
1997). 
Comorbid Conditions 
3. Self-Administered Comorbidity Questionnaire (SCQ) assesses for 
the presence of 12 medical conditions for people with no prior medical 
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knowledge (Sangha et al., 2003). There are an additional 3 optional 
questions regarding any other medical conditions. The SCQ 
demonstrated good test-retest reliability (ICCs: 0.94; 95% CI: 0.72 to 
0.99) and acceptable validity (Sangha et al., 2003). 
Pain 
4. PainDETECT is a self-report screening tool to identify features of 
neuropathic pain (Freynhagen & Baron, 2006). It consists of 9 items 
over 3 categories: pain quality, pain pattern and pain radiation. The 
questionnaire is a reliable screening tool with good internal 
consistency (Cronbach’s Alpha: 0.83), high sensitivity (85%), 
specificity (80%) and positive predictive accuracy (83%) of a 
neuropathic pain component being present in chronic low back pain 
sufferers (Freynhagen & Baron, 2006). It has also been used in a 
number of studies looking at the presence of neuropathic pain 
components in other musculoskeletal conditions including 
osteoarthritis (Gwilym et al., 2011; Jespersen et al., 2010; Ohtori et al., 
2012; Shigemura et al., 2011). 
5. Pain Quality Assessment Scale (PQAS) is used to provide 
additional data regarding the dimensions of spontaneous pain 
experienced by participants (Victor et al., 2008). The PQAS was 
developed by adding additional items to the 10-item Neuropathic Pain 
Scale (NPS) (Jensen, 2006). The 10 NPS items have been shown to 
have adequate discriminant validity (Pearson’s r: 0.05 to 0.73) and 
predictive validity (Galer & Jensen, 1997). The PQAS is able to 
provide more comprehensive information about pain quality than 
alternative one-dimensional pain scales (Jensen et al., 2012). It has 
also been shown to have validity for assessing treatment-related 
changes in pain quality and spatial characteristics (Jensen et al., 
2006). Factor analysis of the PQAS revealed 3 clear pain quality 
domains: (1) Paroxysmal pain, (2) Superficial pain and (3) Deep pain 
(Victor et al., 2008). The 3 pain quality domains have been shown to 
have adequate to good internal consistency (Cronbach’s Alpha: 
Paroxysmal>0.80, Superficial= 0.73 and Deep=0.68) (Gould et al., 
2009).  
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Quantitative Sensory Tests:  
All quantitative sensory tests (QST) were performed at the medial joint line of 
the operated knee and over the ipsilateral extensor carpi radialis brevis 
(ECRB) muscle in the upper limb. The ECRB muscle has been used 
previously in other QST studies (Slater et al., 2003; Slater et al., 2005). The 
ECRB was located by using the standardized method as described by Riek 
et al. (2000). The quantitative sensory testing was conducted with the 
participant lying in a relaxed position on a plinth. The method of limits 
approach was used for the quantitative sensory tests stated below. 
1. Pressure Pain Threshold (PPT) was measured using an electronic, 
digital algometer (Somedic, Sweden) with a 1cm² round rubber tip at 
the end connected to a pressure transducer within the handle of the 
unit. The algometer was applied at 90° angle to the skin at a constant 
rate of 40 kPa/sec. The subject was given a control switch and 
instructed to press the switch when the sensation changes from 
pressure to pain, at which time the test was terminated. PPT has been 
shown to have good test-retest reliability for the knee (ICC: 0.83; 95% 
CI: 0.72-0.90) and forearm (ICC: 0.86; 95% CI: 0.77-0.92) in OA 
patients (Wylde et al., 2011). 1 practice trial was followed by 3 
measurements, with the mean calculated for analysis (Lacourt et al., 
2012; Persson et al., 2004).  
2. Cold/Heat Detection and Pain Thresholds were measured using a 
peltier thermode (Medoc, Israel). The minimum temperature was set at 
0°C, and the maximum temperature set at 50°C. A 30x30mm contact 
probe was attached to the test site with a strap and the participant was 
given several minutes to adapt to the baseline temperature of 32°C. 
When the device was activated, the thermode temperature rose or fell 
at a rate of 1°C/sec. This rate of temperature change has been shown 
to reduce intra-individual variation (Palmer et al., 2000). The subject 
was given a control switch and instructed to press the switch when 
they perceived the relevant sensation (i.e. if it was a heat detection 
threshold test, the participant was instructed to depress the switch 
once they detected an increase in heat). The respective thermal 
detection thresholds were always tested before the thermal pain 
  37 
thresholds to minimise sensitization of receptors by the noxious input. 
The thresholds were tested in the order of cold detection threshold 
(CDT), cold pain threshold (CPT), heat detection threshold (HDT) 
and heat pain threshold (HPT). CDT has been demonstrated to have 
moderate test-retest reliability for the knee (ICC: 0.70; 95% CI: 0.53-
0.82) and fair test-retest reliability for the forearm (ICC: 0.41; 95% CI: 
0.15-0.62) in knee OA sufferers (Wylde et al., 2011). CPT has been 
demonstrated to have excellent test-retest reliability across several 
sites with ICCs ranging from 0.93 to 0.94 in healthy participants (Moss 
et al., 2016). HDT has been demonstrated to have moderate test-
retest reliability for the knee (ICC: 0.70; 95% CI: 0.49-0.83) and fair 
test-retest reliability for the forearm (ICC: 0.52; 95% CI: 0.29-0.70) in 
knee OA sufferers (Wylde et al., 2011). HPT has been demonstrated 
to have moderate test-retest reliability for the knee (ICC: 0.77; 95% CI: 
0.62-0.92) and excellent test-retest reliability for the forearm (ICC: 
0.86; 95% CI: 0.76-0.92) in knee OA sufferers (Wylde et al., 2011). 
HPT demonstrated moderate test-retest reliability (ICC: 0.68; 95% CI: 
0.55-0.79) in normals (Felix & Widerström-Noga, 2009). Each stimulus 
was separated by a randomised 3 to 6 second interval. For each 
threshold, 1 practice trial was followed by 3 measurements, with the 
mean calculated for analysis. 
 
2.4.4. Power Analysis 
Power calculations found that to detect a clinically relevant difference of 15% 
(β set at 0.80, α < 0.05) between participants in the good outcome and poor 
outcome groups, a total sample of 56 was needed for pressure pain 
threshold and 50 for cold pain threshold. Given the considerably smaller 
standard deviations relative to means reported previously for heat pain 
threshold compared with pressure pain threshold or cold pain threshold 
(Hochman et al., 2013; Suokas et al., 2012; Wylde et al., 2013) a smaller 
sample size would suffice for HPT. A total sample size of 55 was considered 
adequate. 
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2.4.5. Data Analysis 
IBM SPSS Statistics version 22 was used for the statistical analysis, with 
alpha set at 0.05. Normality of the data was determined by using the Shapiro-
Wilk test, any variable that had p>0.05 was considered normally distributed. 
Levene´s test was used to confirm whether the data for each group 
demonstrated equal variance. Degrees of freedom were corrected when 
equal variances were not assumed (p<0.05). Independent T tests were used 
to analyse group differences in pressure pain threshold and WOMAC data. 
The rest of the data were not normally distributed and so were analysed 
using Mann Whitney U tests. All data were reported as mean ± standard 
deviation. Significant results were considered as p < 0.05. Table 2.3 shows 
the statistical tests for each hypothesis. 
 
Table 2.3: Hypotheses and Statistical Test Used 
Hypotheses and Related Data Statistical Analysis 
1. Difference in pressure pain threshold (PPT) 
between good outcome versus poor outcome 
groups. 
2. Difference in thermal (cold and heat) pain and 
detection thresholds between good outcome 
versus poor outcome groups. 
3. Difference in self-reported pain between good 
outcome versus poor outcome groups. 
PainDETECT 
PQAS 
4. Difference in self-reported health status and 
function between good outcome versus poor 
outcome groups. 
WOMAC 
EQ5D 
SCQ 
PQAS 
Independent T-Test 
 
 
Mann Whitney U-Test 
 
 
Mann Whitney U-Test 
 
 
 
 
 
 
Independent T-Test 
Mann Whitney U-Test 
Mann Whitney U-Test 
Mann Whitney U-Test 
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2.5. Results 
2.5.1. Participant demographics 
A total of fifty-three participants took part in the study. Thirty-one participants 
in the good outcome group (thirteen male and eighteen female; mean age 
69.9  7.25, range 53-85) and twenty-two participants in the poor outcome 
group (six male and sixteen female; mean age 69.8  7.07, range 51-79) 
(Table 2.4).  
 
Table 2.4: Participant demographics 
 Good outcome group 
(n = 31) 
Poor outcome group 
(n = 22) 
Gender (M : F) 
Age (years) 
Age (range) 
13 : 18 
69.9 ± 7.3 
53 to 85 
6 : 16 
69.8 ± 7.1 
51 to 79 
 
2.5.2. Primary Hypothesis: 
There will be a difference in measures of pressure pain threshold (PPT), 
thermal (cold and heat) pain and detection thresholds, and self-reported 
pain (neuropathic pain and pain quality) between the good outcome and 
the poor outcome groups. 
 
• Pressure Pain Threshold 
The poor outcome group exhibited significantly lower PPT than the good 
outcome group, both at the operated knee (p=0.024) and at the distant ECRB 
site (p=0.002) (Table 2.5). 
 
Table 2.5: Pressure pain threshold (kPa) 
Site 
Good outcome  Poor outcome  
p 
Mean SD Mean SD 
Knee 417 255 283 168 0.024* 
ECRB 454 168 314 140 0.002* 
* Indicates statistical significance at p  0.05 
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• Cold Detection and Cold Pain Thresholds  
The poor outcome group perceived cold at a lower temperature (indicating a 
reduction in sensory acuity) than the good outcome group at the ECRB site 
(p=0.034).  
The poor outcome group had significantly higher cold pain thresholds 
(increased cold pain sensitivity) than the good outcome group, both at the 
operated knee (p=0.008) and at the distant ECRB site (p=0.01) (Table 2.6). 
 
Table 2.6: Cold detection and cold pain thresholds (°C) 
Site Test 
Good outcome  Poor outcome  
p 
Mean SD Mean SD 
Knee 
CDT 26.3 3.9 24.2 7.0 0.259 
CPT 2.7 5.6 9.2 10.3 0.008* 
ECRB 
CDT 28.4 2.1 25.8 6.0 0.034* 
CPT 2.9 5.5 9.9 10.1 0.01* 
* Indicates statistical significance at p  0.05 
 
• Heat Detection and Heat Pain Thresholds  
The poor outcome group detected changes in heat sensation at significantly 
higher temperatures than the good outcome group both at the operated knee 
(p=0.009) and at the ECRB site (p=0.01) indicating the poor outcome group 
had reduced sensory acuity. Heat pain thresholds were not significantly 
different between groups at the knee (p=0.168), although at ECRB the poor 
outcome group exhibited significantly reduced heat pain thresholds 
(increased heat pain sensitivity) (p=0.011) (Table 2.7). 
 
Table 2.7: Heat detection and heat pain thresholds (°C) 
Site Test 
Good outcome  Poor outcome  
p 
Mean SD Mean SD 
Knee 
HDT 39.4 4.0 42.9 4.6 0.009* 
HPT 47.0 3.5 47.5 2.1 0.168 
ECRB 
HDT 38.0 3.7 42.1 5.5 0.010* 
HPT 48.5 2.1 44.3 10.7 0.011* 
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* Indicates statistical significance at p  0.05 
 
• Self-reported pain (neuropathic pain and pain quality) 
PainDETECT  
Those in the poor outcome group reported significantly higher levels of 
neuropathic-type pain as measured by PainDETECT (p=0.001*) (Table 2.8).  
 
Table 2.8: Self-reported neuropathic pain 
 
Good outcome  Poor outcome  
p 
Mean SD Mean SD 
PainDETECT 3.03 3.62 7.27 5.8 =0.001* 
* Indicates statistical significance at p  0.05 
 
PQAS  
The poor outcome group also reported significantly higher scores in the 
various components of the PQAS as compared to the good outcome group. 
This difference was seen for all the subscores (paroxysmal: p=0.008, 
superficial: p=0.025, deep: p<0.001) (Table 2.9). 
 
Table 2.9: PQAS subscores 
 
Good outcome  Poor outcome  
p 
Mean SD Mean SD 
Paroxysmal 
Superficial 
Deep 
0.58 
3.03 
2.55 
1.23 
3.89 
4.11 
4.45 
7.59 
10.95 
7.1 
7.96 
11.32 
0.008* 
0.025* 
<0.001* 
* Indicates statistical significance at p  0.05 
 
2.5.3. Secondary Hypothesis 1: 
There will be a difference in self-reported comorbid conditions, health 
status and function between participants categorized as good outcome 
versus the poor outcome groups. 
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• Self-reported comorbid conditions and health status 
Comorbidity (SCQ), EQ-5D and EQ-5D Health Scores  
 
There was no significant difference in the number of comorbidities between 
the good (5.71 ± 0.74) or poor (7.41 ± 0.94) outcome groups (p=0.216). 
However, those in the poor outcome group rated themselves as having a 
significantly lower quality of life (p=0.018): poor outcome group 2.27 ± 0.32; 
good outcome group 1.35 ± 0.35. There was also a statistically significant 
difference (p=0.03) between the good outcome (82.52 ± 2.94) and poor 
outcome (73.77 ± 3.48) groups for the EQ-5D Health Scores, with the good 
outcome group rating themselves as being in a better state of health as 
compared to the poor outcome group (Table 2.10). 
  
 
Table 2.10: Self-reported comorbid conditions and health status 
 
Good outcome  Poor outcome  
p 
Mean SD Mean SD 
SCQ 5.71 4.12 7.41 4.39 0.216 
EQ-5D 1.35 1.92 2.27 1.49 0.018* 
EQ-5D Health 
Scores 
82.52 16.36 73.77 16.33 0.030* 
* Indicates statistical significance at p  0.05 
 
• Self-reported function 
WOMAC  
The poor outcome group recorded significantly higher levels of pain, stiffness 
and dysfunction than those in the good outcome group: WOMAC-total 
(p<0.001); WOMAC-pain (p<0.001); WOMAC-stiffness (p<0.001); WOMAC-
function (p<0.001) (Table 2.11).  
 
Table 2.11: WOMAC 
 
Good outcome  Poor outcome  
p 
Mean SD Mean SD 
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WOMAC Pain 2.13 2.46 5.77 3.96 <0.001* 
WOMAC Stiffness 0.94 1.31 2.68 2.01 <0.001* 
WOMAC Function 6.1 6.62 17.73 12.14 <0.001* 
WOMAC Total 9.16 9.44 26.18 16.87 <0.001* 
* Indicates statistical significance at p  0.05 
 
2.5.4. Secondary Hypothesis 2: 
There will be a difference in self-reported pre-operative pain and 
function between participants categorized as good outcome versus the 
poor outcome groups. 
 
• Self-reported pre-operative pain and function 
WOMAC  
Due to incomplete/missing data from the RPH JRAC registry, preoperative 
WOMAC scores were only available for 44 of the participants (90% of the 
good outcome group but only 73% of the poor outcome group). There were 
no significant group differences in either the WOMAC total or any sub-score, 
although there was a trend towards higher scores for those in the poor 
outcome group (Table 2.12). 
 
Table 2.12: Pre-operative WOMAC 
 
Good outcome  Poor outcome  
p 
Mean SD Mean SD 
WOMAC Pain 9.32 3.01 10.75 2.98 0.136 
WOMAC Stiffness 4.11 1.77 4.5 1.63 0.471 
WOMAC Function 29.46 11.86 33.06 7.92 0.286 
WOMAC Total 42.89 15.46 48.31 11.59 0.23 
* Indicates statistical significance at p  0.05 
 
When percentage change in WOMAC score from pre to post surgery was 
evaluated, a significant group difference was also seen, with those with good 
outcomes showing significantly greater change in WOMAC score (WOMAC 
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Pain (p=0.004), WOMAC Stiffness (p=0.022), WOMAC Function (p=0.008) 
and WOMAC Total (p<0.001)) than those with poor outcomes.  
 
The good outcome group improved in all aspects of pain and function by an 
average of 78% from preoperative baseline, whereas those in the poor 
outcome group only improved by an average 45% (Table 2.13). 
 
Table 2.13: Percentage change from mean pre-operative to mean post-
operative WOMAC scores for good and poor outcome groups. 
Good Outcome Group 
 Pre-Op Post-Op Mean 
Difference 
% 
change WOMAC Mean SD Mean SD 
Pain 9.32 3.01 2.12 2.46 7.2 77.2% 
Stiffness 4.11 1.77 0.94 1.31 3.17 77.1% 
Function 29.46 11.86 6.1 6.62 23.36 79.3% 
TOTAL 42.89 15.46 9.16 9.44 33.73 78.6% 
Poor Outcome Group 
 Pre-Op Post-Op Mean 
Difference 
% 
change WOMAC Mean SD Mean SD 
Pain 10.75 2.98 5.77 3.96 4.98 46.3% 
Stiffness 4.5 1.63 2.68 2.01 1.82 40.4% 
Function 33.06 7.92 17.72 12.14 15.34 46.4% 
TOTAL 48.31 11.59 26.18 16.87 22.13 45.8% 
 
Summary of Results 
Hypotheses  Accepted/Rejected 
1. There will be a difference in measures of 
pressure pain threshold, thermal pain and 
detection thresholds, and self-reported pain 
(neuropathic pain and pain quality) between 
participants categorized as good outcome 
versus the poor outcome groups. 
Partially accepted 
2. There will be a difference in self-reported 
health status, comorbid conditions and 
function between participants categorized as 
good outcome versus the poor outcome 
groups. 
Partially accepted 
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3. There will be a difference in self-reported pre-
operative pain and function between 
participants categorized as good outcome 
versus the poor outcome groups. 
Rejected 
 
 
 
 
2.6. Discussion 
This cross-sectional study aimed to use QST and self-report questionnaires 
to determine if patients with persistent moderate to severe pain one to three 
years following TKR surgery exhibited signs of widespread hyperalgesia, 
sensory deficits and neuropathic-type pain compared with those reporting no 
pain. 
 
The prevalence of persistent pain following TKR has been shown to range 
from 13% to 44% and it is suggested that central augmentation of pain 
related to central sensitization and other factors may contribute to this 
persistent pain (Baker et al., 2007; Brander et al., 2003; Puolakka et al., 
2010; Wylde et al., 2007; Wylde et al., 2011).  
 
The presentation of pain in knee OA ranges from localised pain to 
widespread hyperalgesia (Arendt-Nielsen et al., 2010; Carlesso & Neogi, 
2016; Graven-Nielsen et al., 2012; Imamura et al., 2008; Lundblad et al., 
2008; Wylde et al., 2012; Wylde et al., 2013), the present study 
demonstrated that patients with a poor outcome following TKR surgery 
continue to present with both localised pain and widespread hyperalgesia. 
The present study found that those with poor outcomes had significantly 
different (sensitized) thresholds to pressure pain, cold pain and heat pain 
compared with the good outcome group.  
 
Quantitative Sensory Testing 
A systematic review of quantitative sensory testing in painful OA reported 
that individuals with painful OA had decreased PPTs at the affected joint and 
at a remote site (Suokas et al., 2012). Skou et al. (2013) investigated 
sensitization in patients after revision TKR and reported that patients with 
pain after revision TKR demonstrated both local and widespread mechanical 
  46 
hyperalgesia as compared to patients without pain. The present study’s 
findings of decreased PPTs at the operated knee and the distant ECRB in 
the poor outcome group reflect both the findings of Skou et al. (2013), and 
also the trend seen in the systematic review. 
The poor outcome group also exhibited significantly impaired sensory acuity 
for cold and heat sensation detection at both the local operated knee site and 
at the unaffected and distant ECRB elbow site. This is an important finding 
that may be linked to the development of neuropathic pain. 
Hyperalgesia that spreads beyond the affected site, in particular to a site in a 
different body region may suggest a centrally-driven mechanism which 
maintains pain, even in the absence of pathology (Latremoliere & Woolf, 
2009). These findings are apparently at odds with Graven-Nielsen et al. 
(2012) and Martinez et al. (2007). Those studies found that the pre-operative 
hyperalgesia seen in knee OA patients normalizes following TKR. Martinez et 
al. (2007) investigated multi-modality hyperalgesia in a cohort of 20 patients 
scheduled for TKR and reported that the pre-operative thermal hyperalgesia 
and immediate post-operative thermal and mechanical hyperalgesia had 
normalized by 4 months post-TKR. 
The study by Graven-Nielsen et al. (2012) did not specify whether the post-
surgical PPT values had improved to normal levels and, since a mean of all 
20 participants was used, there were no data exploring whether there were a 
proportion of patients who exhibited no reduction in mechanical hyperalgesia. 
A larger study would help to clarify this. 
 
Self-Report Questionnaires 
There were also group differences in the self-reported questionnaires.  
Although preoperative WOMAC values showed no significant differences 
between groups, only 73% of those in the poor outcomes group had 
preoperative data and there was a trend towards this group reporting higher 
levels of pain, stiffness and dysfunction. Postoperatively there was a clear 
group difference, as might be anticipated. However, when percentage 
change from pre to post surgical WOMAC scores was investigated, it 
became clear that those in the good outcome group exhibited significantly 
greater improvements. This group demonstrated close to an 80% 
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improvement in pain, stiffness and function, a result that compares very 
favourably with pharmacological studies that report improvements in 
WOMAC score ranging from 36% to 45% (Altman et al., 2007; Babul et al., 
2004; Barthel et al., 2009; Kivitz et al., 2008; Williams et al., 2001). In 
contrast, those in the poor outcome group achieved only a 45% improvement 
in WOMAC scores following TKR surgery, strongly suggesting that this is a 
distinct group for whom removal of pathological tissue is not the complete 
solution in terms of pain reduction. 
 
This difference in pain and function improvement post-surgery could not be 
explained by additional comorbid conditions in those reporting poor 
outcomes. SCQ scores showed that there were no significant group 
differences in the number of comorbid conditions. Nevertheless, the poor 
outcome group reported greater difficulties in activities of daily living and 
lower quality of life compared to the good outcome group following TKR 
surgery, according to EQ-5D score.  
 
The significant group differences in values for the PainDETECT neuropathic 
pain questionnaire and the paroxysmal and superficial subscores of PQAS 
suggest that the quality of pain experienced by those with poor outcomes 
may differ and this would support the QST findings above. However, 
although patients with poor outcomes reported significantly higher levels of 
neuropathic-type pain symptoms on PainDETECT, none scored as positive 
for neuropathic pain and only 4 had scores in the intermediate classification 
of “unclear neuropathic”. This poor outcome group therefore did not exhibit 
clear signs of the neuropathic-type pain that has been proposed as an 
additional sign of centrally-driven pain sensitization (Woolf & Mannion, 1999). 
 
Study Limitations 
The limitations of this study must be acknowledged. Any cross-sectional 
study is limited by the inability to establish a temporal relationship between 
events and cannot determine causality, or the direction of any associations. 
Consequently, any findings need to be tested with a longitudinal study. The 
present study also suffered from difficulties with recruitment, particularly of 
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those with poor outcomes, for whom attending a potentially uncomfortable 
test session was too daunting. A larger sample size would increase the 
power of the study and may clarify the extent of neuropathic-type pain in 
those with poor outcomes. It is also worth pointing out some considerations 
regarding group allocation. The initial Knee Society Score was measured by 
JRAC at the standard one-year post-TKR assessment. However, this study 
recruited and tested participants at between 12 and 36 months post-op. 
Finally, participants in this study were not asked to wash out their usual pain 
medications prior to testing, a factor which is likely to have influenced both 
QST values and the questionnaire scores. The present study did not consider 
psychological factors or body mass index as additional factors that may 
predict unsatisfactory outcome following TKR and this would need to be 
addressed in a more comprehensive longitudinal study. 
 
Implications 
This small cross-sectional study has signaled that those with poor outcomes 
up to 3 years following their TKR surgery may experience pain that is driven 
by central mechanisms. A longitudinal study is clearly required, where 
participants are assessed for QST and neuropathic-type pain pre-operatively 
and then at various time points post-operatively. A wash out of all pain 
medications prior to testing at all time points would be essential to clarify the 
extent of hyperalgesia and pain quality. It has also been suggested that 
specific surgical procedures may be more likely to cause persistent pain (e.g. 
sacrificed cruciate ligament, lateral release and fat pad excision) and so 
should be noted as covariates in a future study (Elson & Brenkel, 2006; 
Meneghini et al., 2007).  
 
2.7. Conclusion 
In conclusion, this study found that patients reporting persistent moderate to 
severe pain at one year up following TKR report only a 45% improvement in 
pain, stiffness and function up to three years post-surgery. These participants 
also exhibit widespread mechanical and thermal hyperalgesia, impaired 
thermal sensation and report higher levels of neuropathic-type pain, although 
not at a level that is strongly indicative of neuropathic pain. Those with good 
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outcomes did not exhibit the same degree of hyperalgesia, sensory 
impairment or neuropathic-type pain and reported up to an 80% improvement 
in pain, stiffness and function following surgery. These findings support the 
hypothesis that peripheral nociceptive input is not the only process able to 
maintain central sensitization (Zusman, 2004), given that the source of 
peripheral nociceptive input has been removed as a result of the knee 
replacement surgery.   
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Chapter 3 
Study 2 
Sustained Cold Response 
 
3.1. Abstract 
Background and Aims 
An individual’s response to a cold stimulus may provide an indication of their 
overall pain sensitivity and may be linked to their risk of developing a 
persistent pain problem. Cold pain response is conventionally tested as the 
threshold temperature at which an individual starts to feel pain in response to 
a cooling stimulus. However, this approach is of limited usefulness in a clinic 
setting due to equipment expense and impracticality. Two alternative ways of 
testing cold response have been developed, one using a small thermode 
device set to a specific cool temperature that is placed on the skin and 
another using a previously validated menthol gel formulation that is spread 
on the skin. Both cold tests quantify response using a previously developed 
score that combines measures of intensity and measures of sensation 
quality, known as the Algotect Descriptor Index (ADI). This study aimed to 
assess the reliability and validity of these two methods, when compared to 
the conventional cold pain threshold testing. Correlations between each cold 
response test were also examined. 
Method 
A test-retest design was used, with forty-two healthy participants. The test-
retest reliability of the sustained cold and topical menthol response tests 
were evaluated against a standard cold pain threshold test. The association 
between: (1) Sustained cold response and topical menthol response tests; 
(2) Sustained cold response test and cold pain threshold (CPT) were also 
examined. Lastly, the ability of sustained cold and topical menthol responses 
tests to identify an abnormal CPT response to cold were explored. 
Results 
Excellent test-retest reliability was demonstrated for the sustained cold 
response test (ICC: 0.855; 95% CI: 0.713-0.952), topical menthol response 
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test (ICC: 0.851; 95% CI: 0.739-0.917) and the standard testing of cold pain 
threshold (ICC: 0.941; 95% CI: 0.892-0.968). Positive correlations were also 
found between each cold response test; Algotect Descriptor Index (ADI)-
sustained cold total and CPT temperature (r=0.355, p=0.021), ADI-sustained 
cold and ADI-topical menthol (Visual Analogue Scale (VAS) intensity 
(r=0.458, p=0.002), Mean Word Score (MWS) (r=0.417, p=0.006) and ADI 
total score (r=0.500, p=0.001)), and CPT temperature and ADI-topical 
menthol score (MWS subscore (r=0.389, p=0.009) and total score (r=0.413, 
p=0.007)). 
This study showed no significant difference in CPT values between groups 
for the sustained cold response test, although there was a trend towards 
significance for difference in CPT values between topical menthol high and 
low value groups. 
Conclusion 
The results demonstrated the excellent reliability of the two alternative ways 
of testing cold response, and the positive correlations between the standard 
way of testing for cold pain response and the two alternative cold tests. The 
sustained cold and topical menthol responses were not able to significantly 
differentiate an abnormal CPT response to cold. However, we envisage that 
with a larger sample size, the topical menthol response test will be able to 
significantly differentiate participants with an abnormal response to cold. 
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3.2. Overview, Aims and Objectives 
 
Thermal hyperalgesia has been shown to be a prognostic factor for the 
development of chronic pain and disability in some musculoskeletal 
conditions (Goldsmith et al., 2012; Staud et al., 2012). Cold hyperalgesia is 
an important feature in neuropathic pain states (Freeman et al., 2014), and 
has been proposed as a sign of widespread central sensitization (Woolf, 
2011). Cold hyperalgesia has also been found in individuals who suffer from 
neck pain (Steinmetz & Jull, 2013), cervical radiculopathy (Tampin et al., 
2012), temporomandibular disorders (Park et al., 2010), lateral epicondylalgia 
(Coombes et al., 2012), painful knee osteoarthritis (Moss et al., 2016; Wright 
et al., 2017), and in non-mechanical chronic non-specific low back pain 
(O'Sullivan et al., 2014). In whiplash injury, cold hyperalgesia is one of the 
factors that predicts increased rates of pain and disability (Sterling et al., 
2005). Cold hyperalgesia has also been identified to be a consistent predictor 
of higher pain levels and disability in lateral epicondylalgia (Coombes et al., 
2015). Elevated cold pain thresholds are also associated with increased pain 
and decreased function in patients with knee osteoarthritis (Wright et al., 
2017). The current research evidence therefore suggests that the presence 
of cold hyperalgesia in some musculoskeletal conditions may predict poor 
outcomes. 
 
Cold hyperalgesia however is rarely tested in the clinical setting. Available 
equipment is primitive and includes the use of metal rollers, test tubes filled 
with chilled water, ice or coolants (e.g. acetone) (Baron et al., 2010; Maxwell 
& Sterling, 2013; Uddin & MacDermid, 2016). Such methods of testing are 
imprecise, both in terms of being able to control the cold stimulus and in 
terms of the response provided by the patient. Use of ice or acetone is also 
problematic as the stimulus is supra-threshold for most individuals and so 
evaluation of an abnormally hyperalgesic response is difficult.   
 
In scientific research, cold hyperalgesia is generally assessed using a 
computer-controlled peltier thermode, such as the TSA-II – Neurosensory 
analyzer produced by Medoc, Israel. Such quantitative sensory testing (QST) 
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devices are advantageous in research as they can generate repeatable and 
precise stimuli, however the cost and maintenance of these devices can 
prove prohibitive for healthcare organizations.   
 
This study aimed to assess the reliability and validity relative to CPT testing 
of two simple, relatively inexpensive but precise ways of testing cold 
response that could potentially be used in a clinical setting. If found to be 
reliable, the cold response tests may be used to provide additional valuable 
information about pain system response for primary care practitioners. 
  
The objectives of this study were: 
1. To evaluate the test-retest reliability of the sustained cold response test 
(using a custom-made Dharma thermode set at 12˚C and ADI) and 
menthol cold response test (using a pre-determined dose of topically-
applied menthol and ADI) compared with standard cold pain threshold 
(CPT) reliability. 
2. To evaluate whether the response to sustained cold correlates with the 
response to menthol cold. 
3. To evaluate whether there is a correlation between CPT and response to 
sustained cold and between CPT and response to menthol cold. 
4. To evaluate whether high or low sustained cold and menthol cold 
response could differentiate between high and low CPT temperatures. 
 
3.3. Research Hypotheses 
3.3.1. Primary Hypotheses: 
1. There will be good test-retest reliability for the sustained cold response 
test (ADI-sustained cold), topical menthol cold response test (ADI-topical 
menthol) and cold pain threshold (CPT) temperature. 
2. There will be positive correlations between each cold response test:  
a. Sustained cold response (ADI-sustained cold); 
b. Topical menthol cold response (ADI-topical menthol);  
c. CPT temperature 
3. Participants in high sustained cold and menthol cold groups will exhibit 
higher CPT temperatures.  
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3.4. Methods 
3.4.1. Participants 
The study was conducted in the School of Physiotherapy and Exercise 
Science at Curtin University in Perth, Western Australia. A total of 40 
participants were recruited voluntarily from the community. 
 
Volunteers with current pain or a history of lateral epicondylalgia and/or neck 
pain with radiation to the forearm were excluded due to potential influence on 
thermal stimuli. Volunteers with limited understanding of English were also 
excluded. Inclusion and exclusion criteria were as table 3.1. 
 
Table 3.1: Inclusion / Exclusion criteria 
Inclusion Criteria • Aged between 18 and 65 years old 
• No current pain 
• Good comprehension of spoken and written 
English language 
Exclusion Criteria • History of lateral epicondylalgia / tennis elbow 
History of neck pain with radiation to forearm 
• History of other chronic pain condition 
• Altered / loss of sensation at the volar forearm 
test site 
 
All participants provided written informed consent before participating in the 
study. Ethical approval was granted by Curtin University Human Research 
Ethics Committee (Approval Number PT0188). 
 
3.4.2. Study Design and Procedure 
This study utilized a test-retest design. Participants attended 2 sessions 
within a single week, each session separated by a washout period of at least 
24 hours. On each test occasion the same protocol was followed. A test site 
(2 x 3 cm) on each volar forearm approximately mid-way between the wrist 
and elbow creases was used. Cold detection and cold pain thresholds (CDT 
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and CPT) were first tested at this site on both arms. Sustained cold was then 
tested on a randomly allocated forearm. Randomization was done using a 
random number generator application on a smart phone. Participants 
allocated an odd number started the test on the right forearm, those with an 
even number started the test on the left forearm. Topical menthol cold was 
then tested on the other forearm. Sustained cold was always tested first to 
ensure that any lingering sensory effects of menthol did not influence the 
thermode cold response. The same protocol was used on each occasion. 
The same test site and same order of testing was used on both test 
occasions: sustained cold on one forearm, Topical menthol cold tested on the 
other forearm.  
 
3.4.3. Outcome Measures  
Quantitative Sensory Tests:  
All quantitative sensory testing was conducted with the participant sitting in 
an arm chair, with their arms placed on a table. All instructions were 
standardized.  
1. Cold Detection and Pain Thresholds was measured using a peltier 
thermode (Medoc, Israel). The minimum temperature was set at 0°C. 
A 30x30mm contact probe was attached to the test site with a strap 
and the participant was given several minutes to adapt to the baseline 
temperature of 32°C. When the device was activated, the thermode 
temperature fell at a rate of 1°C/sec. This rate of temperature change 
has been shown to reduce intra-individual variation (Palmer et al., 
2000). The participant was given a control switch and instructed to 
press the switch when they perceived the relevant sensation (i.e. if it 
was a cold detection threshold test, the participant was instructed to 
depress the switch once they detected cold). The cold detection 
threshold was always tested before the cold pain threshold to 
minimise sensitization of receptors by the noxious input. For each 
threshold, 1 practice trial was followed by 3 measurements, with the 
mean calculated for analysis. Each stimulus was separated by a 
randomised 3 to 6 second interval. See Section 2.4.3. for details on 
the reliability of the thermal detection and pain thresholds.  
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Figure 3.1 
Photograph of the Medoc TSA II system with peltier thermode. 
 
2. Sustained Cold Response was tested using a newly developed 
wearable peltier thermode (Dhama, India). This battery powered 
device creates a cool temperature through standard thermo-electric 
methods but has been designed to be worn on the forearm. The 
device comprises a 2x3cm thermode plate that is embedded in a rigid 
arm wrap. The wrap is kept damp in order to facilitate dissipation of 
the heat produced by the cooling process. The thermode can be set to 
several different specific temperatures using touch controls and 
maintains this temperature for up to 5 minutes (Figure 3.1).  
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Figure 3.2 
Photograph of the Dhama thermode system showing the control unit and the pad for 
application to the arm. 
 
For this study, the Dhama thermode was set to 12˚C. This 
temperature was selected as being warmer than the average normal 
CPT of 7-10˚C but sufficiently cold to elicit a response in all 
participants. Before application to each participant, the external 
surface of the thermode was sprayed with water to allow for heat 
evaporation, and the thermode plate temperature checked using a 
thermistor. It was then applied to the participant’s volar forearm for 5 
minutes, using the timer on the ADI Apple iPad application (see 
below). On completion of the 5-minute test it was removed from the 
patient’s forearm before being turned off.  
Response to the sustained cold stimulus was measured using the ADI, 
delivered via an Apple iPad application (Moss, 2013). The ADI 
combines measures of perceived sensation intensity with a measure 
of sensory quality. Intensity of cold, heat, unpleasantness and pain 
sensation is assessed throughout the thermode application using the 4 
calibrated 100mm VAS sliding scales shown on the iPad touch screen 
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(Figure 3.2). A pre-determined algorithm calculates an ADI-VAS index 
score from these 4 scales. 
 
 
Figure 3.3 
Screenshot of the 4 calibrated 100mm VAS sliding scales to assess cold, heat, 
unpleasantness and pain. 
 
Participants are also asked to select words that best describe the 
quality of the sensation experienced during the 5-minute thermode 
application from a set of descriptors based on the key sensory 
elements of the McGill Pain Questionnaire descriptor list (Melzack, 
1975) (Figure 3.3). An algorithm calculates a descriptor index value 
based on words selected. 
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Figure 3.4 
Screenshot of the ADI descriptors showing the range of sensory descriptors that can 
be selected. 
 
Using a specially-designed timed iPad Application, ratings for either 
intensity or quality were taken every 30-seconds in alternating fashion 
during the 5-minute thermode application. A previously developed 
algorithm was used to calculate a total ADI score based on the 
combined intensity and quality responses (Moss, 2013). As well as 
calculating a total sustained cold ADI score (min 0, max 9), a subscore 
for combined VAS intensity for cold, heat, unpleasantness and pain 
(max score 4) and a subscore for sensation quality (mean word score 
(MWS), max score 5) were also calculated, using the method 
described by Moss (2013).  
 
3. Topical Menthol Cold was tested by applying for 15 minutes, a 
previously tested (Moss, 2013) gel formulation of 20% menthol. Before 
application of the menthol gel formulation, the test area was marked 
and gently cleaned with hypoallergenic soap and tepid water. 2ml of 
menthol gel was applied to the test site using a 5ml syringe. A 
Tegaderm© dressing was immediately placed over the gel to minimize 
evaporation, and the gel then gently spread through the dressing so 
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that it exactly filled the 2x3cm dressing window. When the 15-minute 
application ended, the Tegaderm© dressing was removed and the 
menthol gel cleaned from the skin using hypoallergenic soap and tepid 
water. The skin was gently dried with a paper towel. 
Response to the topical menthol cold was measured using the ADI, 
delivered via the same Apple iPad application, although using a 15-
minute version. Once the menthol and dressing had been applied, the 
15-minute timer was started. Every minute, participants were asked 
either to rate the intensity of cold, heat, unpleasantness or pain they 
were feeling, using the 4 calibrated 100mm VAS sliding scales or to 
select descriptors which best describe the quality of sensation they 
were feeling. The same algorithm calculated a topical menthol cold 
ADI score based on the combined intensity and quality responses (min 
0, max 9). Subscores for intensity ratings (max 4) and for sensation 
quality (MWS, max 5) were also calculated (Moss, 2013).  
 
3.4.4. Power Analysis 
Using data from a previous CPT study (Moss et al., 2011) it was calculated 
that a sample size of between 40 and 50 participants would provide 80% 
power (α=0.05) to assess test-retest reliability between the 2 test occasions. 
There are no published data regarding the test-retest reliability for either 
topical menthol cold or sustained cold tests. Data collected during the 
present study will help to inform power analyses for future clinical studies. 
 
3.4.5. Data Analysis 
Statistical analysis was completed using IBM SPSS Statistics version 22, 
with alpha set at 0.05. Data were tested for normality using normal 
distribution curves and Shapiro-Wilks tests. For threshold testing, CDT was 
normally distributed but CPT showed its usual bi-modal distribution. 
Sustained cold ADI values were normally distributed (Shapiro-Wilks 0.974, 
p=0.433) although topical menthol cold ADI values were not (Shapiro-Wilks 
0.335, p<0.001). Due to the mixed normality results, non-parametric tests 
were used where appropriate. Table 3.2 shows the statistical tests for each 
hypotheses. 
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Table 3.2: Hypotheses and Statistical Test Used 
Hypotheses and Related Data Statistical Analysis 
1. Test-retest reliability for ADI-sustained cold, 
ADI-topical menthol and CPT temperature. 
Intra-Class Correlation 
Coefficients (ICC) (2-
way mixed, consistency) 
2. Correlations between each cold response 
test. 
i. ADI-sustained cold 
ii. ADI-topical menthol 
iii. CPT temperature 
Spearman’s Correlation 
Coefficients (2-tailed) 
3. Ability to differentiate abnormal CPT 
response to cold using: 
i. Sustained cold response 
ii. Topical menthol cold response 
Hierarchical cluster 
analysis 
Chi-squared analysis 
Mann Whitney U-Test 
 
Data analysis for primary hypothesis 3 (Ability of sustained and topical 
menthol cold responses to differentiate an abnormal CPT response to cold) 
was more complex and evaluated using several different methods. 
Hierarchical cluster analysis was first used to investigate groupings for topical 
menthol and sustained cold ADI total scores. Optimal cut-offs between 
groups were then calculated. Chi-squared analysis was used to compare 
membership of high and low sustained cold and topical menthol cold groups 
with high and low CPT groups (<>15˚C) (Allchorne et al., 2005; Davis & 
Pope, 2002; Story et al., 2003) and Mann-Whitney-U tests run to investigate 
differences in mean CPT values between high and low cold response groups. 
 
3.5. Results 
3.5.1. Participant Demographics 
A total of forty-two participants (eighteen male and twenty-four female; mean 
age 30.1  8.2, range 18-49) took part in the study. There were no drop outs, 
all forty-two participants completed the study. 
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3.5.2. Primary Hypothesis 1: 
There will be good test-retest reliability for Algotect Descriptor Index 
(ADI)-sustained cold, ADI-topical menthol and CPT temperature. 
• Sustained Cold  
The ADI-sustained cold test demonstrated excellent test-retest reliability for 
the 2 subscores (VAS intensity (ICC: 0.821; 95% CI:0.691-0.900) and MWS 
(ICC3,1: 0.794; 95%CI: 0.648-0.884)) and the total score (ICC: 0.855; 95% CI: 
0.713-0.952) (Table 3.3). 
 
• Topical Menthol 
The ADI-topical menthol test demonstrated excellent test-retest reliability for 
the 2 subscores (VAS intensity (ICC: 0.879; 95% CI:0.776-0.935) and MWS 
(ICC: 0.834; 95%CI: 0.711-0.907)) and the total score (ICC3,1: 0.851; 95% CI: 
0.739-0.917) (Table 3.3). 
 
• Cold Pain Threshold 
The CPT temperature demonstrated excellent test-retest reliability (ICC3,1: 
0.941; 95% CI: 0.892-0.968) (Table 3.3). 
 
Table 3.3 Test-retest reliability over 2 occasions separated by at least 24 
hours – Intra-Class Correlation Coefficient (ICC3,1), showing 95% Confidence 
Intervals (CI) 
 ICC3,1* 
r= 
95% CI 
Sustained cold     
• VAS intensity 0.821 0.691-0.900 
• MWS 0.794 0.648-0.884 
• Total ADI score 0.855 0.713-0.952 
Topical menthol cold   
• VAS intensity 0.879 0.776-0.935 
• MWS 0.834 0.711-0.907 
• Total ADI score 0.851 0.739-0.917 
Cold Pain Threshold    
• CPT temperature (˚C) 0.941 0.892-0.968 
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* All ICCs p<0.001 
 
3.5.3. Primary Hypotheses 2: 
There will be positive correlations between each cold response test:  
a. Sustained cold response (ADI-sustained cold); 
b. Topical menthol cold response (ADI-topical menthol);  
c. Cold pain threshold (CPT) temperature. 
 
• ADI-sustained cold and ADI-topical menthol 
There was a moderate positive strength of association between the ADI-
sustained cold test and the ADI-topical menthol test (VAS intensity (r=0.458, 
p=0.002), MWS (r=0.417, p=0.006) and ADI total (r=0.500, p=0.001)) (Table 
3.4). 
 
Table 3.4: Spearman’s correlation coefficient (ADI-sustained cold and ADI-
topical menthol) 
  ADI-topical menthol 
  VAS intensity MWS ADI total 
ADI-sustained cold 
• VAS intensity  
 
 
r= 
p= 
 
0.458 
0.002* 
 
-0.131 
0.408 
 
0.334 
0.031* 
• MWS 
 
r= 
p= 
0.453 
0.003* 
0.417 
0.006* 
0.545 
0.000* 
• ADI total 
 
r= 
p= 
0.547 
0.000* 
0.098 
0.537 
0.500 
0.001* 
* Indicates statistical significance at p  0.05 
 
• ADI-sustained cold and CPT  
There was a moderate positive strength of association between ADI-
sustained cold total score and CPT (r=0.355, p=0.021). No significant 
associations were established between the VAS intensity and MWS sub 
scores (Table 3.5). 
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Table 3.5: Spearman’s correlation coefficient (ADI-sustained cold and CPT) 
 CPT 
 r p 
ADI-sustained cold 
• VAS intensity 
• MWS 
• ADI total 
 
0.269 
0.283 
0.355 
 
0.085 
0.069 
0.021* 
* Indicates statistical significance at p  0.05 
 
• ADI-topical menthol and CPT  
There was a moderate positive strength of association between ADI-topical 
menthol and CPT (MWS subscore (r=0.389, p=0.009) and total score 
(r=0.413, p=0.007)) (Table 3.6). 
 
Table 3.6: Spearman’s correlation coefficient (ADI-topical menthol and CPT) 
 CPT 
 r p 
ADI-topical menthol 
• VAS intensity 
• MWS 
• ADI total 
 
0.293 
0.398 
0.413 
 
0.059 
0.009* 
0.007* 
* Indicates statistical significance at p  0.05 
 
3.5.4. Primary Hypothesis 3: 
Participants in the high sustained cold response group and the high 
menthol cold response group will exhibit higher CPT temperatures.  
Hierarchical cluster analyses were used to identify clear participant groups 
for sustained cold total ADI and for topical menthol cold total ADI values. 
Group sizes and cut-off values were then calculated.  
 
For ADI-sustained cold total values, two groups could be identified with 38 
participants in the low ADI group, 4 in the high ADI group and a cut-off value 
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of 6.07. Additional descriptive values for each group are shown in Table 3.7 
below.  
 
Table 3.7: Descriptive group values for ADI-sustained cold total 
 Maximum Minimum Median Mean SD* 
Group 1 
(n=38) 
5.14 2.14 3.92 3.80 0.878 
Group 2 
(n=4) 
9.06 5.60 7.00  6.20 0.503 
* SD: Standard Deviation 
 
For ADI-topical menthol total values, two groups were also identified with 38 
participants in the low ADI group and 4 in the high ADI group (Table 3.8). The 
cut-off for the ADI-topical menthol score was 5.10. 
 
Table 3.8: Descriptive group values for ADI-topical menthol total 
 Maximum Minimum Median Mean SD* 
Group 1 
(n=38) 
4.08 1.50 3.0 2.94 0.135 
Group 2 
(n=4) 
6.22 4.50 5.0 5.09 0.166 
* SD: Standard Deviation 
 
Mann-Whitney U-tests were then used to evaluate whether there was a 
difference in conventional cold response test values (CPT temperature) 
between sustained cold or topical menthol cold groups. However, no 
significant difference in CPT value was found between high or low score 
groups for either sustained cold or menthol cold tests, although there was a 
trend towards significance for difference in CPT values between menthol cold 
high and low value groups (Table 3.9). 
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Table 3.9: Differences in CPT temperature between high and low ADI total 
groups for sustained cold and topical menthol  
 Mean (SD) CPT value (˚C) Mann Whitney 
U-Test  
Sustained cold   
• Low ADI total group 
(n=38) 
8.03 (9.07) 
p=0.468 
• High ADI total group 
(n=4) 
9.83 (9.66) 
Topical menthol   
• Low ADI total group 
(n=38) 
7.39 (8.54) 
p=0.067 
• High ADI total group 
(n=4) 
16.40 (9.56) 
 
Summary of Results 
Hypotheses  Accepted/Rejected 
1. There will be good test-retest reliability for 
sustained cold response test (ADI-sustained 
cold), topical menthol cold response test (ADI-
topical menthol) and cold pain threshold 
(CPT) temperature.  
Accepted 
2. There will be positive correlations between 
each cold response test:  
i. Sustained cold response (ADI-sustained 
cold) 
ii. Topical menthol cold response (ADI-
topical menthol) 
iii. Cold pain threshold (CPT) temperature 
Accepted 
 
 
 
3. Participants in high sustained cold and 
menthol cold groups will exhibit higher CPT 
temperatures.  
Rejected 
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3.6. Discussion 
This study aimed to assess the reliability and validity of two alternative simple 
methods of testing cold response, as compared to the conventional cold pain 
threshold testing.  
 
The presence of cold hyperalgesia has been documented in a range of 
musculoskeletal pain conditions (Coombes et al., 2012; Moss et al., 2016; 
Park et al., 2010; Steinmetz & Jull, 2013; Tampin et al., 2012; Wright et al., 
2017), and has been shown to be a consistent predictor of poor outcomes in 
whiplash injury and lateral epicondylalgia (Coombes et al., 2015; Sterling et 
al., 2005). The ‘gold standard’ of assessing cold hyperalgesia is by using a 
computer-controlled peltier thermode, however the cost and maintenance of 
these devices present a major hurdle for its widespread use clinically. 
 
Test-Retest Reliability  
The finding of excellent test-retest reliability of the standard test of cold pain 
threshold supports the current evidence in the scientific literature (Geber et 
al., 2011; Heldestad et al., 2010; Moss et al., 2016; Pigg et al., 2010; Wasner 
& Brock, 2008). The present study has also demonstrated the excellent test-
retest reliability of two alternative ways of testing cold response. As the 
sustained cold response and topical menthol response tests are newly 
developed tests, there are no current evidence available on the reliability and 
validity of these tests with which to compare these reliability data. The data 
collected from this study on the reliability and validity of these two new 
measures of cold response will inform power analyses for future clinical 
studies. 
 
Correlations and Validity 
This study showed that there were moderate to weak correlations between 
CPT values and the new tests of cold response sustained cold and topical 
menthol cold. Although not causative, this suggests that the newly developed 
tests of cold response are evaluating a similar phenomenon to the gold 
standard CPT test, despite using a very different response measurement. 
Hence, it can be assumed that the two new cold response tests have face 
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and content validity in the measurement of cold hyperalgesia. Further studies 
are needed to confirm these findings. 
 
Differentiation of abnormal cold responses 
Sustained cold response and topical menthol tests were not however able to 
clearly differentiate participants with abnormally high responses to standard 
CPT cold testing. Cluster analysis showed a clear delineation between high 
and low scores for both the sustained cold and topical menthol cold ADI 
scores, but there was no significant difference in CPT values between groups 
for either new cold test. It may be noted that there was a visible difference 
and trend towards statistical significance in CPT values between topical 
menthol cold high and low score groups, with the mean value for the high 
topical menthol cold group being >15˚C, a previously suggested cut-off for 
cold hyperalgesia (Allchorne et al., 2005; Davis & Pope, 2002; Story et al., 
2003). This suggests that a future study, with greater participant numbers, 
may demonstrate a clearer association between topical menthol cold 
response with ADI and CPT. Such a finding would indicate the usefulness of 
a simple clinical test for cold hyperalgesia based on intensity and quality 
response to topically-applied menthol. 
 
Study Limitations 
The limitations of this study must be acknowledged. These include a small 
sample size, relatively young age of the participants (mean age of 30.14 
years) and the population tested are all healthy participants. Due to the small 
sample size, the topical menthol response test was not able to significantly 
differentiate an abnormal CPT response to cold. However, we envisage that 
with a larger sample size, the topical menthol response test will be able to 
significantly differentiate an abnormal CPT response to cold. Due to the 
limitations of young age and a healthy population, we are unable to 
definitively conclude that positive correlations found in this study can be 
generalized to an elderly or diseased population. Moving forward, this study 
should be expanded to include a larger sample, a wider range of ages and 
disease specific populations (e.g. knee osteoarthritis, neuropathic pain). 
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Implications 
The results of this study have demonstrated the reliability and validity (face 
and content) of the two alternative simple methods of testing cold response, 
as compared to the conventional cold pain testing. This means that clinicians 
now have alternative ways of assessing cold hyperalgesia quickly and 
accurately, without using the bulky and costly computer-controlled peltier 
thermode devices. 
 
3.7. Conclusion 
In conclusion, this study has proven the reliability and validity of both the 
sustained cold and topical menthol cold tests. Consequently, these two new 
tests appear to offer clinicians an appropriate, quick, low-cost and simple way 
to test for cold hyperalgesia in a young and healthy population. Further 
studies are needed to demonstrate that the results of this study can be 
replicated in an elderly or diseased population. The sustained cold response 
test was chosen as a quantitative sensory test in the next study (Study 3) due 
to its ease of use and shorter application time. 
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Chapter 4 
Study 3 
Evaluation of predictors for persistent pain post-Total 
Knee Replacement 
 
4.1. Abstract 
Background and Aims 
Persistent pain following TKR may reflect new pain resulting from the surgical 
intervention or may reflect lack of success in resolving pre-existing, ‘old’ pain. 
This study aimed to investigate whether persistent pain at 6 months following 
TKR surgery can be predicted by measures of pain, function, psychological 
distress or quantitative sensory testing (QST) at pre-operative baseline 
and/or at 3 months post-surgery.  
Method 
A prospective cohort design was used. A total of ninety-two participants who 
underwent TKR within Royal Perth Hospital, Fremantle Hospital and Health 
Service and at St John Of God Subiaco and Murdoch Hospitals were 
assessed pre-operatively and at 3 months post-operatively using a range of 
self-report, QST and intra-operative measures, all of which have been 
proposed as potential predictors of persistent post-operative pain. At the time 
of submission of this thesis, seventy-four participants had reached the 3 
months post-surgery time point. Out of these seventy-four participants, sixty 
had reached the 6 months post-surgery time point.  
At 3 months post-TKR, participants were divided into ‘no to low pain’ and 
‘moderate to severe pain’ groups, based on their pain levels (Pain Average 
score from the PainDETECT questionnaire). 
At 6 months post-TKR, participants were divided into ‘good outcome’ and 
poor outcome’ groups, based on Knee Society Score. 
Differences in the abovementioned range of measures were investigated 
between the groups at 3 and 6 months post-TKR. Logistic regression was 
then used to determine the predictive value of the measures in determining 
persistent pain post-TKR. 
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Results 
Group differences 
At 3 and 6 months post-TKR, there were significant group differences in a 
range of pre-operative physical measures and self-reported outcomes. 
At 6 months post-TKR, there were significant group differences in a range of 
3 months post-surgery self-reported outcomes. 
Predictors of post-TKR pain. 
Pre-operative predictors of higher pain levels at 3 months post-TKR surgery 
were vibration detection threshold (VDT) at the elbow (odds ratio (OR)=1.38, 
p=0.002) and PainDETECT score (OR=1.16, p=0.041). 
Pre-operative predictors of membership of the poor outcome group at 6 
months post-TKR were VDT average of all sites (OR=1.09, p<0.001) and 
WOMAC Pain score (OR=1.5, p=0.003). 
3 months post-TKR predictors of membership into the poor outcome group at 
6 months post-TKR were pain catastrophising (OR=1.19, p=0.033) and pain 
intensity (OR=5.42, p=0.01).  
Conclusion 
Individuals with higher pain levels at 3 months post-TKR surgery, pre-
operatively exhibited widespread sensory changes, poorer function, higher 
levels of neuropathic-type pain, pain catastrophising, lower health status, 
higher WOMAC scores, psychological distress and reduced sleep quality. 
Individuals with poor outcomes at 6 months post-TKR surgery, preoperatively 
exhibited widespread sensory changes, poorer function, higher levels of 
neuropathic-type pain, pain catastrophising, lower health status, more co-
morbid conditions, higher WOMAC scores and increased psychological 
distress. 
Individuals with poor outcomes at 6 months post-TKR surgery, at the 3 
months post-TKR assessment had higher levels of neuropathic-type pain, 
increased pain catastrophising, lower health status, more co-morbid 
conditions, higher WOMAC scores, increased psychological distress and 
poorer sleep quality. 
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4.2. Overview, Aims and Objectives 
TKR surgery has increased by 92.4% since 2003 (AOANJRR, 2013). 
Persistent pain reduces function and quality of life for between 13% and 44% 
of patients post-TKR surgery (Baker et al., 2007; Brander et al., 2003; 
Puolakka et al., 2010; Wylde et al., 2007; Wylde et al., 2011). Based on the 
number (AOANJRR, 2013) and cost (Independent Hospital Pricing Authority, 
2013) of TKR operations in Australia in 2012, and the rates of persistent 
post-TKR pain reported in the literature (Baker et al., 2007; Beswick et al., 
2012; Brander et al., 2003; Puolakka et al., 2010; Wylde et al., 2007; Wylde 
et al., 2011), it can be postulated that the cost of the failed surgery alone 
ranges from $102 million - $128 million (13%) to $347 million - $436 million 
(44%). Yet the interactions between factors contributing to this pain are still 
poorly understood and have not yet been comprehensively evaluated in a 
longitudinal study. Persistent post-surgical pain is often a combination of pre-
existing unresolved pain and newly acquired pain post-surgery (Kehlet et al., 
2006; Perkins & Kehlet, 2000; Suokas et al., 2012; Vilardo & Shah, 2011; 
Wylde et al., 2013). Therefore, greater clarity is needed about the relative 
roles of these 2 issues in the development of persistent post-surgical pain. 
This study used a wide range of peri-operative data from self-report, QST, 
and medical notes to evaluate predictors of pain that persists up to 6 months 
post-TKR surgery. It is hoped that the findings from this study will assist in 
the pre-operative assessment and post-operative pain management of 
patients undergoing TKR.  
 
The objectives of this study were: 
1. To investigate whether there is a difference at pre-operative baseline in 
QST measures, pain report, functional level and health status between 
participants categorized as having no to low pain (<4 in NRS pain) versus 
moderate to severe pain (≥4 in NRS pain) at 3 months following TKR 
surgery. 
2. To investigate whether there is a difference at pre-operative baseline and 
at 3 months post-surgery in QST measures, pain report, functional level 
and health status between participants categorized as showing ‘poor’ 
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versus ‘good’ outcomes (based on Knee Society Score) at 6 months 
following TKR surgery.  
 
4.3. Research Hypotheses 
4.3.1. Primary Hypotheses: 
1. There will be a difference at pre-operative baseline in QST measures, 
pain report, functional level, health status, psychological distress and 
sleep quality between participants categorized as having no to low pain 
(<4 in NRS pain) versus moderate to severe pain (≥4 in NRS pain) at 3 
months following TKR surgery. 
2. There will be a difference at pre-operative baseline and at 3 months post-
surgery in QST measures, pain report, functional level, health status, 
psychological distress and sleep quality between participants categorized 
as showing ‘poor’ versus ‘good’ outcomes (based on Knee Society Score) 
at 6 months following TKR surgery. 
 
4.3.2. Secondary Hypotheses: 
1. Pre-operative baseline measures (which may include cold pain threshold 
(CPT), pressure pain threshold (PPT), PainDETECT score, WOMAC 
score, psychological distress or sleep quality index score) will predict 
moderate to severe pain levels at 3 months post-TKR surgery. 
2. Pre-operative baseline measures (which may include cold pain threshold 
(CPT), pressure pain threshold (PPT), PainDETECT score, WOMAC 
score, psychological distress or sleep quality index score) will predict 
‘poor’ outcome at 6 months post-TKR surgery. 
3. 3 months post-TKR surgery measures (which may include CPT, PPT, 
PainDETECT score, surgical approach, immediate post-operative pain 
intensity or pain catastrophising) will predict ‘poor’ outcome at 6 months 
post-TKR surgery. 
4. Baseline CPT values will predict membership into the ‘poor’ outcome 
group at 6 months with good sensitivity and specificity. 
5. Baseline PainDETECT scores will predict membership into the ‘poor’ 
outcome group at 6 months with good sensitivity and specificity. 
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4.4. Methods 
4.4.1. Participants 
The study was conducted in Royal Perth Hospital (RPH), Fremantle Hospital 
and Health Service (FHHS), and St John of God (SJOG) Subiaco and 
Murdoch Hospitals in Perth, Western Australia.  
 
Inclusion/exclusion criteria are listed below. All individuals listed on the 
surgical lists were contacted, initially by providing written information by post 
and then following up with a phone call. No RPH, FHHS, SJOG Subiaco and 
Murdoch Hospitals’ staff were involved in direct recruitment of participants to 
the present study, to avoid power and ethical issues.  
 
Volunteers with numbness around the knee, haemophilia or previous history 
of stroke were excluded from the study because those factors can possibly 
influence the perception of thermal and pressure stimuli. Volunteers with 
limited understanding of English were also excluded because of the need to 
complete questionnaires in English. Inclusion and exclusion criteria were as 
in Table 4.1.  
 
Table 4.1: Inclusion / Exclusion criteria 
Inclusion Criteria • Above 50 years old 
• Undergoing primary uni-lateral TKR because of 
OA 
• Good comprehension of English language 
Exclusion Criteria • Recent surgery (<6 months) in the contralateral 
knee and/or ipsilateral elbow 
• Any cognitive impairment 
• Any neurological conditions (i.e. previous stroke) 
• Numbness around the knee and/or ipsilateral 
elbow 
• Haemophilia 
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All participants were advised to continue with their usual medications prior to 
attending the assessment session.  
All participants provided written informed consent before participating in the 
study. Ethical approval was granted by Royal Perth Hospital Medical 
Research Ethics Committee (Approval Number: REG 14-141), Curtin 
University Human Research Ethics Committee (Approval Number: HR 
220/2014) and St John of God Health Care Human Research Ethics 
Committee (Approval Number: 926). 
 
4.4.2. Study Design and Procedure 
This study utilized a prospective cohort method, in which patients undergoing 
TKR within RPH, FHHS and at SJOG Subiaco and Murdoch Hospitals were 
assessed pre-operatively and at 3 months post-operatively using a range of 
self-report, QST and intra-operative measures, all of which have been 
proposed as potential predictors of persistent post-operative pain (Elson & 
Brenkel, 2006; Kehlet et al., 2006; Macrae & Davies, 1999; Vilardo & Shah, 
2011). The timeline for assessments and range of self-report and physical 
tests utilized are as shown in Appendix 2. 
 
4.4.3. Outcome Measures  
Self-Reported Measures: 
All participants completed a paper version of all the questionnaires on the 
day of their research assessment. The questionnaires were as stated below. 
Disease-specific 
1. Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) is a disease-specific self-report measure designed for 
standardised reporting of individuals with knee or hip osteoarthritis 
(Bellamy, 1989). It consists of 24 items divided over 3 subscales: pain, 
joint stiffness and physical function. The WOMAC questionnaire (Likert 
version 3.1) was administered with the pain subscale last, as it has 
been hypothesized that participants’ responses to the pain questions 
may bias the responses to some of the questions in the physical 
function subscale (Pua et al., 2009; Terwee et al., 2006). See Section 
2.4.3. for details on the reliability of the WOMAC questionnaire. 
  76 
Health and Well-being 
2. Short-Form 36 Health Survey (SF-36) was used to measure 
functional health and well-being. It contains 8 health domains 
(Physical functioning (PF), Role limitations due to physical functioning 
(RP), Bodily pain (BP), General health perceptions (GH), Vitality (VT), 
Social functioning (SF), Role limitations due to emotional problems 
(RE) and Mental health (MH)) and 2 component summary measures 
(Physical component summary (PCS) and Mental component 
summary (MCS)) (McHorney et al., 1994). The SF-36 questionnaire 
has demonstrated good discriminant validity and adequate reliability 
(Cronbach’s Alpha: 0.75 to 0.91) (Kosinski et al., 1999; Kosinski et al., 
1999; McHorney et al., 1994).  
Comorbid Conditions 
3. Self-Administered Comorbidity Questionnaire (SCQ) is a 15-item 
self-report questionnaire that assesses for the presence of 12 medical 
conditions for people with no prior medical knowledge. There are an 
additional 3 optional questions regarding any other medical conditions. 
See Section 2.4.3. for details on the reliability of the SCQ 
questionnaire. 
Pain 
4. PainDETECT is a self-report screening tool to identify neuropathic 
pain components (Freynhagen & Baron, 2006). It consists of 9 items 
over 3 categories: pain quality, pain pattern and pain radiation. It has 
also been used in a number of studies looking at the presence of 
neuropathic pain components in other musculoskeletal conditions 
including osteoarthritis (Gwilym et al., 2011; Jespersen et al., 2010; 
Moss et al., 2017; Ohtori et al., 2012; Shigemura et al., 2011). See 
Section 2.4.3. for details on the reliability of the PainDETECT 
questionnaire. 
5. Pain Quality Assessment Scale (PQAS) is used to provide 
additional data regarding the dimensions of spontaneous pain 
experienced by participants (Victor et al., 2008). The PQAS was 
developed by adding additional items to the 10-item Neuropathic Pain 
Scale (NPS) (Jensen, 2006). The PQAS has been reported to provide 
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more comprehensive information about pain quality than alternative 
single dimensional pain scales (Jensen et al., 2012). It has also been 
shown to have validity for assessing treatment-related changes in pain 
quality and spatial characteristics (Jensen et al., 2006). Factor 
analysis of the PQAS questionnaire revealed 3 clear pain quality 
domains: (1) Paroxysmal pain, (2) Superficial pain and (3) Deep pain 
(Victor et al., 2008). See Section 2.4.3. for details on the reliability of 
the PQAS questionnaire. 
6. Pain Catastrophising Scale (PCS) is a self-report questionnaire 
describing thoughts and feelings that individuals might experience 
when in pain. It has 13 items over 3 subscales: rumination, 
magnification and helplessness (Sullivan et al., 1995). The PCS 
demonstrates adequate reliability (Cronbach’s Alpha: 0.87) (Sullivan et 
al., 1995); (Cronbach’s Alpha: 0.91 for rumination subscale; 0.75 for 
magnification subscale; 0.87 for helplessness subscale; 0.93 for total 
PCS) (Osman et al., 1997), and good criterion-related, concurrent and 
discriminant validity (Osman et al., 2000). 
7. Numeric Rating Scale (NRS) is a single 11-point numeric scale for 
rating pain intensity. It has also been shown to have high test-retest 
reliability (Pearson’s r: 0.95 to 0.96) (Ferraz et al., 1990), and high 
construct validity (0.86 to 0.95) (Downie et al., 1978; Ferraz et al., 
1990). 
Psychological Distress 
8. Patient Health Questionnaire-8 (PHQ-8) is an 8-item self-report 
questionnaire screening for severity of depression. The PHQ-8 is used 
in place of the PHQ-9 in this study, as the PHQ-8 can be done via self-
administration (Kroenke & Spitzer, 2002). PHQ-9 has demonstrated 
good reliability (Cronbach’s Alpha: 0.89) (Kroenke & Spitzer, 2002) 
and has been found to have a sensitivity of 77% and specificity of 94% 
for detection of a depressive disorder (Wittkampf et al., 2007). The 
PHQ-8 and PHQ-9 have been shown to have similar abilities in 
predicting any depressive disorder, as well as having similar 
sensitivity, specificity and positive prediction values (Kroenke & 
Spitzer, 2002). 
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Sleep Quality 
9. Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report 
questionnaire used to measure sleep quality and disturbances for the 
past one month and to discriminate between ‘good’ and ‘poor’ 
sleepers (Buysse et al., 1988). It contains 7 components: subjective 
sleep quality, sleep latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medications and daytime 
dysfunction. The PSQI has been demonstrated to have a high degree 
of internal homogeneity (Cronbach’s Alpha: 0.83), acceptable test-
retest reliability (Pearson’s r: 0.46 to 0.85), validity, and high sensitivity 
(89.6%) and specificity (86.5%) in distinguishing good and poor 
sleepers (Buysse et al., 1988). 
 
Physical / Sensory measures: 
Physical Measures 
1. Range of Motion (ROM) of the knee (flexion and extension) was 
measured using a handheld goniometer. Both active and passive 
ROM were measured. The standard handheld goniometer has been 
shown to be a reliable instrument for measurement of active ROM 
(ICC: 0.95 for flexion, ICC: 0.85 for extension) and passive ROM 
(intra-tester reliability (ICC: 0.99 for flexion, ICC: 0.98 for extension) 
and inter-tester reliability (ICC: 0.90 for flexion, ICC: 0.86 for 
extension)) of the knee (Clapper & Wolf, 1998; Watkins et al., 1991). 
The position for measurement of ROM was standardised to the supine 
position. 3 measurements were taken, with the mean calculated for 
analysis. 
2. Aggregated Locomotor Function Score (ALF) is a measure of 
observed locomotor function. It consists of 3 components: 8 metre 
walk time, stair ascent and descent time and transferring time 
(McCarthy & Oldham, 2004). 3 repetitions of the 8 metre walk were 
undertaken, with the mean calculated for analysis. 
• 4 repetitions of the stair ascent and descent were undertaken, with 
the mean calculated for analysis. 
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• 3 repetitions of the transfer were undertaken, with the mean 
calculated for analysis. 
The total time (sum of the mean time for each section) was used for 
analysis and comparison with previous studies. 
The ALF has been shown to have excellent intra-tester reliability 
(ICC2,k: 0.99; 95% CI: 0.98-0.99), low standard error of measurement 
(0.86 s) and low smallest detectable difference (9.5%) values 
(McCarthy & Oldham, 2004). 
3. Knee Extensor Strength was measured using a handheld 
dynamometer, with the participants in supine position, and the knee 
positioned at 35° of knee flexion. Participants were put through an 
isometric make test. The isometric make test is easier to perform and 
produces more reliable results (Smidt & Rogers, 1982). Martin et al. 
(2006) showed that testing of quadriceps strength in this position with 
handheld dynamometry shows a strong positive correlation (Pearson’s 
r: 0.91) and agreement with Biodex dynamometry values. 3 
measurements were taken, with the mean calculated for analysis. 
 
Quantitative Sensory Tests:  
Test sites: 
Apart from the sustained cold response test, all other quantitative sensory 
tests were performed at the medial joint line of both knees and over the 
ipsilateral extensor carpi radialis brevis (ECRB) muscle in the upper limb. For 
sustained cold response, the test site was at the ipsilateral ECRB. The ECRB 
muscle has been used previously in other quantitative sensory test studies 
(Slater et al., 2003; Slater et al., 2005). The site was located by using the 
standardized method as described by Riek et al. (2000). The quantitative 
sensory testing was conducted with the participant lying in a relaxed position 
on a plinth. With the exception of the sustained cold response test, the 
method of limits approach was used for all of the quantitative sensory tests 
stated below. 
 
4. Pressure Pain Threshold (PPT) was measured using an electronic, 
digital algometer (Somedic, Sweden) with a 1cm² round rubber tip at 
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the end connected to a pressure transducer within the handle of the 
unit. The algometer was applied at a 90° angle to the skin at a 
constant rate of 40 kPa/sec. The subject was given a control switch 
and instructed to press the switch when the sensation changed from 
pressure to pain, at which time the test was terminated. 1 practice trial 
was followed by 3 measurements, with the mean calculated for 
analysis (Lacourt et al., 2012; Persson et al., 2004). See Section 
2.4.3. for details on the reliability of PPT. 
5. Cold/Heat Detection and Pain Thresholds were measured using a 
peltier thermode (Medoc, Israel). The minimum temperature was set at 
0°C, and the maximum temperature set at 50°C. A 30x30mm contact 
probe was attached to the test site with a strap and the participant was 
given several minutes to adapt to the baseline temperature of 32°C. 
When the device was activated, the thermode temperature rose or fell 
at a rate of 1°C/sec. This rate of temperature change has been shown 
to reduce intra-individual variation (Palmer et al., 2000). The subject 
was given a control switch and instructed to press the switch when 
they perceived the relevant sensation (i.e. if it was a heat detection 
threshold test, the participant was instructed to depress the switch 
once they detected heat). The respective thermal detection thresholds 
were always tested before the thermal pain thresholds to minimise 
sensitization of receptors by the noxious input. The thresholds were 
tested in the order of cold detection threshold (CDT), cold pain 
threshold (CPT), heat detection threshold (HDT) and heat pain 
threshold (HPT). For each threshold, 1 practice trial was followed by 
3 measurements, with the mean calculated for analysis. Each stimulus 
was separated by a randomised 3 to 6 second interval. See Section 
2.4.3. for details on the reliability of the thermal detection and pain 
thresholds. 
6. Vibration Detection Threshold (VDT) was assessed using an 
electronic vibrameter (Medoc, Israel), which has a threshold range of 
0-130µm, at a rate of 0.5µm/sec. The participant was given a control 
switch and instructed to press the switch when they first become 
aware of the stimulus. VDT has demonstrated excellent test-retest 
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reliability (ICC: 0.86; 95% CI: 0.79-0.91) in normals (Felix & 
Widerström-Noga, 2009). 1 practice trial was followed by 3 
measurements, with the mean calculated for analysis. 
7. Sustained Cold Response was tested using a newly developed 
wearable peltier thermode (Dhama, India). This battery powered 
device creates a cool temperature through standard thermo-electric 
methods but has been designed to be worn on the forearm. The 
device comprises a 2x3cm thermode plate that is embedded in a rigid 
arm wrap. The wrap is kept damp in order to facilitate dissipation of 
the heat produced by the cooling process. The thermode can be set to 
several different specific temperatures using touch controls and 
maintains this temperature for up to 5 minutes (Figure 4.1).  
 
       
 Figure 4.1 
 Photograph of the Dhama thermode system showing the control unit and the pad for 
application to the arm. 
 
For this study, the Dhama thermode was set to 12˚C. Before 
application to each participant, the external surface was sprayed with 
water and the thermode plate temperature checked using a thermistor. 
It was then applied to the participant’s ECRB test site for 5 minutes, 
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using the timer on the Algotect Descriptor Index (ADI) Apple iPad 
application (see below). On completion of the 5-minute test it was 
removed from the patient’s forearm before being turned off.  
Response to the sustained cold stimulus was measured using the ADI 
scales, delivered via an Apple iPad application (Moss, 2013). The ADI 
combines measures of perceived sensation intensity with a measure 
of sensory quality. Intensity of sensation was assessed using the 4 
calibrated 100mm VAS sliding scales shown on the iPad touch screen 
(Figure 4.2). 
 
 
Figure 4.2 
Screenshot of the 4 calibrated 100mm VAS sliding scales to assess cold, heat, 
unpleasantness and pain. 
 
Participants were also asked to select words that best describe the 
quality of the sensation experienced from a set of descriptors based 
on the key sensory elements of the McGill Pain Questionnaire 
descriptor list (Melzack, 1975) (Figure 4.3).  
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Figure 4.3 
Screenshot of the ADI descriptors showing the range of sensory descriptors that can 
be selected. 
 
Ratings for either intensity or quality were taken every 30-seconds for 
5-minutes.  A previously developed algorithm was used to calculate a 
total ADI score based on the combined intensity and quality responses 
(Moss, 2013). As well as calculating a total sustained cold ADI score 
(min 0, max 9), a subscore for combined VAS intensity for cold, heat, 
unpleasantness and pain (max score 4) and a subscore for sensation 
quality (mean word score (MWS), max score 5) were also calculated, 
using the method described by Moss (2013).  
 
4.4.4. Power Analysis 
Primary hypotheses: An a priori power and sample size analysis was 
calculated based on anticipated difference between ‘good’ and ‘poor’ 
outcome groups at 6 months post-surgery in self-report, physical and QST 
measures (primary hypothesis 2). The sample size was calculated using data 
from Study 1 in patients at 12-18 months post-TKR.  
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The mean and SD data for good and poor outcome groups for the key QST 
measures of knee PPT, knee CPT and key self-report measures of 
PainDETECT and WOMAC Pain are shown in Table 4.2.  
 
Table 4.2: Mean and SD values for Knee PPT, PainDETECT and WOMAC 
Total 
 Knee PPT (kPa) PainDETECT WOMAC Pain 
 Mean SD Mean SD Mean SD 
Good 
outcome 
group 
416.72 254.83 3.03 3.62 2.13 2.46 
Poor 
outcome 
group 
282.64 167.92 7.27 5.80 5.77 3.96 
 
Using this data and with alpha set at 0.05, for a power of 80%, it was 
calculated that a sample size of 108 (108 for knee PPT, 60 for PainDETECT 
and 96 for WOMAC Pain) would be needed to show a significant difference 
between groups. The targeted sample size was therefore set at 120 to 
account for a 10% dropout rate. 
 
Secondary Hypotheses: For the logistic regression required for secondary 
hypotheses 1, 2 & 3, an initial sample size analysis was completed (alpha set 
at 0.05; beta at 80%). The widely-accepted assumption of 10 outcomes per 
predictor variable is assumed. In the previous study (Study 1) the ratio of 
participants with good to poor KSS outcome at 12 months post-TKR at JRAC 
was approximately 3:1. It is anticipated that 4 predictor variables will be 
applied to each of the logistic regression models. This would therefore mean 
that a sample size of approximately 120 would be needed (30 participants 
with poor KSS outcomes) (Stoltzfus, 2011).  
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4.4.5. Data Analysis 
Cut off point for mild, moderate and severe pain 
For neck pain, the Numeric Rating Scale (NRS) cut off points for mild, 
moderate and severe pain are 1-3, 4-6 and 7-10 (Fejer et al., 2005).  
Zelman et al. (2005) established that the NRS cut off points for mild, 
moderate and severe pain for diabetic peripheral neuropathy are 1-3 (mild), 
4-6 (moderate) and 7-10 (severe). For cancer pain, the optimal NRS pain cut 
off points based on the degree of interference with cancer patients’ function 
for mild, moderate and severe pain are: 1-4 (mild), 5-6 (moderate) and 7-10 
(severe) (Serlin et al., 1995). The NRS cut off points for phantom limb pain 
(mild pain: 1-4, moderate pain: 5-7, severe pain: 8-10), back pain (mild pain: 
1-4, moderate pain: 5-6, severe pain: 7-10) and pain ‘in general’ (mild pain: 
1-3, moderate pain: 4-6, severe pain: 7-10) all differ slightly (Jensen et al., 
2001).  
Due to the slight differences in pain cut off points in the literature, NRS 
scores of 1-3, 4-6 and 7-10 will be classified as mild, moderate and severe 
pain for the purposes of this study. 
 
‘Good’ and ‘Poor’ Outcome  
Outcome at 6 months post-surgery according to the self-report Knee Society 
Score (KSS) (Insall et al., 1989) of ‘good’ or ‘poor’ was used to group patients 
dichotomously. Group allocation was determined by the pain component of 
the KSS as per Wright et al. (2014). The pain component of the KSS is 
categorized as no pain (none), mild or occasional pain (stairs only, walking 
and stairs), moderate pain (occasional, continual), and severe pain (Insall et 
al., 1989). Participants who reported no pain and mild or occasional pain 
were allocated to the ‘good’ outcome group, and those with moderate to 
severe pain were allocated to the ‘poor’ outcome group.  
 
Criterion Variable 
At 3 months post-TKR, the criterion variable for the logistic regression model 
was the average pain (moderate pain and above) felt over the last 4 weeks in 
the PainDETECT questionnaire (Freynhagen & Baron, 2006).  
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At 6 months post-TKR, the criterion variable for the logistic regression model 
was the KSS outcome (Insall et al., 1989). The KSS has been demonstrated 
to have adequate convergent construct validity, and its pain and function 
scores have moderate to strong correlations to the pain and function domains 
of the WOMAC and SF-36 (Lingard et al., 2001). Participants were classified 
using the KSS as belonging to either the ‘good’ or ‘poor’ outcome group.  
 
Predictor Variables 
Predictor variables were selected according to previous studies suggesting 
likely risk factors for persistent post-operative pain (Elson & Brenkel, 2006; 
Kehlet et al., 2006; Lunn et al., 2013; Macrae & Davies, 1999; Suokas et al., 
2012; Vilardo & Shah, 2011; Wylde et al., 2011; Wylde, Jeffery, et al., 2012). 
Self-reported measures of pain, function, psychological distress and quality 
of life and physical / sensory measures were used.  
 
Confounding Variables 
A range of confounding variables were also measured. They included age, 
gender, body mass index (height, weight), smoker or non-smoker and 
duration of pain pre-operatively. Presence of post-operative infection 
(prosthesis, respiratory or other) was also recorded as a potentially 
confounding factor. 
 
Other types of data that were collected from medical notes include analgesia 
used (pre-operatively, intra-operatively and post-operatively), type of 
prosthesis used for the knee replacement and surgical approach (Appendix 
3). Data with regards to treatment received before (Appendix 4) and after the 
total knee replacement were also collected (Appendix 5).  
 
IBM SPSS Statistics version 22 was used for the statistical analysis, with 
alpha set at 0.05. Normality of the data was determined by using the Shapiro-
Wilk test, any variable that had p>0.05 was normally distributed. Levene´s 
test was used to confirm whether the data for each group demonstrated 
equal variance. Degrees of freedom were corrected when equal variances 
were not assumed (p<0.05).  
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Group differences were analysed using Independent-Samples t test if the 
variable was normally distributed, and Mann-Whitney U test was used if the 
variable was not normally distributed.  
Logistic regression was used to determine the predictive value of a range of 
key measures (quantitative sensory testing, PainDETECT score, functional 
level, quality of life and psychological distress) in determining persistent pain 
post-TKR. Variables that were significant in the test for group differences 
were entered into the univariate logistic regression. Following that, 
multivariate logistic regression analysis was performed by entering the 
variables that showed significance on the univariate logistic regression 
analysis. 
In addition, receiver operating characteristic (ROC) curve analysis was used 
to determine the sensitivity and specificity of any measures identified in the 
logistic regression model in terms of their capacity to identify those who did 
or did not have persistent pain post-surgery. All data were reported as mean 
± standard deviation. Significant results were considered as p < 0.05. Table 
4.3 shows the statistical tests for each hypotheses. 
 
Table 4.3: Hypotheses and Statistical Test Used 
Hypotheses and Related Data Statistical Analysis 
1. Difference in pre-operative baseline 
measures between ‘no to low pain’ versus 
‘moderate to severe pain’ groups at 3 
months following TKR surgery. 
Independent-Samples T 
tests (Normal data) 
Mann-Whitney U Tests 
(Non-normal data) 
2. Difference in pre-operative baseline and at 3 
months post-surgery measures between 
participants categorized as showing ‘poor’ 
versus ‘good’ outcome groups at 6 months 
following TKR surgery 
Independent-Samples T 
tests (Normal data) 
Mann-Whitney U Tests 
(Non-normal data) 
3. Predicting membership of the moderate to 
severe pain group at 3 months post-surgery 
using pre-operative baseline measures. 
Logistic Regression 
ROC Curve Analysis 
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4. Predicting membership of the ‘poor’ outcome 
group at 6 months post-surgery using pre-
operative baseline measures. 
Logistic Regression 
ROC Curve Analysis 
5. Predicting membership of the ‘poor’ outcome 
group at 6 months post-surgery using pre-
operative baseline CPT. 
ROC Curve Analysis 
6. Predicting membership of the ‘poor’ outcome 
group at 6 months post-surgery using pre-
operative baseline PainDETECT. 
ROC Curve Analysis 
 
4.5. Results 
4.5.1. Recruitment of participants 
A total of ninety-two participants took part in the study.  
Figure 4.4 shows the participant numbers and loss to follow-up through the 
phases of the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Underwent pre-operative assessment (n=92) 
• Completed full assessment (n=90) 
• Completed only self-report measures (due to 
transport issues, participants were unable to 
attend physical assessment) (n=2) 
Follow-up at 3 months post-
TKR 
Assessed for eligibility 
(n=411) 
Excluded (n=319) 
• Not meeting inclusion 
criteria (n=38) 
• Declined to participate  
(n=281) 
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Figure 4.4  
Flow diagram of participants through the phases of the study.  
 
4.5.2. Pain level at 3 months post-TKR 
Participant demographics at 3 months post-TKR 
At 3 months post-surgery, there were seventy-four participants whose data 
were used for analysis. Fifty-seven participants in the ‘no to low pain’ 
(Numeric Rating Scale (NRS) < 4 group (twenty-three male and thirty-four 
female: mean age 70.03  7.26, range 51-82) and seventeen participants in 
the ‘moderate to severe pain’ (NRS ≥ 4) group (seven male and ten female: 
mean age 67.65  7.68, range 55-80) (Table 4.4). 
 
Table 4.4: Participant demographics at 3 months post-TKR 
 No to Low Pain group 
(n = 57) 
Moderate to Severe Pain 
group (n = 17) 
Gender (M : F) 
Age (years) 
Age (range) 
23 : 34 
70.03 ± 7.26 
51 to 82 
7 : 10 
67.65 ± 7.68 
55 to 80 
 
 
Participant numbers at 6 months post-TKR at the 
point of write up of this thesis (n=61) 
• Lost to follow-up (fell into coma) (n=1) 
 
Analysed (n=60) 
Follow-up at 6 months post-
TKR 
Participant numbers at 3 months post-TKR at the 
point of write up of this thesis (n=75) 
• Lost to follow-up (withdrew from study) (n=1) 
• Completed only self-report measures (due to 
transport issues, participants were unable to 
attend physical assessment) (n=3) 
Analysed (n=74) 
  90 
Primary Hypothesis 1: 
There will be a difference at pre-operative baseline in measures of QST, 
pain, functional level, health status, psychological distress and sleep 
quality between participants categorized as having ‘no to mild pain’ (<4 
in NRS pain) versus ‘moderate to severe pain’ (≥4 in NRS pain) at 3 
months following TKR surgery. 
 
• Quantitative Sensory Testing 
Pressure Pain Threshold 
There were no significant differences between the ‘no to mild pain’ and 
‘moderate to severe pain’ groups for pre-operative pressure pain threshold 
across all test sites (Table 4.5). 
 
Table 4.5: Pre-operative PPT (kPa) (3 months post-TKR) 
Site 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
Ipsilateral ECRB 282.88 121.71 289.02 140.58 0.893 
Contralateral Knee 349.87 180.92 267.56 133.99 0.079 
Ipsilateral Knee 337.06 203.03 327.54 171.99 0.923 
All sites (Average) 323.27 157.86 294.71 135.28 0.594 
* Indicates statistical significance at p  0.05 
 
Heat Detection and Heat Pain Thresholds  
Pre-operatively, the ‘moderate to severe pain’ group detected changes in 
heat sensation significantly later than the ‘no to mild pain’ group at the 
contralateral knee (p=0.001), but not at the ECRB site (p=0.115) and the 
operated knee (p=0.537). Pre-operative heat pain thresholds were not 
significantly different across all sites between groups.  
Taking an average of readings at all sites, there was a significant difference 
in pre-operative heat detection threshold (p=0.023) between the ‘no to mild 
pain’ and ‘moderate to severe pain’ groups (Table 4.6). 
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Table 4.6: Pre-operative HDT and HPT (°C) (3 months post-TKR) 
Site Test 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
HDT 
HPT 
36.23 
46.19 
2.79 
3.18 
37.16 
47.15 
3.1 
3.26 
0.115 
0.154 
Contralateral 
Knee 
HDT 
HPT 
37.19 
44.9 
3.53 
3.46 
40.24 
45.66 
4.06 
4.32 
0.001* 
0.247 
Ipsilateral 
Knee 
HDT 
HPT 
37.44 
44.59 
3.6 
3.8 
38.16 
46.27 
4.12 
3.27 
0.537 
0.095 
All Sites 
Average 
HDT 
HPT 
36.95 
45.23 
2.63 
2.9 
38.53 
46.35 
2.92 
2.78 
0.023* 
0.112 
* Indicates statistical significance at p  0.05 
 
Cold Detection and Cold Pain Thresholds  
The ‘moderate to severe pain’ group demonstrated a reduction in sensory 
acuity as compared to the ‘no to mild pain’ group, perceiving cold at a 
significantly lower temperature at the ECRB site (p=0.049). Cold pain 
thresholds were not significantly different across all sites between groups. 
Taking an average of readings at all sites, there were no significant group 
differences in pre-operative cold detection (p=0.073) and cold pain threshold 
(p=0.974) (Table 4.7). 
 
Table 4.7: Pre-operative CDT and CPT (°C) (3 months post-TKR) 
Site Test 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
CDT 
CPT 
28.25 
5.64 
2.68 
7.48 
26.23 
7.87 
3.87 
10.21 
0.049* 
0.680 
Contralateral 
Knee 
CDT 
CPT 
27.54 
6.84 
2.94 
9.71 
26.71 
6.21 
2.54 
10.16 
0.125 
0.766 
Ipsilateral 
Knee 
CDT 
CPT 
28.1 
8.77 
1.96 
9.75 
26.69 
10.26 
3.14 
11.15 
0.082 
0.573 
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All Sites 
Average 
CDT 
CPT 
27.96 
7.09 
2.23 
7.63 
26.55 
8.11 
2.82 
9.53 
0.073 
0.974 
* Indicates statistical significance at p  0.05 
 
Vibration Detection Threshold  
The ‘moderate to severe pain’ group detected changes in vibration sensation 
significantly later than the ‘no to mild pain’ group across all 3 test sites 
(ECRB: p<0.001; Contralateral knee: p<0.001; Operated knee: p<0.001). 
This demonstrated that the ‘moderate to severe pain’ group had reduced 
sensory acuity as compared to the ‘no to mild pain’ group (Table 4.8). 
 
Table 4.8: Pre-operative VDT (µm) (3 months post-TKR) 
Site 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
4.06 2.85 13.51 10.81 <0.001* 
Contralateral 
Knee 
6.61 7.39 18.88 16.05 <0.001* 
Ipsilateral 
Knee 
7.64 9.92 20.81 16.97 <0.001* 
All Sites 
(Average) 
6.1 5.95 17.73 13.33 <0.001* 
* Indicates statistical significance at p  0.05 
 
Sustained Cold Response 
There were no significant differences in the pre-operative sustained cold 
response ADI scores between groups (Table 4.9). 
 
Table 4.9: Pre-operative Sustained Cold Response ADI (3 months post-TKR) 
 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
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ADI VAS 1.26 1.09 1.76 1.39 0.189 
MWS 2.45 0.76 2.46 0.68 0.867 
 ADI Total 3.71 1.51 4.23 1.76 0.226 
* Indicates statistical significance at p  0.05 
 
• Pain 
PainDETECT  
The ‘moderate to severe pain’ group had significantly higher scores in pre-
operative Pain (Now) (p=0.003) and Pain (Average) (p=0.037) as compared 
to the ‘no to mild pain’ group (Table 4.10).  
 
Table 4.10: Pre-operative Pain levels (3 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Pain (Now) 2.82 2.3 4.88 2.47 0.003* 
Pain (Strongest) 6.58 2.24 7.53 1.94 0.102 
Pain (Average) 4.63 2.03 5.82 2.01 0.037* 
* Indicates statistical significance at p  0.05 
 
The pre-operative PainDETECT scores were significantly higher in the 
‘moderate to severe pain’ group (p<0.001). The mean value for the ‘moderate 
to severe pain’ group was 13.88 suggesting that a neuropathic pain 
component could be present in some members of this group (Table 4.11). 
 
Table 4.11: Pre-operative PainDETECT score (3 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
PainDETECT 7.70 4.47 13.88 6.49 <0.001* 
* Indicates statistical significance at p  0.05 
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PQAS 
The ‘moderate to severe pain’ group scored significantly higher for the pre-
operative PQAS Paroxysmal (p=0.008) and PQAS Deep (p=0.001) quality 
factors (Table 4.12). 
 
Table 4.12: Pre-operative PQAS Quality Factors (3 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Paroxysmal 12.65 8.84 20.18 10.48 0.008* 
Superficial 2.88 4.44 7.53 12.5 0.217 
Deep 13.38 8.74 22.65 11.26 0.001* 
* Indicates statistical significance at p  0.05 
 
PCS  
The ‘moderate to severe pain’ group scored higher on all 3 subscales of the 
PCS, but there were only significant differences in the Rumination (p=0.038) 
and Magnification (p=0.001) subscales. The ‘moderate to severe pain’ group 
also scored significantly higher on the total score of the PCS (p=0.016) 
(Table 4.13). 
 
Table 4.13: Pre-operative PCS scores (3 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Rumination 3.02 3.37 5.41 4.56 0.038* 
Magnification 1.39 1.92 2.82 1.81 0.001* 
Helplessness 3.37 3.88 4.94 4.01 0.071 
Total 7.77 8.41 13.18 9.31 0.016* 
* Indicates statistical significance at p  0.05 
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• Functional Level 
ALF 
The ‘moderate to severe pain’ group were significantly slower pre-operatively 
in the ALF Walk (p=0.018) and Transfer (p=0.002) components as compared 
to the ‘no to mild pain’ group (Table 4.14). The ALF Stairs component was 
not analysed as the data set was incomplete due to the lack of a suitable 
stairs assessment area for 35 participants. 
 
 Table 4.14: Pre-operative ALF (Secs) (3 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
8 Metre Walk 8.89 3.84 10.26 3.62 0.018* 
Transfer 10.39 4.16 15.54 10.76 0.002* 
Total 19.27 7.76 25.8 14.2 0.003* 
* Indicates statistical significance at p  0.05 
 
ROM  
There were no significant group differences in both pre-operative active and 
passive range of motion at the operated knee (Table 4.15). 
 
Table 4.15: Pre-operative ROM of operated knee (Degrees) (3 months post-
TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Flexion 
(AROM) 
113.03 15.46 110.81 17.08 0.571 
Extension 
(AROM)** 
4.39 4.38 5.55 5.4 0.445 
Flexion 
(PROM) 
116.78 16.26 113.84 18.71 0.700 
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Extension 
(PROM)** 
3.58 4.17 4.81 5.16 0.339 
* Indicates statistical significance at p  0.05 
** Extension values are expressed as lack of degrees to full extension 
 
Knee Extensor Strength  
There was no significant difference in pre-operative knee extensor strength 
across groups (p=0.264) (Table 4.16). 
 
Table 4.16: Pre-operative knee extensor strength (Kg) (3 months post-TKR) 
 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
Knee 
Extensor 
Strength 
18.28 8.83 15.02 5.8 0.264 
* Indicates statistical significance at p  0.05 
 
• Health status 
SF-36  
There were significant differences in the SF-36 PF (p=0.024), BP (p=0.002), 
GH (p=0.009), VT (p=0.017), SF (p=0.037), MH(p=0.05) and PCS (0.004) 
health domains between the ‘no to mild pain’ and ‘moderate to severe pain’ 
groups (Table 4.17). These results indicate that the ‘moderate to severe pain’ 
group had more limitations in performing physical activities (PF), higher 
levels of pain that impacted on normal activities (BP), a belief that they were 
in worse health (GH), lower energy levels (VT), ability to perform normal 
social activities was hampered due to interference from physical or emotional 
problems (SF), increased feelings of nervousness and depression (MH) and 
more limitations in physical functioning and role participation due to physical 
problems, a high degree of bodily pain, and poor general health (PCS).  
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Table 4.17: Pre-operative SF-36 scores (3 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
PF 40.54 24.55 25 16.96 0.024* 
RP 52.08 28.18 37.5 27.51 0.072 
BP 48.75 17.57 32.94 18.82 0.002* 
GH 78.28 16.71 64.65 20.23 0.009* 
VT 57.13 24.28 42.28 20.79 0.017* 
SF 78.01 25.19 61.76 28.46 0.037* 
RE 75.73 27.47 68.63 32.48 0.464 
MH 81.84 14.66 71.18 20.96 0.05* 
PCS 38.60 7.77 32.24 7.65 0.004* 
MCS 55.52 10.1 50.86 13.52 0.21 
* Indicates statistical significance at p  0.05 
 
SCQ 
There was no significant group difference in the number of co-morbid 
conditions reported (p=0.07). However, it is interesting to note that the 
‘moderate to severe pain’ group was afflicted on average with 3 more co-
morbidities as compared to the ‘no to mild pain’ group (Table 4.18). 
 
Table 4.18: Pre-operative SCQ (3 months post-TKR) 
 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
SCQ 6.42 3.1 9.41 6.06 0.07 
* Indicates statistical significance at p  0.05 
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WOMAC  
The ‘moderate to severe pain’ group scored significantly higher on the pre-
operative WOMAC Pain (p<0.001), WOMAC Function (p=0.001) and 
WOMAC Total (p<0.001) scores, indicating that they had higher levels of 
pain and more difficulty with daily activities as compared to the ‘no to mild 
pain’ group (Table 4.19). 
 
Table 4.19: Pre-operative WOMAC scores (3 months post-TKR) 
 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
Pain 7.89 3.2 11.82 4.25 <0.001* 
Stiffness 3.81 1.38 4.65 1.5 0.075 
Function 26.91 11.25 37.88 11.96 0.001* 
Total 38.61 14.86 54.35 17.03 <0.001* 
* Indicates statistical significance at p  0.05 
 
• Psychological distress 
PHQ-8  
The ‘moderate to severe pain’ group scored significantly higher on the pre-
operative PHQ-8 as compared to the ‘no to mild pain’ group (p=0.002) (Table 
4.20). Based on the PHQ-8 scoring system, the ‘moderate to severe pain’ 
group was classified on average as having mild depression. The respective 
surgeons were informed if their participants (n=10) had a score of ≥ 10 on the 
PHQ-8.   
 
Table 4.20: Pre-operative PHQ-8 score (3 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
PHQ-8 3.58 3.99 7.88 6.24 0.002* 
* Indicates statistical significance at p  0.05 
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Sleep Quality  
The ‘moderate to severe pain’ group scored significantly lower in PSQI sleep 
quality (p=0.004) and day dysfunction (p=0.036), indicating that they had 
worse sleep quality and an increase in daytime disruption as compared to the 
‘no to mild pain’ group (Table 4.21).   
 
Table 4.21: Pre-operative PSQI scores (3 months post-TKR) 
 
No to Mild Pain Moderate to 
Severe Pain p 
Mean SD Mean SD 
Sleep quality 1.04 0.76 1.76 0.83 0.004* 
Sleep latency 1.32 1.09 1.47 1.33 0.714 
Sleep duration 1.12 0.98 1.47 1.07 0.216 
Sleep efficiency 1.12 1.25 1.47 1.23 0.271 
Sleep disturbances 1.53 1.39 1.71 0.66 0.079 
Sleep medications 0.54 1 0.82 1.29 0.463 
Day dysfunction 0.81 0.72 1.18 0.39 0.036* 
Total 7.47 4.38 9.88 5.02 0.079 
* Indicates statistical significance at p  0.05 
 
Secondary Hypothesis 1: 
Pre-operative baseline measures (which may include cold pain 
threshold (CPT), pressure pain threshold (PPT), PainDETECT score, 
WOMAC score, psychological distress or sleep quality index score) will 
predict pain levels at 3 months post-TKR surgery. 
 
Univariate Logistic Regression 
A range of pre-operative variables were statistically significant in the 
univariate logistic regression analysis. These included body mass index, a 
range of QST measures, ALF measures, a range of pain report measures, 
the PHQ8 score, sleep quality measures and several components of the SF-
36. The univariate logistic regression results are in table 4.22. 
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Table 4.22: Logistic regression (univariate) for ‘moderate to severe pain’ 
group at 3 months post-surgery 
Univariate Logistic Regression 
 OR 95%CI (OR) p 
BMI 1.11 (1.01, 1.23) 0.027* 
Ipsilateral ECRB CDT  1.03 (0.97, 1.10) 0.325 
Contralateral Knee HDT  1.21 (1.05, 1.39) 0.007* 
HDT All Sites Average 1.22 (1.01, 1.47) 0.045* 
Ipsilateral ECRB VDT  1.46 (1.21, 1.77) <0.001* 
Contralateral Knee VDT  1.10 (1.04, 1.17) 0.002* 
Ipsilateral Knee VDT  1.08 (1.03, 1.13) 0.002* 
VDT All Sites Average 1.15 (1.06, 1.25) 0.001* 
ALF 8 Metre Walk  1.09 (0.96, 1.24) 0.206 
ALF Transfer  1.14 (1.02, 1.28) 0.024* 
ALF Total 1.14 (1.02, 1.28) 0.018* 
WOMAC Pain 1.36 (1.13, 1.63) 0.001* 
WOMAC Function 1.09 (1.03, 1.15) 0.003* 
WOMAC Total 1.07 (1.02, 1.11) 0.002* 
Pre-operative Pain Now 1.42 (1.11, 1.81) 0.005* 
Pre-operative Pain Average 1.34 (1.01, 1.78) 0.042* 
PainDETECT 1.24 (1.10, 1.41) 0.001* 
PCS Rumination 1.17 (1.02, 1.34) 0.030* 
PCS Magnification 1.40 (1.07, 1.84) 0.015* 
PQAS Paroxysmal Quality Factor 1.09 (1.02, 1.15) 0.008* 
PQAS Deep Quality Factor 1.10 (1.03, 1.17) 0.003* 
PHQ8 1.19 (1.05, 1.35) 0.006* 
PSQI Sleep Quality 3.20 (1.48, 6.91) 0.003* 
PSQI Day Dysfunction 2.35 (0.99, 5.56) 0.052 
SF36 PF 0.97 (0.94, 1.00) 0.022* 
SF36 BP 0.95 (0.92, 0.99) 0.005* 
SF36 GH 0.96 (0.93, 0.99) 0.011* 
SF36 VT 0.98 (0.95, 1.00) 0.031* 
SF36 SF 0.98 (0.96, 1.00) 0.032* 
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SF36 PCS 0.89 (0.81, 0.97) 0.008* 
* Indicates statistical significance at p  0.05 
 
Multivariate Logistic Regression 
Multivariate logistic regression analysis was performed by entering the pre-
operative variables that showed significance on the univariate logistic 
regression analysis. 3 logistic regression models were considered (Physical 
measures only, Self-report measures only and Combined measures). 
Physical measures 
The physical measures multivariate logistic regression analysis identified 
ipsilateral ECRB VDT as the sole pre-operative physical measures predictor 
of membership into the ‘moderate to severe pain’ group at 3 months post-
TKR surgery (Table 4.23). 
  
Table 4.23: Logistic regression (multivariate) for ‘moderate to severe pain’ 
group at 3 months post-surgery (Physical measures) 
Multivariate Logistic Regression 
 OR 95%CI (OR) p 
Ipsilateral ECRB VDT  1.46 (1.21, 1.77) <0.001* 
* Indicates statistical significance at p  0.05 
 
ROC curve analysis was performed on ipsilateral ECRB VDT to ascertain the 
cut-off point, as well as its sensitivity and specificity (Figure 4.5). 
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Figure 4.5  
ROC curve for pre-operative ipsilateral ECRB VDT. 
 
The area under the curve (AUC) was 0.852 (95% CI: 0.73, 0.98) (p<0.001), 
indicating that pre-operative ipsilateral ECRB VDT testing was significantly 
better than chance in predicting membership into the ‘moderate to severe 
pain’ group at 3 months post-TKR surgery (Table 4.24). 
 
Table 4.24: AUC for pre-operative ipsilateral ECRB VDT 
   Asymptotic 95%CI 
Area Std. Error Asymptotic Sig. Lower Bound Upper Bound 
0.852 0.063 0.000* 0.73 0.98 
* Indicates statistical significance at p  0.05 
 
A pre-operative ipsilateral ECRB VDT reading of 6.97µm (sensitivity: 0.824, 
specificity 0.877) gave a positive likelihood ratio of 1.46 for membership into 
the ‘moderate to severe pain’ group at 3 months post-TKR surgery. 
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Self-report measures 
The self-report measures multivariate logistic regression analysis identified 
PainDETECT and the PHQ8 questionnaire as pre-operative self-report 
measures that predict membership into the ‘moderate to severe pain’ group 
at 3 months post-TKR surgery (Table 4.25). 
 
Table 4.25: Logistic regression (multivariate) for ‘moderate to severe pain’ 
group at 3 months post-surgery (Self-report measures) 
Multivariate Logistic Regression 
 OR 95%CI (OR) p 
PainDETECT 1.22 (1.07, 1.39) 0.003* 
PHQ8 1.15 (1, 1.33) 0.045* 
* Indicates statistical significance at p  0.05 
 
ROC curve analysis was performed on PainDETECT and PHQ8 scores to 
ascertain the cut-off point, as well as the sensitivity and specificity of these 
measures (Figure 4.6). 
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Figure 4.6  
ROC curves for pre-operative PainDETECT and PHQ8. 
 
The AUC for pre-operative PainDETECT was 0.798 (95% CI: 0.66, 0.93) 
(p<0.001) and pre-operative PHQ8 was 0.741 (95% CI: 0.60, 0.88) indicating 
that these 2 self-report measures were significantly better than chance in 
predicting membership into the ‘moderate to severe pain’ group at 3 months 
post-TKR surgery (Table 4.26). 
 
Table 4.26: AUC for pre-operative PainDETECT and PHQ8 
    Asymptotic 95%CI 
Test Area Std. 
Error 
Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
PainDETECT 0.798 0.069 <0.001* 0.66 0.93 
PHQ8 0.741 0.07 0.003* 0.60 0.88 
* Indicates statistical significance at p  0.05 
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A pre-operative PainDETECT score of 11.5 (sensitivity: 0.765, specificity 
0.877) gave a positive likelihood ratio of 1.22, and a pre-operative PHQ8 
score of 4.5 (sensitivity: 0.706, specificity 0.632) gave a positive likelihood 
ratio of 1.15 for membership into the ‘moderate to severe pain’ group at 3 
months post-TKR surgery. 
 
Combined measures 
The significant variables (pre-operative ipsilateral ECRB VDT, PainDETECT 
and PHQ8) that were identified from the above 2 models (Physical and Self-
report measures) were entered into a combined multivariate logistic 
regression analysis.  
Pre-operative ipsilateral ECRB VDT and PainDETECT were then identified 
as predictors for membership into the ‘moderate to severe pain’ group at 3 
months post-TKR surgery. (Table 4.27). 
 
Table 4.27: Logistic regression (multivariate) for ‘moderate to severe pain’ 
group at 3 months post-surgery (Combined measures) 
Multivariate Logistic Regression 
 OR 95%CI (OR) p 
Ipsilateral ECRB VDT  1.38 (1.13, 1.68) 0.002* 
PainDETECT 1.16 (1.01, 1.34) 0.041* 
* Indicates statistical significance at p  0.05 
 
ROC curve analysis was performed on pre-operative ipsilateral ECRB VDT 
and PainDETECT measures to determine the cut-off point of the individual 
measures and their respective sensitivity and specificity (Figure 4.7). 
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Figure 4.7  
ROC curves for pre-operative ipsilateral ECRB VDT and PainDETECT. 
 
The AUC for pre-operative ipsilateral ECRB VDT was 0.852 (95% CI: 0.73, 
0.98) (p<0.001) and PainDETECT was 0.787 (95% CI: 0.66, 0.93) (p=0.007) 
indicating that these measures were significantly better than chance in 
predicting membership into the ‘moderate to severe pain’ group at 3 months 
post-TKR surgery (Table 4.28). 
 
Table 4.28: AUC for pre-operative ipsilateral ECRB VDT and PainDETECT  
    Asymptotic 
95%CI 
Measure Area Std. Error Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
Ipsilateral ECRB 
VDT 
0.852 0.063 <0.001* 0.73 0.98 
PainDETECT 0.798 0.069 0.000* 0.66 0.93 
* Indicates statistical significance at p  0.05 
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A pre-operative ipsilateral ECRB VDT reading of 6.97µm (sensitivity: 0.824, 
specificity 0.877) gave a positive likelihood ratio of 1.38 and a PainDETECT 
score of 11.5 (sensitivity: 0.765, specificity: 0.877) gave a positive likelihood 
ratio of 1.16 for membership into the ‘moderate to severe pain’ group at 3 
months post-TKR surgery. 
 
Model Fit 
Model fit for the combined measures (pre-operative ipsilateral ECRB VDT 
and pre-operative PainDETECT) multivariate logistic regression was 
analysed using the ‘Omnibus Tests of Model Coefficients’ and the ‘Hosmer 
and Lemeshow Test’. 
Based on the results of the ‘Omnibus Tests of Model Coefficients’, the model 
for the combined measures (pre-operative ipsilateral ECRB VDT and pre-
operative PainDETECT) multivariate logistic regression is statistically 
significant (p < 0.0005) (Table 4.29). 
The results of the model summary indicate that there is a 38% probability of 
being in the ‘moderate to severe pain’ group at 3 months (Table 4.30) 
The results of the ‘Hosmer and Lemeshow Test’ is not statistically significant 
(p = 0.199), indicating that the model is not a poor fit (Table 4.31). 
 
Table 4.29: Omnibus Tests of Model Coefficients 
  Chi-square df Sig. 
Step 1 Step 30.505 1 0.000 
Block 30.505 1 0.000 
Model 30.505 1 0.000 
Step 2 Step 4.578 1 0.032 
Block 35.083 2 0.000 
Model 35.083 2 0.000 
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Table 4.30: Model Summary  
 -2 Log likelihood Cox & Snell R 
Square 
Nagelkerke R 
Square 
Step 1 49.260 0.338 0.512 
Step 2 44.681 0.378 0.572 
 
Table 4.31: Hosmer and Lemeshow Test 
 Chi-Square df Sig. 
Step 1 13.160 8 0.106 
Step 2 11.054 8 0.199 
 
4.5.3. Outcome group at 6 months post-TKR  
Participant Demographics at 6 months post-TKR 
At 6 months post-surgery, there were sixty participants. Fifty-one participants 
in the good outcome group (twenty-one male and thirty female: mean age 
69.9  7.47, range 51-82) and nine participants in the poor outcome group 
(three male and six female: mean age 66.56  7.42, range 55-77) (Table 
4.32). 
 
Table 4.32: Participant demographics at 6 months post-TKR 
 Good outcome group  
(n = 51) 
Poor outcome group  
(n = 9) 
Gender (M : F) 
Age (years) 
Age (range) 
21 : 30 
69.9 ± 7.47 
51 to 82 
3 : 6 
66.56 ± 7.42 
55 to 77 
 
Primary Hypothesis 2: 
There will be a difference at pre-operative baseline and at 3 months 
post-surgery in measures of QST, pain, functional level, health status, 
psychological distress and sleep quality between participants 
categorized as showing ‘poor’ versus ‘good’ outcomes at 6 months 
following TKR surgery. 
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Pre-operative baseline measures 
• Quantitative Sensory Testing 
Pressure Pain Threshold  
There were no significant pre-operative differences between groups in PPT 
at all test sites (Table 4.33). 
 
Table 4.33: Pre-operative PPT (kPa) (6 months post-TKR) 
Site 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Ipsilateral ECRB 289.16 123.05 260.81 121.74 0.425 
Contralateral Knee 350.18 177.5 257.83 155.38 0.111 
Ipsilateral Knee 341.85 176.98 275.58 156.72 0.305 
All sites (Average) 327.06 147.69 264.74 139.4 0.182 
* Indicates statistical significance at p  0.05 
 
Heat Detection and Heat Pain Thresholds  
The poor outcome group detected changes in heat sensation at significantly 
higher temperatures than the good outcome group at the contralateral knee 
(p=0.043). Pre-operative heat pain thresholds were not significantly different 
across all sites between groups (Table 4.34). 
 
Table 4.34: Pre-operative HDT and HPT (°C) (6 months post-TKR) 
Site Test 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
HDT 
HPT 
36.5 
46.42 
3.04 
3.03 
37.23 
47.5 
3.25 
2.67 
0.259 
0.329 
Contralateral 
Knee 
HDT 
HPT 
37.82 
45.36 
4 
3.3 
40.47 
45.92 
4.21 
4.99 
0.043* 
0.362 
Ipsilateral 
Knee 
HDT 
HPT 
37.72 
45.22 
3.75 
3.38 
39.01 
46.59 
4.42 
3.35 
0.21 
 0.255 
All Sites 
Average 
HDT 
HPT 
37.34 
45.67 
2.85 
2.67 
38.91 
46.67 
2.78 
2.2 
0.084 
0.293 
* Indicates statistical significance at p  0.05 
  110 
 
Cold Detection and Cold Pain Thresholds  
There were no significant differences between groups for cold detection and 
cold pain thresholds across all sites (Table 4.35). 
 
Table 4.35: Pre-operative CDT and CPT (°C) (6 months post-TKR) 
Site Test 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
CDT 
CPT 
27.87 
5.34 
2.85 
7.13 
26.14 
9.51 
3.72 
11.54 
0.159 
0.584 
Contralateral 
Knee 
CDT 
CPT 
27.03 
7 
2.95 
9.49 
26.39 
6.99 
2.92 
11.35 
0.501 
0.896 
Ipsilateral 
Knee 
CDT 
CPT 
27.61 
9.35 
2.25 
9.47 
26.84 
7.98 
3 
12.02 
0.475 
0.671 
All Sites 
Average 
CDT 
CPT 
27.5 
7.23 
2.33 
7.4 
26.47 
8.14 
2.9 
10.88 
0.305 
0.925 
* Indicates statistical significance at p  0.05 
 
Vibration Detection Threshold  
The poor outcome group detected changes in vibration sensation at 
significantly larger amplitudes than the good outcome group across all 3 test 
sites (ECRB: p<0.001; Contralateral knee: p=0.001; Operated knee: 
p=0.001), indicating that the poor outcome group had reduced tactile sensory 
acuity as compared to the good outcome group (Table 4.36). 
 
Table 4.36: Pre-operative VDT (µm) (6 months post-TKR) 
Site 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
5.74 7.4 11.54 4.81 <0.001* 
Contralateral 
Knee 
7.37 8.99 17.52 12.45 0.001* 
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Ipsilateral 
Knee 
8.18 10.94 20.16 13.67 0.001* 
All Sites 
(Average) 
7.10 8.49 16.41 8.02 0.000* 
* Indicates statistical significance at p  0.05 
 
Sustained Cold Response  
There were no significant differences in the pre-operative sustained cold 
response ADI scores between groups (Table 4.37). 
 
Table 4.37: Pre-operative Sustained Cold Response ADI (6 months post-
TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
ADI VAS 1.31 1.09 2 1.12 0.085 
MWS 2.4 0.72 2.43 0.62 0.715 
 ADI Total 3.71 1.52 4.43 1.28 0.099 
* Indicates statistical significance at p  0.05 
 
• Pain 
PainDETECT  
The poor outcome group scored significantly higher in pre-operative Pain 
(Now) (p=0.014) as compared to the good outcome group (Table 4.38).  
 
Table 4.38: Pre-operative Pain levels (6 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Pain (Now) 2.94 2.32 5.11 2.26 0.014* 
Pain (Strongest) 6.71 2.31 7.33 2 0.474 
Pain (Average) 4.69 1.94 6.11 1.76 0.056 
* Indicates statistical significance at p  0.05 
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The pre-operative PainDETECT scores were significantly higher for the poor 
outcome group (p=0.031), indicating the possible presence of a neuropathic 
pain component for some members of this group (Table 4.39). 
 
Table 4.39: Pre-operative PainDETECT score (6 months post-TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
PainDETECT 8.57 5.22 12.44 4.77 0.031* 
* Indicates statistical significance at p  0.05 
 
PQAS  
The poor outcome group scored significantly higher for the pre-operative 
PQAS Deep (p=0.006) quality factor (Table 4.40). 
 
Table 4.40: Pre-operative PQAS scores (6 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Paroxysmal 13.20 9.19 19.11 8.49 0.077 
Superficial 3.25 4.38 3.44 5.83 0.605 
Deep 14.12 8.83 23.33 8.49 0.006* 
* Indicates statistical significance at p  0.05 
 
PCS  
The poor outcome group scored significantly higher on the PCS 
Magnification subscale (p=0.002) and PCS Total scores (p=0.032) (Table 
4.41).  
 
Table 4.41: Pre-operative PCS scores (6 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Rumination 3.04 3.49 5.67 4.24 0.074 
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Magnification 1.45 1.99 3.44 1.81 0.002* 
Helplessness 3.35 3.9 4.56 2.46 0.082 
Total 7.84 8.61 13.67 7.68 0.032* 
* Indicates statistical significance at p  0.05 
 
• Functional Level 
ALF 
The poor outcome group were significantly slower pre-operatively in the ALF 
Transfer (p=0.008) and ALF Total (p=0.018) measures as compared to the 
good outcome group (Table 4.42). The ALF Stairs component was not 
analysed as the data set was incomplete due to the lack of a suitable stairs 
assessment area for 19 participants. 
 
 Table 4.42: Pre-operative ALF (Secs) (6 months post-TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
8 Metre Walk 9.02 3.78 10.94 3.42 0.064 
Transfer 10.79 4.22 14.57 4.9 0.008* 
Total 19.81 7.73 25.51 7.76 0.018* 
* Indicates statistical significance at p  0.05 
 
ROM  
There were no significant pre-operative differences across groups in both 
active and passive range of motion of the operated knee (Table 4.43). 
 
Table 4.43: Pre-operative ROM of operated knee (Degrees) (6 months post-
TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Flexion 
(AROM) 
111.63 15.77 107.41 22.62 0.844 
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Extension 
(AROM)** 
5.02 4.39 5.37 4.59 0.739 
Flexion 
(PROM) 
115.05 16.58 111.03 24.47 0.967 
Extension 
(PROM)** 
4.18 4.26 4.19 3.81 0.9 
* Indicates statistical significance at p  0.05 
** Extension values are expressed as lack of degrees to full extension 
 
Knee Extensor Strength 
There was no significant difference in pre-operative knee extensor strength 
between groups (p=0.264) (Table 4.44). 
 
Table 4.44: Pre-operative knee extensor strength (Kg) (6 months post-TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Knee 
Extensor 
Strength 
16.81 7.85 11.83 5.16 0.072 
* Indicates statistical significance at p  0.05 
 
• Health status 
SF-36  
There were significant group differences in the SF-36 PF (p=0.024), BP 
(p=0.018), GH (p=0.002), VT (p=0.008), SF (p=0.027), MH(p=0.032) health 
domains and PCS (0.008) component summary measure (Table 4.45). 
These results indicate that the poor outcome group had more limitations in 
performing physical activities (PF), higher levels of pain that impacted on 
normal activities (BP), a belief that they were in poorer health (GH), lower 
energy levels (VT), ability to perform normal social activities was hampered 
due to interference from physical or emotional problems (SF), increased 
feelings of nervousness and depression (MH) and more limitations in 
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physical functioning and role participation due to physical problems, a high 
degree of bodily pain, and poor general health (PCS).    
 
Table 4.45: Pre-operative SF-36 scores (6 months post-TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
PF 37.86 23.31 18.89 14.95 0.018* 
RP 49.39 28.84 29.86 19.21 0.057 
BP 48.33 17.62 27.89 14.99 0.002* 
GH 77.39 17.01 61 15.75 0.008* 
VT 55.76 25.09 36.81 19.63 0.027* 
SF 78.12 24.27 55.56 30.69 0.034* 
RE 75.98 28.22 62.04 28.9 0.16 
MH 81.18 15.28 67.22 18.89 0.032* 
PCS 37.7 7.59 30.13 7.97 0.008* 
MCS 55.63 10.73 48.48 11.94 0.084 
* Indicates statistical significance at p  0.05 
 
SCQ  
The poor outcome group had significantly more co-morbid conditions as 
compared to the good outcome group (p=0.005) (Table 4.46). 
 
Table 4.46: Pre-operative SCQ (6 months post-TKR) 
 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
SCQ 6.41 3.24 11.44 5.81 0.005* 
* Indicates statistical significance at p  0.05 
 
WOMAC 
The poor outcome group scored significantly higher on the pre-operative 
WOMAC Pain (p<0.001), WOMAC Function (p=0.007) and WOMAC Total 
(p=0.003) scores, indicating that they had higher levels of pain and more 
  116 
difficulty with daily activities as compared to the good outcome group (Table 
4.47). 
 
Table 4.47: Pre-operative WOMAC scores (6 months post-TKR) 
 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
Pain 8.06 3.32 12.67 3.71 <0.001* 
Stiffness 3.96 1.34 4.56 1.42 0.293 
Function 28.43 11.12 39.44 10.19 0.007* 
Total 40.45 14.76 56.67 14.4 0.003* 
* Indicates statistical significance at p  0.05 
 
• Psychological distress 
PHQ-8  
The poor outcome group scored significantly higher on the pre-operative 
PHQ-8 as compared to the good outcome group (p=0.001) (Table 4.48). 
Based on the PHQ-8 scoring system, the poor outcome group is classified as 
having mild depression on average. The respective surgeons were informed 
if their patients (n=10) had a score of ≥ 10 on the PHQ-8.   
 
Table 4.48: Pre-operative PHQ-8 score (6 months post-TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
PHQ-8 3.63 4.21 9.11 4.08 0.001* 
* Indicates statistical significance at p  0.05 
 
Sleep Quality  
There were no significant group differences in the pre-operative PSQI scores 
(Table 4.49).   
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Table 4.49: Pre-operative PSQI scores (6 months post-TKR) 
 
No to Mild Pain Moderate to 
Severe Pain p 
Mean SD Mean SD 
Sleep quality 1.06 0.7 1.56 1.01 0.163 
Sleep latency 1.33 1.16 1.33 1.22 0.991 
Sleep duration 1.12 0.97 1.33 1 0.516 
Sleep efficiency 1.08 1.21 1.44 1.13 0.309 
Sleep disturbances 1.57 1.46 1.67 0.5 0.167 
Sleep medications 0.49 1.01 1.11 1.45 0.153 
Day dysfunction 0.86 0.72 1.11 0.33 0.267 
Total 7.51 4.38 9.56 4.39 0.163 
* Indicates statistical significance at p  0.05 
 
3 months post-surgery measures 
• Quantitative Sensory Testing 
Pressure Pain Threshold  
There were no significant differences at 3 months post-surgery between 
groups in PPT values across all test sites (Table 4.50). 
 
Table 4.50: 3 months post-TKR PPT (kPa) (outcome at 6 months post-TKR) 
Site 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Ipsilateral ECRB 322.64 125.98 242.93 99 0.088 
Contralateral Knee 357.24 142.99 284.33 84.48 0.145 
Ipsilateral Knee 365.07 168.74 292.68 148.17 0.187 
All sites (Average) 348.31 138.46 273.31 99.71 0.114 
* Indicates statistical significance at p  0.05 
 
Heat Detection and Heat Pain Thresholds  
There were no significant differences at 3 months post-surgery between 
groups across all heat detection and heat pain threshold test sites (Table 
4.51). 
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Table 4.51: 3 months post-TKR HDT and HPT (°C) (outcome at 6 months 
post-TKR) 
Site Test 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
HDT 
HPT 
36 
46.54 
2.5 
3 
37.42 
46.84 
3.9 
3.61 
0.35 
0.667 
Contralateral 
Knee 
HDT 
HPT 
37.73 
45.66 
3.8 
2.94 
39.26 
46.56 
3.9 
3.21 
0.163 
0.334 
Ipsilateral 
Knee 
HDT 
HPT 
38.34 
45.92 
3.92 
2.81 
39.88 
46.23 
4.34 
3.33 
0.096 
0.636 
All Sites 
Average 
HDT 
HPT 
37.35 
46.04 
2.98 
2.53 
38.86 
46.54 
3.12 
2.82 
0.109 
0.547 
* Indicates statistical significance at p  0.05 
 
Cold Detection and Cold Pain Thresholds  
There were no significant differences between groups for cold detection and 
cold pain thresholds across all sites (Table 4.52). 
 
Table 4.52: 3 months post-TKR CDT and CPT (°C) (outcome at 6 months 
post-TKR) 
Site Test 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
CDT 
CPT 
27.84 
4.5 
2.9 
5.67 
27.52 
9.99 
4.18 
11.83 
0.889 
0.282 
Contralateral 
Knee 
CDT 
CPT 
27.3 
5.73 
2.62 
8.52 
28.28 
12.7 
2.28 
11.99 
0.153 
0.101 
Ipsilateral 
Knee 
CDT 
CPT 
27.86 
7.47 
2.34 
8.5 
26.77 
12.49 
3.3 
11.23 
0.396 
0.182 
All Sites 
Average 
CDT 
CPT 
27.67 
0.07 
2.27 
0.13 
27.5 
0.03 
3.04 
0.1 
0.88 
0.38 
* Indicates statistical significance at p  0.05 
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Vibration Detection Threshold  
There were no significant group differences at 3 months post-surgery in 
vibration detection thresholds across all sites (Table 4.53). 
 
Table 4.53: 3 months post-TKR VDT (µm) (outcome at 6 months post-TKR) 
Site 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Ipsilateral 
ECRB 
3.52 2.43 4.37 1.56 0.08 
Contralateral 
Knee 
5.47 7.53 8.03 9.33 0.273 
Ipsilateral 
Knee 
5.85 9.19 8.72 9.91 0.088 
All Sites 
(Average) 
4.95 5.91 7.04 6.6 0.169 
* Indicates statistical significance at p  0.05 
 
Sustained Cold Response  
There were no significant differences in the 3 months post-surgery sustained 
cold response ADI scores between groups (Table 4.54). 
 
Table 4.54: 3 months post-TKR Sustained Cold Response ADI (outcome at 6 
months post-TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
ADI VAS 1.08 1.11 1.78 1.2 0.103 
MWS 2.3 0.7 2.6 0.63 0.236 
 ADI Total 3.42 1.64 4.38 1.69 0.124 
* Indicates statistical significance at p  0.05 
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• Pain 
PainDETECT  
The poor outcome group had significantly higher scores in Pain (Now) 
(p<0.001), Pain (Strongest) (p<0.001) and Pain (Average) (p<0.001) as 
compared to the good outcome group (Table 4.55).  
 
Table 4.55: 3 months post-TKR Pain levels (outcome at 6 months post-TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Pain (Now) 0.88 1.03 3.11 1.17 <0.001* 
Pain (Strongest) 2.53 2.39 6.56 2.13 <0.001* 
Pain (Average) 1.43 1.4 4.78 1.39 <0.001* 
* Indicates statistical significance at p  0.05 
 
The 3 months post-surgery PainDETECT scores were significantly higher in 
the poor outcome group (p=0.001), indicating the possible presence of a 
neuropathic pain component in some members of this group (Table 4.56). 
 
Table 4.56: 3 months post-TKR PainDETECT score (outcome at 6 months 
post-TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
PainDETECT 6.04 5.73 13.22 4.29 0.001* 
* Indicates statistical significance at p  0.05 
 
PQAS  
The poor outcome group scored significantly higher for the 3 months post-
surgery PQAS Paroxysmal (p=0.001) and PQAS Deep (p<0.001) quality 
factors (Table 4.57). 
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Table 4.57: 3 months post-TKR PQAS score (outcome at 6 months post-
TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Paroxysmal 5.2 7.69 16.67 10.48 0.001* 
Superficial 4.82 7.06 7 7.75 0.341 
Deep 5.73 7.57 17.89 6.9 <0.001* 
* Indicates statistical significance at p  0.05 
 
PCS  
The poor outcome group scored significantly higher on all 3 subscales of the 
PCS (Rumination (p=0.013), Magnification (p<0.001) and Helplessness 
(p=0.010)) and PCS Total (p=0.001) at 3 months post TKR (Table 4.58). 
 
Table 4.58: 3 months post-TKR PCS scores (outcome at 6 months post-
TKR) 
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Rumination 0.94 1.89 3.44 3.81 0.013* 
Magnification 0.29 0.83 2.11 1.62 <0.001* 
Helplessness 1.12 2.1 4.56 6.06 0.01* 
Total 2.35 4.4 10.11 9.57 0.001* 
* Indicates statistical significance at p  0.05 
 
• Functional Level 
ALF  
There were no significant group differences in the ALF. The ALF Stairs 
component was not analysed as the data set was incomplete due to the lack 
of a suitable stairs assessment area for 19 participants (Table 4.59). 
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 Table 4.59: 3 months post-TKR ALF (Secs) (outcome at 6 months post-
TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
8 Metre Walk 7.95 2.45 8.95 2.56 0.16 
Transfer 8.76 2.62 11.99 7.27 0.144 
Total 16.71 4.86 20.94 9.72 0.147 
* Indicates statistical significance at p  0.05 
 
ROM  
There were no significant group differences in 3 months post-surgery active 
and passive range of motion of the operated knee (Table 4.60). 
 
Table 4.60: 3 months post-TKR ROM of operated knee (Degrees) (outcome 
at 6 months post-TKR)  
 
No to Mild Pain  Moderate to 
Severe Pain p 
Mean SD Mean SD 
Flexion 
(AROM) 
110.23 13.65 106.92 16.41 0.755 
Extension 
(AROM)** 
1.53 2.05 2.44 3.28 0.618 
Flexion 
(PROM) 
114.57 13.4 110.67 16.47 0.554 
Extension 
(PROM)** 
1.01 1.35 2 2.69 0.479 
* Indicates statistical significance at p  0.05 
** Extension values are expressed as lack of degrees to full extension 
 
Knee Extensor Strength  
There was no significant difference in 3 months post-surgery knee extensor 
strength between groups (Table 4.61). 
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Table 4.61: 3 months post-TKR knee extensor strength (Kg) (outcome at 6 
months post-TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
Knee 
Extensor 
Strength 
21.72 7.62 16.91 6.73 0.083 
* Indicates statistical significance at p  0.05 
 
• Health status 
SF-36 
There were significant group differences in all of the 3 months post-surgery 
SF-36 health domains (PF (p<0.001), RP (p=0.01), BP (p<0.001), GH 
(p=0.032), VT (p=0.002), SF (p=0.002), RE (p=0.003), MH(p=0.009)), as well 
as both PCS (0.008) and MCS (p=0.023) component summary measures 
(Table 4.62). These results indicate that the poor outcome group had more 
limitations in performing physical activities (PF), had issues performing work 
or daily activities due to physical problems (RP), had higher levels of pain 
that impacted on normal activities (BP), a belief that they were in poorer 
health (GH), had lower energy levels (VT), frequent interference with normal 
social activities due to physical or emotional problems (SF), had problems 
with work or other activities due to emotional problems (RE), frequent 
feelings of nervousness and depression (MH), had limitations in physical 
functioning and role participation due to physical problems (PCS) and had 
frequent psychological distress, social and role disability due to emotional 
problems and poor general health (MCS).    
 
Table 4.62: 3 months post-TKR SF-36 scores (outcome at 6 months post-
TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
PF 64.61 24.18 31.11 16.91 <0.001* 
RP 68.01 27.91 41.67 23.39 0.01* 
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BP 66.67 21.5 35.67 9.91 <0.001* 
GH 79.39 16.51 66.22 19.95 0.032* 
VT 62.75 20.12 38.19 20.36 0.002* 
SF 83.58 21.72 55.56 21.75 0.002* 
RE 87.58 20.51 66.67 19.54 0.003* 
MH 83.63 13.42 70.56 13.1 0.009* 
PCS 45.84 9.04 34.48 8.63 0.001* 
MCS 55.91 8.5 48.38 8.87 0.023* 
* Indicates statistical significance at p  0.05 
 
SCQ  
The poor outcome group had significantly more co-morbid conditions as 
compared to the good outcome group (p=0.025) (Table 4.63). 
 
Table 4.63: 3 months post-TKR SCQ (outcome at 6 months post-TKR) 
 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
SCQ 5.33 3.5 9.44 5.96 0.025* 
* Indicates statistical significance at p  0.05 
 
WOMAC  
The poor outcome group scored significantly higher on the 3 months post-
surgery WOMAC Pain (p=0.001), WOMAC Stiffness (p=0.024), WOMAC 
Function (p=0.001) and WOMAC Total (p=0.001) scores, indicating that they 
had higher levels of pain, more stiffness and more difficulty with daily 
activities as compared to the good outcome group (Table 4.64). 
 
Table 4.64: 3 months post-TKR WOMAC scores (outcome at 6 months post-
TKR) 
 
No to Mild Pain  Moderate to Severe 
Pain p 
Mean SD Mean SD 
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Pain 3.1 3.32 8.33 3.71 0.001* 
Stiffness 2.51 1.53 4.11 1.83 0.024* 
Function 13.37 11.13 27.33 8.03 0.001* 
Total 18.98 15.21 39.78 12.55 0.001* 
* Indicates statistical significance at p  0.05 
 
• Psychological distress 
PHQ-8  
The poor outcome group scored significantly higher on the 3 months post-
surgery PHQ-8 as compared to the good outcome group (p<0.001) (Table 
4.65). Based on the PHQ-8 scoring system, the poor outcome group is 
classified as having mild depression. The respective surgeons were informed 
if their patients (n=10) had a score of ≥ 10 on the PHQ-8.   
 
Table 4.65: 3 months post-TKR PHQ-8 score (outcome at 6 months post-
TKR) 
 
Good Outcome Poor Outcome 
p 
Mean SD Mean SD 
PHQ-8 3.1 3.61 9 3.32 <0.001* 
* Indicates statistical significance at p  0.05 
 
Sleep Quality  
There were significant group differences for 3 months post-surgery PSQI 
Sleep Quality (p=0.029), Sleep Disturbances (p=0.001), Sleep Medications 
(p=0.049), Day Dysfunction (p=0.04) and Total score (p=0.022) (Table 4.66). 
This indicates that the poor outcome group had poorer sleep quality, more 
disturbances from sleep, increased consumption of over the counter sleep 
medications and more daytime dysfunction as compared to the good 
outcome group. 
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Table 4.66: 3 months post-TKR PSQI scores (outcome at 6 months post-
TKR) 
 
No to Mild Pain Moderate to 
Severe Pain p 
Mean SD Mean SD 
Sleep quality 1.14 0.78 1.89 0.93 0.029* 
Sleep latency 1.27 1.1 1.67 1.22 0.35 
Sleep duration 1.06 1.05 1.33 1.22 0.529 
Sleep efficiency 1.22 1.24 1.89 1.17 0.109 
Sleep disturbances 1.37 1.2 1.89 0.33 0.001* 
Sleep medications 0.51 0.99 1.33 1.41 0.049* 
Day dysfunction 0.71 0.58 1.11 0.33 0.04* 
Total 7.27 4.44 11.11 3.92 0.022* 
* Indicates statistical significance at p  0.05 
 
Secondary Hypothesis 2: 
Pre-operative baseline measures (which may include cold pain 
threshold (CPT), pressure pain threshold (PPT), PainDETECT score, 
WOMAC score, psychological distress or sleep quality index score) will 
predict ‘poor’ outcome at 6 months post-TKR surgery. 
 
Univariate Logistic Regression 
A range of pre-operative variables were statistically significant in the 
univariate logistic regression analysis. The significant univariate logistic 
regression results are in table 4.67. These included a range of QST 
measures, ALF measures, a range of pain report measures, the PHQ8 score 
and several components of the SF-36. 
 
Table 4.67: Logistic regression (univariate) for ‘poor’ outcome group at 6 
months post-TKR 
Univariate Logistic Regression 
 OR 95%CI (OR) p 
Contralateral Knee HDT  1.15 (0.98, 1.38) 0.084 
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Ipsilateral ECRB VDT 1.08 (0.99, 1.18) 0.075 
Contralateral Knee VDT  1.08 (1.01, 1.14) 0.015* 
Ipsilateral Knee VDT  1.07 (1.01, 1.12) 0.014* 
VDT All Sites Average 1.09 (1.02, 1.17) 0.015* 
ALF Transfer  1.16 (1.01, 1.34) 0.031* 
ALF Total (Walk + Transfer) 1.08 (1, 1.16) 0.065 
WOMAC Pain 1.48 (1.14, 1.94) 0.004* 
WOMAC Function 1.1 (1.02, 1.18) 0.015* 
WOMAC Total 1.08 (1.02, 1.14) 0.009* 
Pain Now 1.5 (1.06, 2.10) 0.021* 
Pain Average 1.48 (0.99, 2.22) 0.054 
PainDETECT 1.14 (1, 1.30) 0.052 
PCS Magnification 1.47 (1.07, 2.02) 0.016* 
PCS Total 1.07 (0.99, 1.16) 0.074 
PQAS Deep Quality Factor 1.11 (1.02, 1.21) 0.012* 
SCQ 1.31 (1.08, 1.58) 0.006* 
PHQ8 1.28 (1.07, 1.51) 0.006* 
SF36 PF 0.95 (0.9, 1) 0.031* 
SF36 BP 0.92 (0.88, 0.98) 0.007* 
SF36 GH 0.95 (0.91, 0.99) 0.017* 
SF36 VT 0.97 (0.94, 1) 0.045* 
SF36 SF 0.97 (0.94, 1) 0.026* 
SF36 MH 0.95 (0.91, 0.99) 0.027* 
SF36 PCS 0.86 (0.76, 0.97) 0.017* 
* Indicates statistical significance at p  0.05 
 
Multivariate Logistic Regression 
Multivariate logistic regression analysis was performed on the pre-operative 
variables that were significant on the univariate logistic regression analyses. 
3 logistic regression models were considered (Physical measures only, Self-
report measures only and Combined measures). 
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Physical measures 
The physical measures multivariate logistic regression analysis identified 
VDT all sites average as the sole pre-operative physical measures predictor 
of membership into the ‘poor’ outcome group at 6 months post-TKR surgery 
(Table 4.68). 
 
Table 4.68: Logistic regression (multivariate) for ‘poor’ outcome group at 6 
months post-surgery (Physical measures) 
Multivariate Logistic Regression 
 OR 95%CI (OR) p 
VDT All Sites Average 1.09 (1.01, 1.18) 0.029* 
ALF Transfer 1.15 (1, 1.37) 0.057 
* Indicates statistical significance at p  0.05 
 
ROC curve analysis was performed on VDT all sites average to ascertain the 
cut-off point, as well as its sensitivity and specificity (Figure 4.8). 
 
Figure 4.8  
ROC curve for pre-operative VDT All Sites Average. 
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The AUC was 0.871 (95% CI: 0.78, 0.96) (p=0.000), indicating that pre-
operative VDT All Sites Average was significantly better than chance in 
predicting membership into the ‘poor’ outcome group at 6 months post-TKR 
surgery (Table 4.69). 
 
Table 4.69: AUC for pre-operative VDT All Sites Average 
   Asymptotic 95%CI 
Area Std. Error Asymptotic Sig. Lower Bound Upper Bound 
0.871 0.045 0.000* 0.78 0.96 
* Indicates statistical significance at p  0.05 
 
A pre-operative VDT All Sites Average reading of 8.04µm (sensitivity: 1, 
specificity 0.804) gave a positive likelihood ratio of 1.09 of membership into 
the ‘poor’ outcome group at 6 months post-TKR surgery. 
 
Self-report measures 
The self-report measures multivariate logistic regression analysis identified 
WOMAC Pain as the pre-operative self-report measure that predicted 
membership into the ‘poor’ outcome group at 6 months post-TKR surgery 
(Table 4.70). 
 
Table 4.70: Logistic regression (multivariate) for ‘poor’ outcome group at 
6 months post-surgery (Self-report measures) 
Multivariate Logistic Regression 
 OR 95%CI (OR) p 
WOMAC Pain 1.37 (1.04, 1.8) 0.025* 
SCQ 1.23 (0.99, 1.53) 0.063 
* Indicates statistical significance at p  0.05 
 
ROC curve analysis was performed on WOMAC Pain to determine the cut-off 
point, as well as its sensitivity and specificity (Figure 4.9). 
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Figure 4.9  
ROC curve for pre-operative WOMAC Pain. 
 
The AUC for pre-operative WOMAC Pain was 0.815 (95% CI: 0.68, 0.96) 
(p=0.003) indicating that was significantly better than chance in predicting 
membership into the ‘poor’ outcome group at 6 months post-TKR surgery 
(Table 4.71). 
 
Table 4.71: AUC for pre-operative WOMAC Pain 
    Asymptotic 95%CI 
Test Area Std. 
Error 
Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
WOMAC Pain 0.815 0.071 0.003* 0.68 0.96 
* Indicates statistical significance at p  0.05 
 
A pre-operative WOMAC Pain score of 10.5 (sensitivity: 0.778, specificity 
0.725) gave a positive likelihood ratio of 1.37 of membership into the ‘poor’ 
outcome group at 6 months post-TKR surgery. 
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Combined measures 
The significant variables (pre-operative VDT All Sites Average and WOMAC 
Pain) that were identified from the above 2 models (Physical and Self-report 
measures) were then combined in an all measures multivariate logistic 
regression model.  
Pre-operative VDT All Sites Average and WOMAC Pain were then identified 
as predictors for membership into the poor outcome group at 6 months post-
TKR surgery (Table 4.72).  
 
Table 4.72: Logistic regression (multivariate) for ‘poor’ outcome group at 6 
months post-surgery (All measures) 
Multivariate Logistic Regression 
 OR 95%CI (OR) p 
VDT All Sites Average 1.09 (1.01, 1.18) 0.03* 
WOMAC Pain 1.5 (1.11, 2.03) 0.008* 
* Indicates statistical significance at p  0.05 
 
ROC curve analysis was performed on pre-operative VDT All Sites Average 
and WOMAC Pain to determine the cut-off point of the individual measures 
and their respective sensitivity and specificity (Figure 4.10). 
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Figure 4.10  
ROC curves for pre-operative VDT All Sites Average and WOMAC Pain. 
 
The AUC for pre-operative VDT All Sites Average was 0.84 (95% CI: 0.72, 
0.96) (p<0.001) and WOMAC Pain was 0.815 (95% CI: 0.68, 0.96) (p=0.003) 
indicating that these measures were significantly better than chance in 
predicting membership into the ‘poor’ outcome group at 6 months post-TKR 
surgery (Table 4.73). 
 
Table 4.73: AUC for pre-operative VDT All Sites Average and WOMAC 
Pain 
    Asymptotic 
95%CI 
Measure Area Std. 
Error 
Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
VDT All Sites 
Average 
0.871 0.045 <0.001* 0.78 0.96 
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WOMAC Pain 0.815 0.071 0.003* 0.68 0.96 
* Indicates statistical significance at p  0.05 
 
A pre-operative VDT All Sites Average of 9.2µm (sensitivity: 0.889, specificity 
0.824) gave a positive likelihood ratio of 1.09 and a WOMAC Pain score of 
10.5 (sensitivity: 0.778, specificity 0.725) gave a positive likelihood ratio of 
1.5 for membership into the ‘poor’ outcome group at 6 months post-TKR 
surgery.  
 
Model Fit 
Model fit for the combined measures (pre-operative VDT All Sites Average 
and pre-operative WOMAC Pain) multivariate logistic regression was 
analysed using the ‘Omnibus Tests of Model Coefficients’ and the ‘Hosmer 
and Lemeshow Test’. 
Based on the results of the ‘Omnibus Tests of Model Coefficients’, the model 
for the combined measures (pre-operative VDT All Sites Average and pre-
operative WOMAC Pain) multivariate logistic regression is statistically 
significant (p < 0.0005) (Table 4.74). 
The results of the model summary indicate that there is a 25% probability of 
being in the poor outcome group at 6 months (Table 4.75). 
The results of the ‘Hosmer and Lemeshow Test’ is not statistically significant 
(p = 0.342), indicating that the model is not a poor fit (Table 4.76). 
 
Table 4.74: Omnibus Tests of Model Coefficients 
  Chi-square df Sig. 
Step 1 Step 12.401 1 0.000 
Block 12.401 1 0.000 
Model 12.401 1 0.000 
Step 2 Step 4.689 2 0.030 
Block 17.090 2 0.000 
Model 17.090 2 0.000 
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Table 4.75: Model Summary  
 -2 Log likelihood Cox & Snell R 
Square 
Nagelkerke R 
Square 
Step 1 38.324 0.187 0.327 
Step 2 33.635 0.248 0.434 
 
Table 4.76: Hosmer and Lemeshow Test 
 Chi-Square df Sig. 
Step 1 9.002 8 0.342 
Step 2 2.739 8 0.950 
 
Alternative model for pre-op measures predicting pain levels at 3 
months post-TKR 
 
Pre-operative ipsilateral ECRB VDT and PainDETECT were identified as 
predictors for membership into the ‘moderate to severe pain’ group at 3 
months post-TKR surgery. Predictors for membership into the ‘poor’ outcome 
group at 6 months post-TKR surgery were identified as pre-operative VDT All 
Sites Average and WOMAC Pain. Even though ipsilateral ECRB VDT and 
VDT All Sites Average are measures of vibration sensitivity and, 
PainDETECT and WOMAC Pain are both measures of pain. It was 
interesting to note that there was a difference in the measures identified as 
predictors for pain groups at 3 and 6 months post-TKR.  
The most likely reason for this is due to the difference in participant numbers 
at these 2 time points.  
In order to offer a better comparison, another analysis (investigating pre-
operative measures which will predict pain levels at 3 months post-TKR) was 
completed where only participants who had reached 6 months post-surgery 
were included.  
The results showed that even though pre-operative VDT All Sites Average 
was still a significant predictor of membership into the ‘moderate to severe’ 
pain group at 3 months post-TKR, WOMAC Pain was not (Table 4.77). 
However, it is important to note that the WOMAC Pain was very close to 
significance. It is anticipated that once more participants reach the 6 months 
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post-surgery time point and the analysis is repeated, WOMAC Pain will show 
statistical significance. 
 
Table 4.77: Logistic regression (multivariate) for ‘moderate to severe 
pain’ group at 3 months post-surgery 
Multivariate Logistic Regression 
 OR 95%CI (OR) p 
VDT All Sites Average 1.13 (1.04, 1.24) 0.004* 
WOMAC Pain 1.23 (0.99, 1.53) 0.064 
* Indicates statistical significance at p  0.05 
 
Model Fit 
Model fit for the combined measures (pre-operative VDT All Sites Average 
and pre-operative WOMAC Pain) multivariate logistic regression was 
analysed using the ‘Omnibus Tests of Model Coefficients’ and the ‘Hosmer 
and Lemeshow Test’. 
Based on the results of the ‘Omnibus Tests of Model Coefficients’, the model 
for the combined measures (pre-operative VDT All Sites Average and pre-
operative WOMAC Pain) multivariate logistic regression is statistically 
significant (p < 0.0005) (Table 4.78). 
The results of the model summary indicate that there is a 30% probability of 
being in the ‘moderate to severe pain’ group at 3 months (Table 4.79). 
The results of the ‘Hosmer and Lemeshow Test’ is not statistically significant 
(p = 0.216), indicating that the model is not a poor fit (Table 4.80). 
 
Table 4.78: Omnibus Tests of Model Coefficients 
  Chi-square df Sig. 
Step 1 Step 18.370 1 0.000 
Block 18.370 1 0.000 
Model 18.370 1 0.000 
Step 2 Step 8.028 2 0.005 
Block 26.398 2 0.000 
Model 26.398 2 0.000 
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Table 4.79: Model Summary  
 -2 Log likelihood Cox & Snell R 
Square 
Nagelkerke R 
Square 
Step 1 61.394 0.220 0.333 
Step 2 53.367 0.300 0.455 
 
Table 4.80: Hosmer and Lemeshow Test 
 Chi-Square df Sig. 
Step 1 8.609 8 0.376 
Step 2 10.751 8 0.216 
 
Secondary Hypothesis 3: 
3 months post-TKR surgery measures (which may include CPT, PPT, 
PainDETECT score, surgical approach, immediate post-operative pain 
intensity or pain catastrophising) will predict ‘poor’ outcome at 6 
months post-TKR surgery. 
 
Univariate Logistic Regression 
A range of 3 months post-TKR measures were statistically significant in the 
univariate logistic regression analysis. The univariate logistic regression 
results are in table 4.81. These included post-operative day 1 pain scores, a 
range of pain report measures, the PHQ8 score, sleep quality measures and 
all components of the SF-36. 
 
Table 4.81: Logistic regression (univariate) for ‘moderate to severe pain’ 
group at 3 months post-surgery 
Univariate Logistic Regression 
 OR 95%CI (OR) p 
1st POD NRS Rest 1.73 (1.24, 2.43) 0.001* 
1st POD NRS Movt 1.93 (1.36, 2.75) <0.001* 
WOMAC Pain 1.42 (1.14, 1.77) 0.002* 
WOMAC Stiffness 1.86 (1.14, 3.05) 0.014* 
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WOMAC Function 1.11 (1.03, 1.19) 0.004* 
WOMAC Total 1.08 (1.03, 1.14) 0.003* 
Pain Now (at 3 months) 4.57 (1.82, 11.5) 0.001* 
Pain Strongest (at 3 months) 1.78 (1.26, 2.5) 0.001* 
Pain Average (at 3 months) 3.78 (1.73, 8.26) 0.001* 
PainDETECT 1.22 (1.07, 1.39) 0.004* 
PCS Rumination 1.38 (1.05, 1.82) 0.02* 
PCS Magnification 2.83 (1.53, 5.24) 0.001* 
PCS Helplessness 1.3 (1.03, 1.65) 0.029* 
PCS Total 1.2 (1.04, 1.37) 0.011* 
PQAS Paroxysmal Quality Factor 1.12 (1.04, 1.21) 0.003* 
SCQ 1.23 (1.04, 1.45) 0.016* 
PHQ8 1.4 (1.14, 1.72) 0.001* 
PSQI Sleep Quality 3.03 (1.2, 7.64) 0.019* 
PSQI Sleep Efficiency 1.57 (0.86, 2.86) 0.142 
PSQI Sleep Disturbances 1.33 (0.81, 2.17) 0.265 
PSQI Sleep Meds 1.79 (1.01, 3.16) 0.047* 
PSQI Day Dysfunction 4.18 (0.96, 18.21) 0.057 
PSQI Total 1.23 (1.02, 1.47) 0.028* 
SF36 PF 0.94 (0.91, 0.98) 0.003* 
SF36 RP 0.97 (0.94, 0.99) 0.018* 
SF36 BP 0.91 (0.85, 0.97) 0.002* 
SF36 GH 0.96 (0.93, 1) 0.051 
SF36 VT 0.95 (0.92, 0.99) 0.006* 
SF36 SF 0.95 (0.92, 0.99) 0.004* 
SF36 RE 0.96 (0.93, 0.99) 0.013* 
SF36 MH 0.94 (0.89, 0.99) 0.017* 
SF36 PCS 0.87 (0.79, 0.96) 0.006* 
SF36 MCS 0.91 (0.84, 0.99) 0.027* 
* Indicates statistical significance at p  0.05 
 
Multivariate Logistic Regression 
Multivariate logistic regression analysis was performed on the 3 months post-
TKR variables that showed significance on the univariate logistic regression 
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analysis. Pain Average (at 3 months) and PCS Total were identified as 
measures that predict membership into the ‘poor’ outcome group at 6 months 
post-TKR surgery (Table 4.82). 
 
Table 4.82: Logistic regression (multivariate) for ‘poor’ outcome group at 
6 months post-surgery 
Multivariate Logistic Regression 
 OR 95%CI (OR) p 
Pain Average (at 3 months) 5.42 (1.5, 19.6) 0.01* 
PCS Total 1.19 (1.01, 1.39) 0.033* 
* Indicates statistical significance at p  0.05 
 
ROC curve analysis was performed on 3 months post-TKR data variables 
PCS Total and Pain Average (at 3 months) to determine the cut-off point of 
the individual measures and their respective sensitivity and specificity (Figure 
4.11). 
 
Figure 4.11  
ROC curves for 3 months post-TKR PCS Total and Pain Average (at 3 months).  
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The AUC for PCS Total was 0.836 (95% CI: 0.68, 0.99) (p=0.001) and Pain 
Average (at 3 months) was 0.941 (95% CI: 0.87, 1) (p=0.000) indicating that 
these measures were significantly better than chance in predicting 
membership into the ‘poor’ outcome group at 6 months post-TKR surgery 
(Table 4.83). 
 
Table 4.83: AUC for 3 months post-TKR PCS total and Pain Average (at 
3 months) 
    Asymptotic 
95%CI 
Measure Area Std. Error Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
PCS Total 0.836 0.078 0.001* 0.68 0.99 
Pain Average (at 
3 months) 
0.941 0.036 0.000* 0.87 1 
* Indicates statistical significance at p  0.05 
 
A 3 months post-TKR PCS Total score of 3.5 (sensitivity: 0.778, specificity 
0.824) gave a positive likelihood ratio of 1.19 and a Pain Average (at 3 
months) score of 3.5 (sensitivity: 0.889, specificity 0.902) gave a positive 
likelihood ratio of 5.42 for membership into the ‘poor’ outcome group at 6 
months post-TKR surgery.  
 
Model Fit 
Model fit for the combined measures (3 months post-TKR PCS Total score 
and 3 months post-TKR Pain Average score) multivariate logistic regression 
was analysed using the ‘Omnibus Tests of Model Coefficients’ and the 
‘Hosmer and Lemeshow Test’. 
Based on the results of the ‘Omnibus Tests of Model Coefficients’, the model 
for the combined measures (3 months post-TKR PCS Total score and 3 
months post-TKR Pain Average score) multivariate logistic regression is 
statistically significant (p < 0.0005) (Table 4.84). 
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The results of the model summary indicate that there is a 41% probability of 
being in the ‘poor’ outcome group at 6 months (Table 4.85). 
The results of the ‘Hosmer and Lemeshow Test’ is not statistically significant 
(p = 0.937), indicating that the model is not a poor fit (Table 4.86). 
 
Table 4.84: Omnibus Tests of Model Coefficients 
  Chi-square df Sig. 
Step 1 Step 26.347 1 0.000 
Block 26.347 1 0.000 
Model 26.347 1 0.000 
Step 2 Step 5.684 1 0.017 
Block 32.031 2 0.000 
Model 32.031 2 0.000 
 
 Table 4.85: Model Summary  
 -2 Log likelihood Cox & Snell R 
Square 
Nagelkerke R 
Square 
Step 1 24.378 0.355 0.623 
Step 2 18.694 0.414 0.725 
 
Table 4.86: Hosmer and Lemeshow Test 
 Chi-Square df Sig. 
Step 1 3.039 4 0.551 
Step 2 2.360 4 0.937 
 
 
Secondary Hypothesis 4: 
Baseline CPT values will predict membership into the ‘poor’ outcome 
group at 6 months with good sensitivity and specificity. 
ROC curve analysis of all pre-operative CPT values determined that they 
were not able to predict membership into ‘poor’ outcome group at 6 months 
post-TKR (Figure 4.12 and Table 4.87). 
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Figure 4.12  
ROC curves for pre-operative CPT across all test sites. 
 
Table 4.87: AUC for pre-operative CPT across all test sites 
    Asymptotic 
95%CI 
Measure Area Std. Error Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
Ipsilateral ECRB 
CPT 
0.556 0.121 0.598 0.32 0.79 
Contralateral 
Knee CPT 
0.487 0.117 0.901 0.26 0.72 
Ipsilateral Knee 
CPT 
0.456 0.116 0.679 0.23 0.68 
CPT All Sites 
Average 
0.49 0.118 0.926 0.26 0.72 
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Secondary Hypothesis 5: 
Baseline PainDETECT score will predict membership into the ‘poor’ 
outcome group at 6 months with good sensitivity and specificity. 
 
ROC curve analysis was performed on pre-operative PainDETECT to 
determine the cut-off point and its sensitivity and specificity (Figure 4.13). 
 
 
Figure 4.13  
ROC curve for pre-operative PainDETECT score.  
 
The AUC for PainDETECT score was 0.727 (95% CI: 0.55, 0.9) (p=0.031) 
indicating that it was significantly better than chance in predicting 
membership into the ‘poor’ outcome group at 6 months post-TKR surgery 
(Table 4.88). 
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Table 4.88: AUC for pre-operative PainDETECT score 
    Asymptotic 
95%CI 
Measure Area Std. Error Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
PainDETECT 0.727 0.088 0.031* 0.553 0.9 
* Indicates statistical significance at p  0.05 
 
A pre-operative PainDETECT score of 11.5 (sensitivity: 0.778, specificity 
0.804) gave a positive likelihood ratio of 1.14 for membership into the ‘poor’ 
outcome group at 6 months post-TKR surgery. It must be noted that pre-
operative PainDETECT was very close to significance (p=0.052) in the 
univariate logistic regression analysis. 
 
Summary of Results 
Hypotheses  Accepted/Rejected 
1. There will be a difference at pre-operative 
baseline in QST measures, pain report, 
functional level, health status, psychological 
distress and sleep quality between 
participants categorized as having no to low 
pain (<4 in NRS pain) versus moderate to 
severe pain (>4 in NRS pain) at 3 months 
following TKR surgery. 
Partially accepted 
2. There will be a difference at pre-operative 
baseline and at 3 months post-surgery in QST 
measures, pain report, functional level, health 
status, psychological distress and sleep 
quality between participants categorized as 
showing ‘poor’ versus ‘good’ outcomes at 6 
months following TKR surgery. 
Partially accepted 
 
 
 
 
 
 
3. Pre-operative baseline measures (which may 
include cold pain threshold (CPT), pressure 
Accepted 
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pain threshold (PPT), PainDETECT score, 
WOMAC score, psychological distress or 
sleep quality index score) will predict pain 
levels at 3 months post-TKR surgery. 
 
 
 
 
4. Pre-operative baseline measures (which may 
include cold pain threshold (CPT), pressure 
pain threshold (PPT), PainDETECT score, 
WOMAC score, psychological distress or 
sleep quality index score) will predict ‘poor’ 
outcome at 6 months post-TKR surgery. 
Accepted 
5. 3 months post-TKR surgery measures (which 
may include CPT, PPT, PainDETECT score, 
surgical approach, immediate post-operative 
pain intensity or pain catastrophising) will 
predict ‘poor’ outcome at 6 months post-TKR 
surgery. 
Accepted 
6. Baseline CPT values will predict membership 
into ‘poor’ outcome group at 6 months with 
good sensitivity and specificity. 
Rejected 
7. Baseline PainDETECT scores will predict 
membership into ‘poor’ outcome group at 6 
months with good sensitivity and specificity. 
Accepted 
 
4.6. Discussion 
This study aimed to use a wide range of pre-, peri- and post-operative data 
from self-report, QST, and medical notes to evaluate the predictors of pain 
that persists up to 6 months post-TKR surgery. 
 
The present study identified several key measures that predict pain and 
outcome after TKR surgery. The strongest pre-operative determinants of pain 
levels at 3 months post-TKR are VDT and PainDETECT. The strongest pre-
operative determinants of outcome at 6 months post-TKR are VDT and 
WOMAC Pain. A search of the current literature failed to turn up any 
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research on VDT and its predictive value in determining persistent pain post-
TKR. 
 
Quantitative Sensory Testing 
Pre-operative 
The present study reported findings of pre-operative widespread multi-
modality sensory impairments (thermal detection thresholds and vibration 
detection thresholds) in the higher pain group at 3 months and poor outcome 
group at 6 months post-TKR.  
Current QST research has found that OA patients have lower PPTs at both 
local and distal sites as compared to healthy controls, indicating that OA 
patients suffer from widespread pain sensitisation (Fingleton et al., 2015; 
Suokas et al., 2012; Wylde et al., 2012; Wylde et al., 2013). 
An ongoing QST study reported PPT as not being a predictor of persistent 
pain post-TKR at 3 to 4 months post-surgery (Cornelius et al., 2015).  
Petersen et al. (2016) investigated the relationship between pre-operative 
pain mechanisms in knee OA patients and the subsequent amount of pain 
relief gained at 1 year post-TKR surgery. The investigators reported that the 
presence of pre-operative widespread pain sensitisation was associated with 
reduced pain relief at 1 year post-TKR. However, it is important to note that 
PPT alone was not predictive of post-operative pain relief. The 2 above 
studies support the findings of this present study. 
Wylde et al. (2013) investigated the predictive value of pre-operative QST 
(PPTs and HPTs) on the likelihood of developing persistent pain post-TKR, 
and reported that lower pre-operative PPT at a distant site (forearm) is 
significantly correlated with higher pain levels reported at the operated knee 
at 1 year post-surgery. This present study did not find any correlation 
between PPTs and pain levels post-TKR. 
Graven-Nielsen et al. (2012) investigated the role of ongoing tissue pathology 
in the maintenance of enhanced central pain processing in knee OA. The 
investigators reported that knee OA patients had widespread mechanical 
hyperalgesia as compared to healthy controls. In this present study, the 
comparison of PPT was between 2 groups of knee OA patients following 
TKR surgery. Hence there is no basis for comparison between the studies. 
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Martinez et al. (2007) reported that pre-operative QST assessment of a small 
cohort of patients scheduled for TKR showed evidence of localised heat 
hyperalgesia, which normalized at 4 months after surgery. The present study 
showed that pre-operatively, patients with higher pain levels at 3 months and 
poor outcomes at 6 months post-TKR took longer to detect heat changes at 
the non-operated knee as compared to the lower pain group. However, there 
was no significant difference in heat detection thresholds at 3 months after 
the TKR surgery. 
 
Post-operative 
There were no significant group differences seen in the QST measures at the 
post-operative 3 month assessment.  
The results of the present study demonstrate that at 3 months post-TKR, 
there were no significant group differences in the QST measures. This is in 
line with the results reported by Graven-Nielsen et al. (2012) and Martinez et 
al. (2007) which showed normalization of the QST results following TKR 
surgery. However, this directly contradicts the findings of Skou et al. (2013) 
and Study 1, which reported widespread hyperalgesia in TKR patients who 
reported significant pain post-surgery.  
There are 2 possible explanations for the disparity in results. Both studies by 
Graven-Nielsen et al. (2012) and Martinez et al. (2007) had small sample 
sizes. The likelihood of the small sample size in the 2 studies being 
representative of the entire knee OA population is extremely low. Another 
explanation is the difference in the assessment time point of the QST testing 
protocol of this present study and study 1. The present study conducted the 
QST at 3 months post-TKR, whereas study 1 conducted QST between 12 to 
36 months after the TKR surgery. Similarly, Graven-Nielsen et al. (2012) and 
Martinez et al. (2007) conducted the QST at approximately 4 months post-
TKR surgery, whereas Skou et al. (2013) conducted the QST at about 56 
months after the revision TKR surgery. Hence it is possible that following 
TKR surgery, a ‘reset’ of the neural pathways is triggered due to the removal 
of the damaged tissue. However, in a small sub-group of patients this ‘reset’ 
of the neural pathways is halted or reversed due to the presence of other 
pain mechanisms.  
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Neuropathic Pain 
Victor et al. (2008) investigated the dimensionality of pain quality using the 
PQAS and reported a difference in the pain quality of neuropathic versus 
non-neuropathic pain. The PQAS subscales results of the poor outcome 
group in this present study reported scores that were higher than the 
neuropathic pain sample used in the study by Victor et al. (2008). 
 
The significant differences in the levels of self-reported neuropathic pain and 
pain quality support the QST findings that pre-operatively the nature of pain 
differs between the groups. The results of this present study support the 
presence of a neuropathic pain component in a proportion of patients 
suffering from persistent pain post-TKR. This finding has also been reported 
in several previous studies (Albayrak et al., 2016; Buvanendran et al., 2010; 
Fuzier et al., 2015; Harden et al., 2003; Haroutiunian et al., 2013). 
 
Self-Reported Measures 
Several studies have investigated the effects of pre-operative pain levels and 
psychological factors on persistent pain post-TKR surgery. Sullivan et al. 
(2009) examined the role of psychological factors in predicting pain and 
disability post-TKR, the results of their study demonstrated that pre-operative 
pain severity and pain catastrophizing are predictors of post-TKR pain 
severity at 6 weeks’ follow-up.  
Brander et al. (2003) conducted a prospective observational study to 
investigate the natural history of pain following TKR surgery and to identify 
the predictors of significant persistent pain post-TKR. The investigators 
reported that the presence of pre-operative depression and anxiety 
symptoms predicted higher pain levels at 1 year post-TKR. Higher pre-
operative pain predicted poor outcome and worse function at 1 year after 
surgery (Brander et al., 2003).  
Duivenvoorden et al. (2013) reported that TKR patients with pre-operative 
depressive symptoms had worse outcomes at 3 and 12 months following 
surgery, similar results were also noted in the present study.  
Riddle et al. (2010) conducted a prospective cohort study of the effect of 
psychological status on outcomes after TKR and reported that pain 
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catastrophizing was a powerful and consistent predictor of poor outcome at 6 
months post-TKR.  
Judge et al. (2012) investigated the pre-operative predictors of outcomes 
following TKR surgery and reported that high levels of pain pre-operatively 
and the presence of pre-operative anxiety/depression predicted poor 
outcomes at 6 months post-TKR. 
The findings of higher levels of pre-operative pain and the presence of 
psychological distress in the poor outcome group of this present study 
support the results of the above studies. 
 
The present study found that a higher number of co-morbid conditions is 
associated with having a poor outcome post-TKR, which supports the results 
from previous research studies (Escobar et al., 2007; Fitzgerald et al., 2004; 
Kennedy et al., 2003; Lingard et al., 2004; Mahomed et al., 2002; Wylde et 
al., 2012). A recent study on diabetic patients with knee OA concluded that 
the presence of diabetes mellitus significantly increased pain intensity in 
knee OA (Eitner et al., 2017). 
 
A study investigating sleep disruptions in TKR patients reported that patients 
who had more post-operative sleep disruptions reported higher pain levels at 
1 month post-TKR and reduced function at 3 months post-TKR (Cremeans-
Smith et al., 2006). The present study found that TKR patients with higher 
pain levels at 3 months post-TKR reported significantly reduced sleep quality 
pre-operatively, and that the poor outcome group at 6 months post-TKR also 
reported reduced sleep quality at 3 months post-TKR.  
 
Minimal Clinically Important Difference 
The minimal clinically important difference (MCID) is defined as the “smallest 
difference in score in the domain of interest which patients perceive as 
beneficial and which would mandate, in the absence of troublesome side 
effects and excessive cost, a change in the patient’s management.” 
(Jaeschke et al., 1989). 
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Escobar et al. (2007) used the WOMAC and SF-36 questionnaires to 
establish the MCID in patients undergoing TKR. At 6 months post-TKR, the 
investigators reported the MCID for WOMAC to be 15 points (ranging from 14 
to 22 points); and 10 points (physical domains: ranging from 0.85 to 16 
points; mental domains: ranging from -0.32 to 11 points) for the SF-36. In that 
study, the investigators standardized the WOMAC scores to a range of 0 to 
100, with 0 being the best health status and 100 being the worst. 
 
Based on the present study, at 3 months post-TKR the ‘no to low pain’ group 
demonstrated scores which are well above the MCID as indicated by 
Escobar et al. (2007) for all WOMAC domains. The ‘moderate to severe pain’ 
group demonstrated scores below the MCID for all domains of the WOMAC.  
Studies on the efficacy of pharmacological interventions in the treatment of 
knee OA have reported improvements in the WOMAC score ranging from 
36% to 45% (Altman et al., 2007; Babul et al., 2004; Barthel et al., 2009; 
Kivitz et al., 2008; Williams et al., 2001). Looking at the percentage change in 
the WOMAC scores at 3 months post-TKR surgery, the ‘no to low pain’ group 
demonstrated an average improvement of 54.8% versus the ‘moderate to 
severe pain’ group’s 32.13% improvement.  
The WOMAC results in this present study illustrates that the short-term 
efficacy and benefits of TKR does not span across the whole spectrum of 
knee OA patients undertaking a TKR.  
 
Table 4.89 shows the change in the pre-operative mean to post-operative 
mean of WOMAC scores for this present study. In order to enable a proper 
comparison, the values in the table have been converted to reflect the same 
scoring system used by Escobar et al. (2007). 
 
Table 4.89: Change from mean pre-operative to mean post-operative 
WOMAC scores for ‘no to low pain’ and ‘moderate to severe pain’ groups. 
‘No to Low Pain’ Group 
 Pre-Op Post-Op Mean 
Difference 
% 
change WOMAC Mean SD Mean SD 
Pain 39.45 16 15.1 15.55 24.35 61.7% 
 Stiffness 47.63 17.25 30.63 18.63 17 35.69% 
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Function 39.57 16.54 17.26 14.57 22.31 56.38% 
 TOTAL 40.22 15.48 18.18 14.6 22.04 54.8% 
 ‘Moderate to Severe Pain’ Group 
 Pre-Op Post-Op Mean 
Difference 
% 
change WOMAC Mean SD Mean SD 
Pain 59.1 21.25 37.2 17.3 21.9 37.06% 
 Stiffness 58.13 18.75 49.25 17.38 8.88 15.28% 
 Function 55.71 17.59 37.5 13.07 18.21 32.69% 
 TOTAL 56.61 17.7 38.42 13.04 18.19 32.13% 
  
Table 4.90 shows the change in the pre-operative mean to post-operative 
mean of the SF-36 scores for this present study. In the present study, the ‘no 
to low pain’ group reported scores well above the MCID for all the physical 
domains (PF, RP, BP and GH), and most of the mental health domains (VT, 
RE and MH). The ‘moderate to severe pain’ group reported scores above the 
MCID for most of the physical domains (PF, RP and GH), and only one of the 
mental health domains (MH). 
 
Table 4.90: Change from mean pre-operative to mean post-operative SF-36 
scores for ‘no to low pain’ and ‘moderate to severe pain’ groups. 
‘No to Low Pain’ Group 
 Pre-Op Post-Op Mean 
Difference 
% 
change SF-36 Mean SD Mean SD 
PF 40.54 24.55 67.81 22.91 27.27 67.26% 
RP 52.08 28.18 70.07 26.03 17.99 34.54% 
BP 48.75 17.57 68.25 20.4 19.5 40% 
GH 78.28 16.71 80.53 15.27 2.25 2.87% 
VT 57.13 24.28 64.69 18.05 7.56 13.23% 
SF 78.01 25.19 84.43 21.17 6.42 8.23% 
RE 75.73 27.47 87.28 19.55 11.55 15.25% 
MH 81.84 14.66 84.47 13.01 2.63 3.21% 
PCS 38.6 7.77 46.77 8.49 8.17 21.17% 
MCS 55.52 10.1 55.93 7.97 0.41 0.74% 
‘Moderate to Severe Pain’ Group 
 Pre-Op Post-Op Mean 
Difference 
% 
change SF-36 Mean SD Mean SD 
PF 25 16.96 38.75 20.21 13.75 55% 
RP 37.5 27.51 49.61 28.27 12.11 32.29% 
BP 32.94 18.82 41.44 15.81 8.5 25.8% 
GH 64.65 20.23 70.06 20.46 5.41 8.37% 
VT 42.28 20.79 41.8 21.74 -0.48 -1.14% 
SF 61.76 28.46 62.5 25.41 0.74 1.2% 
RE 68.63 32.48 73.96 24.7 5.33 7.77% 
MH 71.18 20.96 73.44 14.46 2.26 3.18% 
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PCS 32.24 7.65 37.03 8.5 4.79 14.86% 
MCS 50.86 13.52 50.31 9.79 -0.55 -1.08% 
 
A longer-term (at 1-2 years) follow-up will shed more light on whether the 
poor outcome group’s WOMAC and SF-36 results will improve over time.  
 
Study Limitations  
The limitations of this study must be acknowledged. A wash out of all pain 
medications prior to testing was not possible due to ethical concerns.  
The longitudinal nature of the study meant that an extended length of time 
was needed to complete the study. This proved to be particularly challenging 
as at the point of the write up of this thesis, the investigator was not able to 
complete data collection for all the participants who took part in this present 
study.  
Another limitation of cohort studies is the attrition of participants due to the 
length of time needed to complete the study, however, only 2 participants 
were lost at follow-up for this study. The small sample size of this study 
meant that it is potentially underpowered. Recruitment of participants was 
adversely affected, due to a change in Western Australia’s Public Health 
funding model. This included the restructuring of RPH (which was the 
intended primary site of this research project’s data collection). The closure 
of RPH Shenton Park Campus and the subsequent shut down of the RPH 
Joint Replacement Assessment Clinic were the result of RPH’s restructuring 
process. Another result of the restructure meant that the RPH focus on 
elective TKR surgery shifted from primary TKRs to complex cases and 
revisions which are not the intended scope of study for this research project. 
FHHS was then added as another site of data collection in September 2015. 
However, participant recruitment proved difficult as only 1 out of every 12 
potential TKR patients agreed to take part in the research. 2 orthopaedic 
surgeons in private practice agreed to collaborate and data collection started 
in SJOG Hospitals in late June 2016. Due to the above factors, it was 
impossible to recruit the 120 participants as planned. 
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Implications 
This prospective cohort study identified several predictors of pain and 
outcome after TKR surgery. By using the predictive models detailed in this 
present study, it is possible to predict pain levels at 3 months and outcomes 
at 6 months post-TKR. This study has also identified factors that contribute to 
the development of persistent pain post-TKR. The results of this study can be 
used as a basis for a model of risk-stratified care management for knee OA 
patients who decide to undertake a TKR.  
 
4.7. Conclusion  
In conclusion, the present study identified several key pre-operative 
measures to predict pain levels and outcomes post-TKR surgery. Validation 
of the predictive models identified in this present study will be needed.  
Patients who report higher pain levels and poor outcomes after TKR surgery 
exhibit widespread multi-modality sensory impairments and reduced physical 
function. They also had significantly higher levels of self-reported pain, 
neuropathic pain, pain catastrophisation, psychological distress; more co-
morbid conditions; and significantly lower scores on the WOMAC and SF-36. 
Short-term follow-up on this group of patients revealed that even though the 
TKR surgery improved the WOMAC scores, the level of improvement did not 
reach the MCID. A longer-term follow-up will help to elucidate the utility and 
effectiveness of TKR surgery for this group of patients. Brander et al. (2003) 
reported the prevalence of significant persistent pain to be 18.4% at 6 
months and 13.1% at 12 months post-TKR surgery. Wylde et al. (2011) 
reported that 15% of patients experienced significant pain at 3 to 4 years 
post-TKR surgery. The present study reported a similar percentage (15%) of 
patients at 6 months post-TKR having a poor outcome. 
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Chapter 5 
Discussion 
 
The overall purpose of this investigation was to develop a standardised 
protocol for predicting prior to undertaking a total knee replacement those 
patients who are likely to develop persistent post-operative pain. The 
investigation identified several key pre-operative measures which can be 
used to predict pain levels and outcomes post-TKR surgery.  
 
Complexity of OA pain 
Historically, the cause of OA pain was believed to be primarily nociceptive in 
nature. However, research has shown that there are multiple mechanisms 
(nociceptive, neuroplastic and neuropathic), pain processes (peripheral and 
central sensitisation), and psychosocial factors that contribute to the 
generation of OA pain.   
Due to the complexity of OA pain, Suokas et al. (2012) stated “that 
treatments targeting one specific mechanism may have low efficacy if offered 
to people whose pain is largely mediated by other mechanisms”. This may be 
relevant to surgical interventions as well as pharmacological treatments. 
 
Persistent pain post-TKR 
The prevalence of persistent pain post-TKR ranges widely from 13.1% to 
44% (Baker et al., 2007; Brander et al., 2003; Puolakka et al., 2010; Wylde et 
al., 2011). This wide variance in the reported prevalence may in part be due 
to differences in pain levels reported. For example, Wylde et al. (2011) 
reported that 44% of TKR patients in their study had persistent post-surgical 
pain at 3 to 4 years post-TKR surgery of any severity, with 15% reporting 
severe-extreme pain. Brander et al. (2003) reported on “significant pain” 
post-TKR, finding that 44.4%, 22.6%, 18.4% and 13.1% of their research 
participants reported this level of pain at 1, 3, 6 and 12 months post-surgery, 
respectively.  
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Study 1 (Quantitative Sensory Testing identifies patients with poor outcomes 
one year following Total Knee Replacement) 
Study 1 utilized a cross sectional study design to investigate if there were 
any differences in QST measures and self-reported measures of pain, health 
and function between patients who had a good or poor outcome following 
TKR surgery. A poor outcome was defined as continuing to experience pain 
more than one year after joint replacement surgery. The study results 
demonstrated that there were significant differences between the good and 
poor outcome groups in most of the QST measures (At the knee: PPT, HDT 
and CPT. At the elbow: PPT, CDT, HDT, CPT and HPT) and self-report 
questionnaires (PainDETECT, PQAS, EQ-5D and WOMAC). The results of 
study 1 showed that there were unequivocal differences between patients 
reporting good and poor outcomes following TKR surgery. The next step 
from study 1 was to conduct a prospective observational study to investigate 
if these significant differences were also present pre-operatively. 
 
Study 2 (Sustained cold response) 
In study 1, CPT was a QST measure that showed significant differences 
between the good and poor outcomes groups at both test sites. The results 
from study 1 showed that CPT and PainDETECT were significantly higher in 
the poor outcome group. Conventional testing of cold pain response is of 
limited utility in the clinical setting due to equipment expense and 
impracticality. Hence, study 2 investigated the reliability and validity of 2 
alternative simple methods of testing cold pain response. Study 2 results 
demonstrated the reliability and validity of both alternative methods of testing 
cold pain response. The sustained cold response test was chosen as one of 
the QST measures in study 3 due to its ease of use.  
 
Study 3 (Evaluation of predictors for persistent pain post-Total Knee 
Replacement) 
Study 3 was designed to build on the results and knowledge that was gained 
from studies 1 and 2. The results from study 3 reported a similar percentage 
(15%) of patients having significant pain levels at 6 months post-TKR as 
Brander et al. (2003) and Wylde et al. (2011). This study also demonstrated 
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that pre-operatively there were significant differences in patients who showed 
higher pain levels both at 3 months, and at 6 months after TKR surgery. 
Based on the results of study 1, QST measures such as PPT, HDT and CPT 
were anticipated to be associated with pain and outcomes following TKR 
surgery but the results of study 3 proved otherwise. VDT was the only QST 
measure which demonstrated a significant association to higher pain levels 
and poor outcomes.  
 
Further analysis revealed that there were a number of pre-operative 
measures which were found to be predictive of higher pain levels and poor 
outcome at 3 and 6 months respectively. Several of these measures are of 
particular interest since they are potentially modifiable. These can be 
grouped into 4 risk factor categories: psychological distress, neuropathic-type 
pain, impaired physical function and reduced sleep quality. 
 
Modifiable predictors of persistent pain post-TKR 
Psychological distress 
Psychological distress has been described as “maladaptive psychological 
functioning in the face of stressful lifestyle events” (Abeloff et al., 2000). 
Psychological distress can include post-traumatic stress disorder, 
depression, anxiety, pain catastrophisation and stress, and is a frequent 
feature of patients suffering from persistent post-surgical pain (Belfer et al., 
2013; Jeffery et al., 2011; Masselin-Dubois et al., 2013; Ross et al., 2015; 
Skogstad et al., 2014; Vilardo & Shah, 2011; Vincent et al., 2015; Wylde et 
al., 2011). Hence, it is not unreasonable that it could play a substantial role in 
the development of persistent pain post-TKR.     
A patient in psychological distress can appear to be anxious, be in low mood, 
having negative beliefs and be unduly worried about their pain.  
Several studies have demonstrated that patients presenting with pre-
operative psychological distress reported poorer outcomes (e.g. high pain 
levels, reduced quality of life, poor patient satisfaction) following total knee 
replacement surgery (Duivenvoorden et al., 2013; Lingard & Riddle, 2007; 
Masselin-Dubois et al., 2013). However, it is currently unknown whether 
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individuals develop psychological distress because they are experiencing 
unexpected and persisting post-surgical pain. 
Wade et al. (2011) investigated the role of pain catastrophizing in patients 
with chronic and severe arthritic pain and suggested that psychological 
intervention could provide a reduction of pain-related suffering. Psychological 
intervention such as cognitive-behavioural therapy (CBT) and acceptance 
and commitment therapy have demonstrated efficacy in treating 
psychological distress and its influence on pain in a number of conditions (i.e. 
eating disorders, inflammatory bowel disease, chronic pain) (Bohlmeijer et 
al., 2011; Darnall et al., 2014; Fledderus et al., 2011; Forman et al., 2007; 
Hofmann et al., 2012; Lappalainen et al., 2014; Mussell et al., 2003; Powers 
et al., 2009; Smeets et al., 2006; Swain et al., 2013; Thorn et al., 2007; 
Wetherell et al., 2011).  
Hence, patients who scored highly on the psychological distress risk factor 
might require a mental health referral and intervention. 
 
Neuropathic-type pain 
Phillips et al. (2014) investigated the natural history of neuropathic pain for at 
least 3 years following TKR surgery. The investigators reported that the 
incidence of post-operative neuropathic pain was highest at 6 weeks (27% 
having scores in the intermediate classification of “unclear neuropathic”, and 
8% in the “likely neuropathic” classification) and that the number reduced 
over time to 7% in “unclear neuropathic” and 6% in “likely neuropathic” at 
their final follow-up (mean of 46 months) (Phillips et al., 2014). This suggests 
that neuropathic pain following TKR surgery gradually reduces over time. 
The current series of studies supports this finding. Study 1 demonstrated that 
TKR patients with a poor outcome at 1 year post-surgery had significantly 
higher PainDETECT scores (at 12-36 months post-TKR) than the good 
outcome group. Study 3 showed that pre-operative PainDETECT scores 
were significantly higher in patients reporting significant pain at 3 months 
post-TKR surgery; and in the poor outcome group at 6 months post-TKR 
surgery. In study 3, the poor outcome group also showed significantly higher 
PainDETECT scores at their 3 months post-surgical assessment. These 
findings provide support for the current OA-neuropathic pain literature in 
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showing that: i) a substantial proportion of patients with OA present with 
features of neuropathic pain; ii) a proportion of patients suffering from 
persistent pain post-TKR continue to report a neuropathic pain component 
(Albayrak et al., 2016; Buvanendran et al., 2010; Fuzier et al., 2015; Harden 
et al., 2003; Haroutiunian et al., 2013). 
The results of study 3 demonstrated that pre-operative PainDETECT score 
was a significant predictor of higher pain levels at 3 months post-TKR. This 
report of pre-surgical neuropathic pain contradicts Kehlet et al. (2006) who 
asserted “that postsurgical chronic pain is the consequence either of ongoing 
inflammation or, much more commonly, a manifestation of neuropathic pain 
resulting from surgical injury to major peripheral nerves”. Even though the 
pre-operative PainDETECT score was not a significant predictor of poor 
outcome at 6 months post-TKR, it was very close to significance. It is 
anticipated that, with ongoing data collection, as more participants pass the 6 
month post-surgery time point, pre-operative PainDETECT will be a 
significant predictor of persistent pain post-TKR.  
It is important to note that in persistent pain post-TKR, the pain may be 
caused by an abnormal neuromodulatory reaction, rather than the peripheral 
nociceptive input. Hence, removal of the nociceptive input is less effective as 
a treatment. 
As stated above, there is mounting evidence to suggest that there is a 
neuropathic pain component in a proportion of patients suffering from 
persistent pain post-TKR and this phenomenon is identifiable in the OA 
population pre-operatively using the PainDETECT questionnaire. This 
suggests therefore that this could be an identifiable and modifiable risk 
factor.  
 
VDT is a QST measure used for the quantification of large fiber sensory 
deficits (reduced perception and/or numbness) which has been strongly 
suggested to be indicative of neuropathic pain (Backonja et al., 2013; Baron 
et al., 2010). A review on the use of VDT testing in diabetic peripheral 
neuropathy (DPN) reported good evidence to support its use in the accurate 
identification of early neuropathic deficits in diabetic patients who are at risk 
of DPN-associated complications (i.e. foot ulcers) (Garrow & Boulton, 2006).  
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Kavchak et al. (2012) investigated the relationship between pain and altered 
somatosensation in individuals with severe knee OA, and reported that VDT 
was significantly increased as compared to healthy controls. The 
investigators also reported a moderate correlation between increased VDT 
and higher levels of perceived instability during a functional task. 
The results from study 3 demonstrated that patients who had higher pain 
levels and poor outcomes following TKR surgery had significantly higher 
VDTs. The presence of hypoesthesia (as measured using VDT) and high 
scores on the PainDETECT supports the presence of neuropathic-type pain 
in patients who report poor outcomes post-TKR.    
 
Patients who score highly on the neuropathic-type pain risk factor may 
benefit from specific pharmacological interventions to address neuropathic 
pain. 
 
Impaired physical function 
Impaired physical function and reduced physical activity levels are hallmark 
features of individuals suffering from knee OA (Farr et al., 2008; 
Herbolsheimer et al., 2016; Liikavainio et al., 2008; McAlindon et al., 1993; 
Sharma et al., 2003). TKR patients with poor outcomes report similar issues 
with impaired physical function (Baker et al., 2007; Walsh et al., 1998; Wylde 
et al., 2009). Although potentially this is a pre-operative modifiable feature, 
impaired function may be influenced by a range of associated factors. For 
example, is impaired function purely physiological and related to decreased 
muscle strength or must factors such as pain-related avoidance, or the 
impact of psychological distress also be considered? Several studies have 
reported a link between the presence of psychological distress and impaired 
physical function (Creamer et al., 2000; Ellis et al., 2012; Lingard et al., 2004; 
Scopaz et al., 2009). Based on the current evidence, impaired physical 
function might be intrinsically linked with psychological distress. Further 
studies will be needed to elucidate this association. 
In the clinical setting, physical function is measured using physical function 
tests (i.e. stairs, timed up and go test, timed walking distance tests), knee 
extensor strength tests (i.e. using handheld dynamometer, isokinetic 
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machines) and self-report questionnaires (i.e. WOMAC) (Creamer et al., 
2000; Fitzgerald et al., 2004; Liikavainio et al., 2008; McAlindon et al., 1993; 
O’Reilly et al., 1998; Sharma et al., 2003). Patients with impaired physical 
function can present with poorer performance in physical function tests, 
reduced knee extensor strength and/or higher scores in the WOMAC 
physical function scale (indicating increased difficulty in performing functional 
tasks) (Creamer et al., 2000; Fitzgerald et al., 2004; Liikavainio et al., 2008; 
McAlindon et al., 1993; O’Reilly et al., 1998; Sharma et al., 2003). 
 
Pre-operative rehabilitation (or prehabilitation) has been described as a 
“process of enhancing functional capacity of the individual to enable him or 
her to withstand the stressor of inactivity associated with an orthopaedic 
procedure” (Ditmyer et al., 2002). Prehabilitation programs usually 
incorporate components of aerobic, strength, flexibility and functional tasks 
training (Ditmyer et al., 2002; Topp et al., 2002). Several studies have 
supported the efficacy of prehabilitation in TKR patients (Brown et al., 2010; 
Huang et al., 2012; Rooks et al., 2006; Swank et al., 2011; Topp et al., 
2009). Huang et al. (2012) investigated the effectiveness of a simple 4 week 
prehabilitation program in TKR patients and reported that patients in the 
prehabilitation program had a shorter length of stay in hospital and reduced 
hospitalization-related expenses as compared to the control group. Rooks et 
al. (2006) evaluated the effectiveness of a 6 week prehabilitation program on 
patients who were undertaking a total joint replacement (TKR or THR). The 
investigators found that those in the prehabilitation program had significantly 
improved muscle strength as compared to controls, and significantly reduced 
the risk of admittance into an inpatient rehabilitation facility after surgery. The 
studies conducted by Rooks et al. (2006) and Huang et al. (2012) showed 
that following prehabilitation, there was no significant difference in post-
operative physical function between groups. 
However, the results of several systematic reviews on the efficacy of 
prehabilitation for TKR were mixed (Kwok et al., 2015; Silkman Baker & 
McKeon, 2012; Simmons & Smith, 2013). Hence, the idea of prehabilitation 
is promising but the evidence of its efficacy is still inconclusive. It is important 
to note that the major limitation to all the current studies on prehabilitation is 
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the small sample sizes, and that none of the above studies investigated the 
effects of prehabilitation on fear avoidance and its influence in the 
development of persistent pain post-TKR. 
Patients who scored highly on the impaired physical function risk factor might 
require a course of prehabilitation with a special focus on modifying fear 
avoidant behaviour. 
 
Reduced sleep quality 
Sleep is complex and generally divided into 2 states, rapid eye movement 
(REM) sleep and non-REM (NREM) sleep which is further divided into 4 
stages (Ancoli-Israel & Ayalon, 2006; Markov & Goldman, 2006). Sleep 
disorders are classified into primary or secondary (Park et al., 2007). The 
construct of sleep is very complex and beyond the scope of this doctoral 
thesis, hence the nature and mechanisms of sleep and its related disorders 
will not be covered here. 
A robust relationship between reduced sleep quality and increased pain 
levels has been demonstrated in chronic pain conditions as well as in healthy 
populations (Call-Schmidt & Richardson, 2003; Kundermann et al., 2004; 
Lautenbacher et al., 2006; Marin et al., 2006; Menefee et al., 2000; Sayar et 
al., 2002; Schuh-Hofer et al., 2013). However, due to the complexity of both 
pain and sleep, the true directional relationship between pain and sleep has 
yet to be elucidated. 
Reduced sleep quality has been associated with higher pain levels and 
increased functional limitations in both knee OA and TKR populations 
(Cremeans-Smith et al., 2006; Hawker et al., 2010; Wilcox et al., 2000; 
Wylde et al., 2011). Cremeans-Smith et al. (2006) reported that TKR patients 
who had more sleep disturbances had significantly more functional limitations 
at 3 months following surgery. Wylde et al. (2011) reported that TKR patients 
who reported more sleep disturbances had significantly higher pain levels 
than those who slept better. The above studies support the results from study 
3 which reported that TKR patients with higher pain levels reported more 
sleep disturbances.  
Treatment of sleep disorders include pharmacological and non-
pharmacological interventions. Pharmacological interventions include the use 
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of hypnotic sedatives, antidepressants and melatonin receptor agonists 
(Ancoli-Israel & Ayalon, 2006; Gong et al., 2015; Lemoine et al., 2007; Park 
et al., 2007; Zhu, 2013). Non-pharmacologic treatment of sleep disorders 
includes sleep hygiene education, CBT, relaxation therapies, sleep assistive 
devices (i.e. continuous positive air pressure therapy), music therapy and 
physical exertion (Lai & Good, 2005; Morin et al., 1999; Park et al., 2007; 
Yang et al., 2012; Zhu, 2013). 
Patients who scored highly on the reduced sleep quality risk factor might 
require a referral to sleep medicine for diagnosis and treatment of their sleep 
disorder.   
 
Based on the 4 identified risk factors, the tables below (Table 5.1, Table 5.2 
and Table 5.3) list the variables that predict pain and poor outcome post-TKR 
surgery.  
 
Table 5.1: Pre-operative variables predicting 3 month pain levels 
  Score OR Sensitivity Specificity 
Psychological 
distress 
PCS 
Magnification 
1.5 
1.4 0.647 0.649 
PHQ8 4.5 1.19 0.706 0.632 
Neuropathic-
type pain 
PainDETECT 11.5 1.24 0.765 0.877 
Impaired 
physical 
function 
ALF Transfer 10.1 1.14 0.706 0.649 
Reduced 
sleep quality 
PSQI Sleep 
Quality 
1.5 3.2 0.529 0.737 
 
Table 5.2: Pre-operative variables predicting 6 month outcomes 
  Score OR Sensitivity Specificity 
Psychological 
distress 
PCS 
Magnification 
2.5 
1.47 0.667 0.784 
PHQ8 7.5 1.28 0.778 0.824 
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Neuropathic-
type pain 
PainDETECT 11.5 1.14 0.778 0.804 
Impaired 
physical 
function 
ALF Transfer 11.1 1.16 0.778 0.725 
 
Table 5.3: 3 month post-operative variables predicting 6 month outcomes 
  Score OR Sensitivity Specificity 
Psychological 
distress 
PCS 
Magnification 
0.5 
2.83 0.889 0.863 
PHQ8 6.5 1.4 0.778 0.843 
Neuropathic-
type pain 
PainDETECT 10.5 1.22 0.778 0.824 
Reduced 
sleep quality 
PSQI Sleep 
Quality 
1.5 3.03 0.556 0.706 
 
Risk factors 
There were a number of variables which were proposed as being pre-
operative risk factors in the development of persistent pain post-TKR, see 
table below (Table 5.4). 
 
Table 5.4: Risk factors for persistent post-surgical pain after TKR. 
Risk factors for persistent post-surgical pain after TKR 
Pre-Operative Intra-Operative Post-Operative 
• Age 
• Female gender 
• Depression 
• Anxiety 
• Pain catastrophising 
• High levels of pain 
• Lower functional 
capacity 
• Pain sensitivity 
• Excessive tissue 
damage (e.g. Nerves, 
muscles, soft tissues)  
• Surgical approach 
(eg PCL sacrifice, 
lateral release) 
 
• High levels of acute 
post-operative pain 
• Anxiety 
• Depression 
• Pain catastrophising 
• Sleep quality 
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• Presence of comorbid 
medical conditions 
Based on Brander et al. (2003); Cremeans-Smith et al. (2006); Elson and 
Brenkel (2006); Fortin et al. (1999); Hawker et al. (2010); Judge et al. (2012); 
Lingard et al. (2004); Riddle et al. (2010); Vilardo and Shah (2011); Wilcox et 
al. (2000) and Wylde et al. (2011) 
 
The results of study 3 did not show age and gender as being predictive of 
persistent pain post-TKR. 
 
Variables associated with outcomes post-TKR 
Table 5.5 below shows some of the variables and their association with 
outcomes after TKR surgery. Refer to Appendix 6 for detailed results. 
 
Table 5.5: Variables and association with outcomes after TKR. 
Variables Outcomes post-TKR 
Smoking history No association 
Duration of pain No association 
Pre-operative medications Very strong association 
Anaesthetic blocks Moderately strong association 
Intra-operative anaesthesia No association 
Surgical approach No association 
Post-operative pain medications No association 
Prosthesis Moderately strong association 
Physiotherapy before TKR Moderately strong association 
Physiotherapy after TKR No association  
 
 
Pre-operative medications 
Even though the statistical analysis demonstrated a strong association 
between the type of pre-operative medication and outcomes at 3 and 6 
months after TKR surgery, it is difficult to draw any real conclusions or 
determine the true associations between them. This is mainly due to the 
numerous combinations of medications (11 combinations of medications) 
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that were taken by the participants. There may be a trend for those on anti-
epileptics and opioids being more likely to have a poor outcome, this could 
be due to higher levels of pain or hint at an association with neuropathic pain. 
 
Anaesthetic blocks 
There was a moderately strong association between type of anaesthetic 
blocks used and outcomes at 6 months after TKR surgery. However, no 
definitive conclusion can be reached. 2 members in the poor outcome group 
received a spinal block for their TKR surgery, compared to none in the good 
outcome group. This possibly drove the results towards significance. Spinal 
blocks are typically only used in isolation in patients with more comorbidities, 
as combination of anaesthetic blocks increases the risks and complications 
of anaesthesia use.   
 
Prosthesis 
Although there appears to be a moderately strong association between type 
of prosthesis and outcomes at 6 months after TKR surgery, it appears to be 
driven by 2 types of prosthesis (Nex Gen and Omni Apex) that were used 
only in the poor outcome group. However, the numbers in the poor outcome 
group (1 participant received the Nex Gen implant, 1 participant received the 
Omni Apex implant) are too small to be able to work out a trend.  
 
Physiotherapy before TKR 
There was a moderately strong association between physiotherapy treatment 
before TKR and outcomes at 3 and 6 months after TKR surgery. This may be 
because pre-operatively, the poor outcome group reported higher levels of 
pain and functional disability. Hence a greater percentage of the poor 
outcome group were undergoing pre-operative physiotherapy treatment. 
 
Differences between study 1 and study 3 
The results from study 1 showed that there were significant differences 
between the groups, with the poor outcome group demonstrating widespread 
mechanical and cold hyperalgesia, sensory changes, lower self-reported 
health status, impaired physical function and higher levels of neuropathic-
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type pain. The results from study 3 did not show any significant group 
differences in the QST measures (PPT, HDT and CPT) that were anticipated 
to have associations with pain and outcomes, but there were significant 
group differences in self-reported health status, sleep quality, psychological 
distress, co-morbidities and physical function.  
There were fundamental differences between study 1 and study 3 which 
could account for the variances in the results between the 2 studies. These 3 
differences are in study design, participant group and assessment time point.  
 
Study design 
The 2 studies utilized different study designs. Study 1 utilized a cross 
sectional study design, whereas study 3 utilized a prospective observational 
study design. 
 
Participant group 
The participant group in study 1 consisted of RPH JRAC patients that were 
12-36 months post-TKR surgery. Participants in study 1 were grouped 
according to the pain component of the KSS. The pain component of the 
KSS is categorized as no pain (none), mild or occasional pain (stairs only, 
walking and stairs), moderate pain (occasional, continual), and severe pain 
(Insall et al., 1989). Participants who had no pain were allocated to the good 
outcome group, and those with moderate to severe pain were allocated to 
the poor outcome group. RPH JRAC patients who reported mild or 
occasional pain were not recruited for the study. 
For study 3, participants were recruited pre-operatively from RPH, FHHS and 
SJOG Subiaco and Murdoch Hospitals. Similarly to study 1, the participants 
were grouped into a good or poor outcome group based on the pain 
component of the KSS. Participants who reported no pain and mild or 
occasional pain were allocated to the good outcome group, and those with 
moderate to severe pain were allocated to the poor outcome group.  
 
Assessment time point 
The assessment time point of the QST testing protocol for the 2 studies was 
also different. The research assessment for study 1 was performed within 12-
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36 months after the TKR surgery, whereas the post-operative research 
assessment for study 3 was done at 3 months after surgery.  
 
Another possible explanation of the difference in results is that following TKR 
surgery, a ‘reset’ of the neural pathways is triggered due to the removal of 
the damaged tissue. However, in a small sub-group of patients this ‘reset’ of 
the neural pathways is halted or reversed due to the presence of other pain 
mechanisms.  
 
Clinical recommendations 
The results of this doctoral research suggest that it may be possible to 
identify patients who will develop persistent pain post-TKR at the pre-
operative consultation with their orthopaedic surgeon.  
There would be considerable clinical benefit in developing a battery of 
measures that could be applied during the initial pre-operative consultation, 
the results of which could be used to assess patients in terms of modifiable 
risk factors. 
The pre-operative screening tool would need to be short and simple to use, 
so as not to increase the burden on both clinicians and patients. 
This pre-operative screening tool can be used to stratify the risk of 
developing persistent pain post-TKR. Based on the identified risk factors, 
patients could then be channeled towards targeted interventions to mitigate 
the development of persistent pain post-TKR. These interventions might 
include programs to address psychological distress, pharmacological 
management of neuropathic pain, programs and medication to improve sleep 
quality and physical prehabilitation programs. Based on the individual risk 
profile, an appropriate preparatory program could be developed.  
 
Predicting persistent pain post-TKR 
Moving forward, there is some degree of refinement that would be needed 
before using this pre-operative screening tool in a large multi-centre trial.  
 
The first step towards validation of the screening tool would be to streamline 
the assessment process. Based on the results of study 3, the assessment 
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process can be streamlined by cutting out the variables that did not 
demonstrate statistical significance. The streamlined assessment process 
can then be applied on knee OA patients who will be undergoing a TKR. The 
patients who have been identified through this process as likely to have a 
poor outcome post-TKR, will then need to be followed through to confirm the 
utility of the tool. The post-surgery (at 3, 6 and 12 months) follow-up 
screening will be used to check the percentage of patients who were 
correctly identified as likely to have a poor outcome in the pre-operative 
assessment and compared against the actual poor outcome numbers.    
 
The second step would be to use the pre-operative screening tool in a large 
multi-centre trial. Using the results of the screening tool, participants would 
be allocated to specific targeted interventions (e.g. psychological intervention 
if results showed that the participant was in psychological distress). The 
participants would then be reassessed again after the targeted intervention 
and prior to TKR surgery. The participants would then be followed up post-
surgery to determine the efficacy of the targeted intervention in terms of 
achieving better post-operative outcomes.   
 
The final step would be the development of a computer program/mobile 
application which could be used by any healthcare professional in predicting 
persistent pain post-TKR, and directing targeted pre-operative intervention 
for each patient to ensure good outcomes and maximize the benefits of TKR 
surgery.   
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Schedule / Timeline for outcome measures 
  
Pre-
operative 
1 day post-
surgery 
At 3 
months 
post-
surgery 
At 6 
months 
post-
surgery 
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WOMAC  ✓  ✓  
SF-36  ✓  ✓  
SCQ ✓  ✓  
PainDETECT ✓  ✓  
PQAS ✓  ✓  
PCS ✓  ✓  
PHQ-8 ✓  ✓  
PSQI ✓  ✓  
NRS  ✓   
P
h
y
s
ic
a
l 
/ 
s
e
n
s
o
ry
 t
e
s
ts
 ROM  ✓  ✓  
ALF ✓  ✓  
Knee extensor 
strength 
✓  ✓  
QST  ✓  ✓  
K
n
e
e
 S
o
c
ie
ty
 S
c
o
re
 
Pain 
component 
(telephone 
interview)  
   ✓ 
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Appendix 3 
 
Data Collection Form 1 
 
Subject ID  
Age  
Gender  
Height (metres)  
Weight (kg)  
Smoking History  
Duration of pain   
Pre-op pain 
meds 
 
Anesthesia used 
in op 
 
Post-op pain 
meds 
 
 
Prosthesis used  
Surgical 
approach 
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Appendix 4 
 
Data Collection Form 2 (Treatment before TKR) 
 
Participant ID  
Physiotherapy 
Treatment Details Number of 
sessions 
Compliance and 
Efficacy 
Hydrotherapy    
Gait training    
Home exercises    
Advice/Education    
EPA    
Other types of intervention 
Treatment Details Number of 
sessions 
Compliance and 
Efficacy 
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Data Collection Form 3 (Treatment after TKR)  
 
Participant ID  
Physiotherapy 
Treatment Details Number of 
sessions 
Compliance and 
Efficacy 
Hydrotherapy    
Gait training    
Home exercises    
Advice/Education    
EPA    
Other types of intervention 
Treatment Details Number of 
sessions 
Compliance and 
Efficacy 
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Appendix 6 
   
Confounding Variables 
• Age 
There was no significant group difference in age at 3 and 6 months post-
surgery (Table A5.1). Therefore, this variable was not included in the logistic 
regression model. 
 
 Table A5.1: Age grouped by 3 and 6 months outcome 
Pain levels at 3 months post-TKR 
 No to mild pain Moderate to severe pain 
p 
 Mean SEM Mean SEM 
Age 70.04 0.96 67.65 1.86 0.257 
Outcome group at 6 months post-TKR 
 Good outcome Poor outcome 
p 
 Mean SEM Mean SEM 
Age 69.9 1.05 66.56 2.47 0.188 
* Indicates statistical significance at p  0.05 
 
• Gender 
Gender as grouped by pain levels at 3 months and outcome at 6 months 
post-TKR are as shown in table A5.2.  
 
Table A5.2: Gender grouped by 3 and 6 months outcome 
Pain levels at 3 months post-TKR 
  No to mild pain Moderate to severe pain Total 
Gender 
Male 23 7 30 
Female 34 10 44 
Total 57 17 74 
Outcome group at 6 months post-TKR 
  Good outcome Poor outcome Total 
Gender 
Male 21 3 24 
Female 30 6 36 
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Total 51 9 60 
 
There was no significant association between gender and outcomes at 3 and 
6 months post-TKR (Table A5.3) 
 
Table A5.3: Pearson’s chi-square tests for gender grouped by outcome at 3 
and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  0.004 1 0.951 
6 months outcome  0.196 1 0.658 
* Indicates statistical significance at p  0.05 
 
• Smoking History 
Smoking history grouped by pain levels at 3 months and outcome at 6 
months post-TKR are as shown in table A5.4.  
 
Table A5.4: Smoking history grouped by 3 and 6 months outcome 
Pain levels at 3 months post-TKR 
  No to mild 
pain 
Moderate to 
severe pain 
Total 
Smoking 
history 
Non-smoker 31 10 41 
Ex-smoker 23 6 29 
Smoker 3 1 4 
Total 57 17 74 
Outcome group at 6 months post-TKR 
  Good 
outcome 
Poor outcome Total 
Smoking 
history 
Non-smoker 24 7 31 
Ex-smoker 24 1 25 
Smoker 3 1 4 
Total 51 9 60 
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There was no statistically significant association between smoking history 
and outcomes at 3 and 6 months post-TKR (Table A5.5). 
 
Table A5.5: Pearson’s chi-square tests for smoking history grouped by 
outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  0.14 2 0.932 
6 months outcome  4.08 2 0.13 
* Indicates statistical significance at p  0.05 
 
• Duration of Pain 
There was no significant group difference in duration of pre-operative pain in 
the index knee at 3 and 6 months post-surgery. Therefore, this variable was 
not included in the logistic regression model. 
 
Table A5.6: Duration of pain grouped by 3 and 6 months outcome 
Pain at 3 months post-TKR 
 No to mild pain Moderate to severe 
pain p 
 Mean SEM Mean SEM 
Duration of pain 6.87 0.84 6.29 1.27 0.781 
Outcome group at 6 months post-TKR 
 Good outcome Poor outcome 
p 
 Mean SEM Mean SEM 
Duration of pain 6.82 0.92 5.61 1.58 0.618 
* Indicates statistical significance at p  0.05 
 
• Presence of post-operative infection 
There was only 1 case of deep infection in the operated knee. The participant 
is recovering well with conservative treatment, and has not reported any pain 
in the operated knee at 6 months follow-up. 
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• Analgesia 
Pre-Operative 
Table A5.7 lists the type of pre-operative pain medication taken by 
participants. 
  
Table A5.7: Pre-operative pain medications grouped by 3 and 6 months 
outcome 
Pre-operative pain medications grouped by pain at 3 months post-
TKR 
Medication Pain <4 % Pain >=4 % 
None 14 25% 2 12% 
Non-Opioid Analgesia 20 35% 5 29% 
NSAIDs 6 11% 0 0% 
Non-Opioids Analgesia + 
NSAIDs 
7 12% 5 29% 
Opioids + Antiepileptics + 
Corticosteroids 
0 0% 1 6% 
Non-Opioid Analgesia + Opioids 5 9% 0 0% 
Non-Opioid Analgesia + Opioids 
+ Antiepileptics + Tricyclic 
Antidepressants 
1 2% 0 0% 
Non-Opioid Analgesia + Opioids 
+ Antiepileptics 
0 0% 1 6% 
Opioids + NSAIDs + 
Antiepileptics 
0 0% 1 6% 
Non-Opioid Analgesia + Opioids 
+ NSAIDs 
3 5% 1 6% 
Opioids + Benzodiazepines 0 0% 1 6% 
Non-opioids + Opioids + 
Tricyclic Antidepressants 
1 2% 0 0% 
Total 57 100% 17 100% 
Pre-operative pain medications grouped by 6 months outcome post-
TKR 
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Medication 
Good 
Outcome 
% 
Poor 
Outcome 
% 
None 13 25% 0 0% 
Non-Opioid Analgesia 17 33% 2 22% 
NSAIDs 6 12% 0 0% 
Non-Opioids Analgesia + 
NSAIDs 
7 14% 2 22% 
Opioids + Antiepileptics + 
Corticosteroids 
0 0% 1 11% 
Non-Opioid Analgesia + Opioids 3 6% 1 11% 
Non-Opioid Analgesia + Opioids 
+ Antiepileptics + Tricyclic 
Antidepressants 
1 2% 0 0% 
Opioids + NSAIDs + 
Antiepileptics 
0 0% 1 11% 
Non-Opioid Analgesia + Opioids 
+ NSAIDs 
3 6% 1 11% 
Opioids + Benzodiazepines 0 0% 1 11% 
Non-opioids + Opioids + 
Tricyclic Antidepressants 
1 2% 0 0% 
Total 51 100% 9 100% 
 
There was a statistically significant association between pre-operative pain 
medication and outcome group at 3 and 6 months post-TKR (Table A5.8). 
The association was very strong for pain levels at 3 months post-TKR 
(Cramer’s V=0.53), and at 6 months post-TKR (Cramer’s V=0.606). 
 
Table A5.8: Pearson’s chi-square tests for pre-operative pain medication 
grouped by outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  20.79 11 0.036* 
6 months outcome  22 10 0.015* 
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* Indicates statistical significance at p  0.05 
 
Intra-Operative 
Anaesthesia used intra-operatively grouped by pain levels at 3 months and 
outcome at 6 months post-TKR are as shown in table A5.9.  
 
Table A5.9: Anaesthesia used grouped by 3 and 6 months outcome 
Pain levels at 3 months post-TKR 
  No to mild 
pain 
Moderate to severe 
pain 
Total 
Anaesthesia 
General 20 2 22 
Sedation 37 15 52 
Total 57 17 74 
Outcome group at 6 months post-TKR 
  Good outcome Poor outcome Total 
Anaesthesia 
General 16 1 17 
Sedation 35 8 43 
Total 51 9 60 
 
There was no significant association between intra-operative anaesthesia 
and outcomes at 3 and 6 months post-TKR (Table A5.10). 
 
Table A5.10: Pearson’s chi-square tests for anaesthesia used grouped by 
outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  3.41 1 0.065 
6 months outcome  1.55 1 0.214 
* Indicates statistical significance at p  0.05 
 
Anaesthetic blocks used intra-operatively grouped by pain levels at 3 months 
and outcome at 6 months post-TKR are as shown in table A5.11.  
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Table A5.11: Anaesthetic blocks grouped by 3 and 6 months outcome 
Pain levels at 3 months post-TKR 
  No to mild 
pain 
Moderate to 
severe pain 
Total 
Anaesthetic 
blocks 
Spinal 2 2 4 
Adductor 
Canal 
7 1 8 
Combination 48 14 62 
Total 57 17 74 
Outcome group at 6 months post-TKR 
  Good 
outcome 
Poor outcome Total 
Anaesthesia 
blocks 
Spinal 0 2 2 
Adductor 
Canal 
5 0 5 
Combination 46 7 53 
Total 51 9 60 
 
There was a statistically significant association between anaesthetic blocks 
and outcome group at 6 months post-TKR (Table A5.12). The association 
was moderately strong (Cramer’s V=0.454). 
 
Table A5.12: Pearson’s chi-square tests for anaesthetic blocks grouped by 
outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  2.15 2 0.341 
6 months outcome  12.35 2 0.002* 
* Indicates statistical significance at p  0.05 
 
Post-Operative 
Table A5.13 lists the type of post-operative pain medication taken by 
participants. 
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Table A5.13: Post-operative pain medications grouped by 3 and 6 months 
outcome 
Post-operative pain medications grouped by pain at 3 months post-
TKR 
Medication Pain <4 % Pain >=4 % 
Opioid Analgesia 0 0% 1 6% 
Non-Opioid Analgesia + Opioids 10 18% 2 12% 
Non-Opioid Analgesia + Opioids 
+ Antiepileptics 
9 16% 5 29% 
Non-Opioid Analgesia + Opioids 
+ NSAIDs 
22 39% 3 18% 
Non-Opioid Analgesia + Opioids 
+ NSAIDS + Antiepileptics 
11 19% 3 18% 
Non-Opioid Analgesia + Opioids 
+ NSAIDS + Antiepileptics + 
Benzodiazepines 
1 2% 1 6% 
Non-Opioid Analgesia + Opioids 
+ NSAIDS + Benzodiazepines 
1 2% 2 12% 
Opioids + NSAIDs 1 50% 0 0% 
Non-Opioid Analgesia + Opioids 
+ Benzodiazepines 
2 4% 0 0% 
Total 57 100% 17 100% 
Post-operative pain medications grouped by 6 months outcome post-
TKR 
Medication 
Good 
Outcome 
% 
Poor 
Outcome 
% 
Opioid Analgesia 1 2% 0 0% 
Non-Opioid Analgesia + Opioids 9 18% 1 11% 
Non-Opioid Analgesia + Opioids 
+ Antiepileptics 
8 16% 2 22% 
Non-Opioid Analgesia + Opioids 
+ NSAIDs 
17 33% 2 22% 
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Non-Opioid Analgesia + Opioids 
+ NSAIDS + Antiepileptics 
12 24% 2 22% 
Non-Opioid Analgesia + Opioids 
+ NSAIDS + Antiepileptics + 
Benzodiazepines 
1 2% 1 11% 
Non-Opioid Analgesia + Opioids 
+ NSAIDS + Benzodiazepines 
2 4% 1 11% 
Opioids + NSAIDs 1 2% 0 0% 
Total 51 100% 9 100% 
 
There was no statistically significant association between post-operative 
analgesia and outcomes at 3 and 6 months post-TKR (Table A5.14). 
 
Table A5.14: Pearson’s chi-square tests for post-operative analgesia 
grouped by outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  11.58 8 0.171 
6 months outcome  3.76 7 0.807 
* Indicates statistical significance at p  0.05 
 
• Prosthesis 
Type of prosthesis grouped by pain levels at 3 months and outcome at 6 
months post-TKR are as shown in table A5.15.  
 
Table A5.15: Prosthesis grouped by 3 and 6 months outcome 
Pain levels at 3 months post-TKR 
  No to mild 
pain 
Moderate to 
severe pain 
Total 
Prosthesis 
Attune 12 6 18 
Triathlon 32 4 36 
Legion + 
Genesis II 
12 6 18 
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Nex Gen 0 1 1 
Omni Apex 1 0 1 
Total 57 17 74 
Outcome group at 6 months post-TKR 
  Good 
outcome 
Poor outcome Total 
Prosthesis 
Attune 10 3 13 
Triathlon 27 1 28 
Legion + 
Genesis II 
14 3 17 
Nex Gen 0 1 1 
Omni Apex 0 1 1 
Total 51 9 60 
 
There was a statistically significant association between type of prosthesis 
and outcome group at 6 months post-TKR (Table A5.16). The association 
was moderately strong (Cramer’s V=0.499). 
 
Table A5.16: Pearson’s chi-square tests for type of prosthesis grouped 
by outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  8.7 4 0.069 
6 months outcome  14.96 4 0.005* 
* Indicates statistical significance at p  0.05 
 
• Surgical Approach 
Surgical approach grouped by pain levels at 3 months and outcome at 6 
months post-TKR are as shown in table A5.17.  
 
Table A5.17: Surgical approach grouped by 3 and 6 months outcome 
Pain levels at 3 months post-TKR 
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  No to mild 
pain 
Moderate to severe 
pain 
Total 
Surgical 
approach 
Medial 55 16 71 
Lateral 2 1 3 
Total 57 17 74 
Outcome group at 6 months post-TKR 
  Good outcome Poor outcome Total 
Surgical 
approach 
Medial 50 8 58 
Lateral 1 1 2 
Total 51 9 60 
 
There was no significant association between surgical approach and 
outcomes at 3 and 6 months post-TKR (Table A5.18). 
 
Table A5.18: Pearson’s chi-square tests for surgical approach grouped by 
outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  0.19 1 0.663 
6 months outcome  1.99 1 0.159 
* Indicates statistical significance at p  0.05 
 
• Treatment 
Before TKR 
Physiotherapy treatment (before TKR) grouped by pain levels at 3 months 
and outcome at 6 months post-TKR are as shown in table A5.19.  
 
Table A5.19: Physiotherapy treatment grouped by 3 and 6 months outcome 
Pain levels at 3 months post-TKR 
  No to mild 
pain 
Moderate to severe 
pain 
Total 
Physiotherapy 
No 49 10 59 
Yes 8 7 15 
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Total 57 17 74 
Outcome group at 6 months post-TKR 
  Good 
outcome 
Poor outcome Total 
Physiotherapy 
No 44 4 48 
Yes 7 5 12 
Total 51 9 60 
 
There was a moderate strength of association between physiotherapy 
treatment (before TKR) and pain levels at 3 months (Cramer’s V=0.284) and 
6 months (Cramer’s V=0.373) post-TKR (Table A5.20). 
 
Table A5.20: Pearson’s chi-square tests for physiotherapy treatment (before 
TKR) grouped by outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  5.97 1 0.015* 
6 months outcome  8.37 1 0.004* 
* Indicates statistical significance at p  0.05 
 
After TKR 
Physiotherapy treatment (after TKR) grouped by pain levels at 3 months and 
outcome at 6 months post-TKR are as shown in table A5.21.  
 
Table A5.21: Physiotherapy treatment (after TKR) grouped by 3 and 6 
months outcome 
Pain levels at 3 months post-TKR 
  No to mild 
pain 
Moderate to severe 
pain 
Total 
Physiotherapy 
No 14 4 18 
Yes 43 13 56 
Total 57 17 74 
Outcome group at 6 months post-TKR 
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  Good 
outcome 
Poor outcome Total 
Physiotherapy 
No 11 1 12 
Yes 40 8 48 
Total 51 9 60 
 
There was no statistically significant association between physiotherapy 
treatment (after TKR) and pain levels at 3 and 6 months post-TKR (Table 
A5.22). 
 
Table A5.22: Pearson’s chi-square tests for physiotherapy treatment (after 
TKR) grouped by outcome at 3 and 6 months post-TKR 
 Value df Asymptotic Significance (2-
sided) 
Pain at 3 months  0.001 1 0.979 
6 months outcome  0.397 1 0.528 
* Indicates statistical significance at p  0.05 
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Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) 
• Permission to reproduce this questionnaire has been granted by 
Professor Nicholas Bellamy. 
 
European Quality of Life Questionnaire (EQ-5D) 
• Permission to reproduce this questionnaire has been granted by EuroQol. 
 
Self-Administered Comorbidity Questionnaire (SCQ) 
• No permission is required to use this questionnaire. 
 
PainDETECT 
• No permission is required to use this questionnaire. 
 
Pain Quality Assessment Scale (PQAS) 
• Permission to reproduce this questionnaire has been granted by Mapi 
Research Trust. 
 
Short-Form 36 Health Survey (SF-36) 
• Permission to reproduce this questionnaire has been granted by 
QualityMetric. 
 
Pain Catastrophising Scale (PCS) 
• No permission is required to use this questionnaire. 
 
Numeric Rating Scale (NRS) 
• No permission is required to use this questionnaire. 
 
Patient Health Questionnaire-8 (PHQ-8) 
• No permission is required to use this questionnaire. 
 
Pittsburgh Sleep Quality Index (PSQI) 
• Permission to reproduce this questionnaire has been granted by 
Professor Daniel J. Buysse. 
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Overview 
As stated in the course overview for the Doctor of Clinical Physiotherapy 
program, “The aims and objectives of the Doctor of Clinical Physiotherapy 
are to provide high-level clinical practice, inquiry and research skills for 
senior health professionals, enabling them to evaluate, commission, 
design, implement and administer research into different aspects of health 
and to understand the policy implications of such research. The primary 
aim is to support the emergence of clinical expertise based on a solid 
foundation of evidence-based practice, clinical reasoning and diagnostic 
skills.” 
I decided to undertake the Doctor of Clinical Physiotherapy program as I 
felt the need to upgrade my skills and knowledge base in the areas of: 
 Musculoskeletal Physiotherapy
 Pain Science
 Clinical Research
The Doctor of Clinical Physiotherapy program offered the perfect fit for my 
aims as the course structure (which is a combination of coursework and 
research units) allowed me to tailor the learning to my areas of interest. 
I enrolled in the following coursework units, as they enabled me to further 
my skills and knowledge base in the areas of Pain Science and 
Musculoskeletal Physiotherapy: 
 Management of Pain Disorders 652
o This unit provides students with current pain knowledge and
skills that are applicable to physiotherapists working in the area
of musculoskeletal physiotherapy.
 Pharmacology for Health Professionals
o This unit provides students with a sound knowledge of
pharmacological principles and how drugs act on major body
systems.
5 
 Physiotherapy Practice 754
o This unit focuses on the development of advanced level of
competency in the clinical management of musculoskeletal
disorders.
 Specialised Physiotherapy Clinics
o This unit allows students to undertake an advanced clinical
placement intended to improve their knowledge and skills in a
specialised are of clinical practice of their choosing.
As I have completed the Master of Manipulative Therapy course at Curtin 
University in 2006, I was granted recognition of prior learning for the 
following units: 
 Clinical Anatomy, Pathology and Diagnosis 751
 Clinical Anatomy, Pathology and Diagnosis 752
 Evidence Based Practice 750
 Research Physiotherapy Project 751
 Physiology of Pain 652
 Musculoskeletal Clinical Practice 750
 Musculoskeletal Practice 751
 Functional Rehabilitation 752
My academic record is as shown in the next 2 pages. 
The following body of work represents all the assessed pieces of work and 
records of professional practice for the coursework units that I have 
undertaken for the degree of Doctor of Clinical Physiotherapy. 
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Chapter 1: Physiotherapy Practice 754 
1.1 Introduction
This unit focused on the development of an advanced level of theoretical 
and clinical specialised competency in clinical management of 
musculoskeletal disorders. Emphasis is placed on advanced clinical 
reasoning of complex clinical cases and synthesis of ethical and 
professional issues relevant to advanced musculoskeletal clinical practice. 
The contact time for this unit was 39 hours.  
1.2 Syllabus 
 Advanced clinical practice assessment and management in an area of
specialized practice.
 Examination of contemporary evidence for best clinical practice.
 Presentation of complex cases.
 Discussion of topics related to specialist clinical practice.
1.3 Learning Outcomes 
1. Demonstrate an advanced level of theoretical and clinical specialised
competency in clinical examination and management in a specialised
area of clinical practice.
2. Integrate an advanced clinical reasoning framework related to the
assessment and management of patients in a specialised area of
clinical practice.
3. Demonstrate an advanced level of specialised clinical knowledge in the
management of patients in a specialist area of clinical practice.
4. Evaluate the issues and levels of evidence for the efficacy of
physiotherapy approaches when managing patients in a specialist area
of clinical practice or evaluate professional and ethical issues relevant
to physiotherapy practice in a specialist area.
1.4 Assessments 
The work handed in for assessment in this unit were: 
1.4.1  Clinical Masterclass Case Presentation 
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 For this assignment, I had to nominate a musculoskeletal
disorder of specific expertise / interest to myself. The brief is that
I have been invited to present this session at an upcoming
professional conference as a 2-hour practical workshop. As an
expert in my field, the conference wishes to provide attendees
with a state of the art update that assists clinicians with the
translation of current evidence into their daily clinical
practice. The task is to present to the group a “Masterclass
Clinical Update” on my chosen topic.
 The topic I had chosen was, “Bacterial infection as a cause of
low back pain”.
1.4.2 Seminar Presentation 
 For this assignment, I had to nominate a professional practice
topic of interest to myself and my target audience. The brief is
that I have been invited by Musculoskeletal Physiotherapy
Australia (MPA) to present a 40 minute seminar (with 20
minutes of discussion time after) on my chosen topic. The MPA
has commenced this series of seminars to update its members
on professional practice issues relevant to clinicians.
 The topic I had chosen was, “Interpretation of MRI for lumbar
spine”.
1.4.3 Specialist Topic Paper 
 For this assignment, I had to nominate a clinical or professional
practice topic of interest to myself and my target audience. The
brief is that I have been commissioned by the Medical Journal of
Australia to write a “Perspectives” article for their journal on my
chosen specialist topic. This is an opportunity to influence the
perception of advanced musculoskeletal physiotherapy practice
in the wider general medical community (my target audience).
 The topic I had chosen was, “Persistent pain post-total knee
replacement: Still an enigma”.
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Presentation 
1.4.1 Clinical Masterclass Case Presentation
BACTERIAL INFECTION 
AS A CAUSE OF LOW 
BACK PAIN
PHILIP CHEONG, FAMEI
APA MUSCULOSKELETAL PHYSIOTHERAPIST
OUTLINE
• Modic changes
• Types
• Mechanisms
• Article review
• Does nuclear tissue infected with bacteria 
following disc herniations lead to Modic 
changes in the adjacent vertebrae?
• Antibiotic treatment in patients with chronic 
low back pain and vertebral bone edema 
(Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy
• Type 1
• Bone marrow edema and inflammation
• Strong association with NSLBP (Toyone et al., 1994;
Mitra et al., 2004; Kjaer et al., 2006; Albert & Manniche, 2007; Kuisma et 
al., 2007; Modic, 2007)
• Prevalence rate of 15-29% (Mitra et al., 2004; Kjaer et 
al., 2006; Albert & Manniche, 2007)
• Type 2
• Conversion of normal red bone marrow to 
yellow fatty marrow
• Type 3
• Subchondral bone sclerosis
MODIC CHANGES (TYPES) MODIC CHANGES (TYPE 1)
Zhang et al. (2008). Modic changes: a systematic review. Eur Spine 
J, 17,1289-1299
MODIC CHANGES (TYPE 2)
Zhang et al. (2008). Modic changes: a systematic review. Eur Spine 
J, 17,1289-1299
MODIC CHANGES (TYPE 3)
http://www.mastmedical.com/modic_en/what_are_modic_changes_en/
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• Biomechanical
• Endplates –’weak link’ 
• Fissures/microfractures
• Biochemical
• Upregulation of inflammatory mediators 
in the nucleus pulposus
• Disc herniation is the entry point of 
anaerobic bacteria
MODIC CHANGES (MECHANISMS)
Zhang et al. (2008). Modic changes: a systematic review. Eur Spine 
J, 17,1289-1299
BACTERIAL INFECTION OF 
NUCLEAR TISSUE 
• Aims:
• To investigate if herniated nucleus 
material from Lx disc herniations is 
infected with bacteria
• To determine if patients with an anaerobic 
infected disc are more likely to develop 
MCs following a disc herniation as 
compared to patients with sterile discs or 
aerobic infections
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
• Primary surgery for Lx disc herniation
• Inclusion criteria
• Between 18-65 years old
• MRI confirmed Lx disc herniation
• Immunocompetent
• No antibiotic Rx within previous 2/52
• No previous epidural or back surgery
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
• Method
• 5 biopsies performed on each subject
• Stringent antiseptic protocols
• New set of sterile instruments with each
biopsy
• Cultures
• All 5 tissue samples incubated under 
aerobic and anaerobic conditions for 7 
days at 37 °C
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
• Method
• MRI at baseline and 1-2 years after 
surgery
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
• Results
• 28 (46%) out of 61 subjects had +ve
cultures
• 26 (43%) had +ve anaerobic cultures
• 4 (7%) had 2 bacteria strains present
• 2 (3%) had +ve aerobic cultures
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
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BACTERIAL INFECTION OF 
NUCLEAR TISSUE
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
• Results
• +ve aerobic cultures
• None developed new MCs
• +ve anaerobic cultures
• 20 (80%) out of 25 subjects developed 
new MCs
• -ve cultures
• 15 (44%) out of 34 subjects developed 
new MCs
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
• Results
• +ve anaerobic cultures is strongly 
associated with development of new MCs
• OR of 5.60 (95% CI 1.51-21.95)
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
• Discussion
• Confirmed findings with 5 previous 
studies of bacteria found in extruded 
nuclear material
• P. acnes
• P. acnes thrive in areas of low vascularity
and low pH 
• Why do the patients with –ve cultures 
develop MC? 
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
BACTERIAL INFECTION OF 
NUCLEAR TISSUE
• Conclusion
• Occurrence of MC Type 1 due to edema 
surrounding an infected disc
• Discs infected with anaerobic bacteria 
significantly more likely to develop MCs 
Albert et al. (2013) Does nuclear tissue infected with bacteria following 
disc herniations lead to Modic changes in the adjacent vertebrae? Eur
Spine J, 22, 690-696
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THOUGHTS/QUERIES/CONCERNS 
• ?Difference in numbers reported for
+ve anaerobic cultures
• Contamination of sample
• Infection after RC repair (Settecerri et al., 1999; Herrera 
et al. 2002)
• Endocarditis (Lazar & Schulman, 1992; Mohsen et al. 2001)
• Corneal infections (Underdahl et al., 2000)
• Postop endophthalmitis (Clark et al., 1999)
• Focal intracranial infections (Chu et al., 2001)
• CSF shunt infections (Thompson & A lbright, 1998)
• Sciatica (Stirling et al., 2001)
• Prosthetic joint infections (Yu et al., 1997; Tunney et al.,
1999)
PROPIONIBACTERIUM ACNES
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Aim
• Test the efficacy of Modic antibiotic spine 
therapy (MAST) in patients with chronic 
LBP, new Modic type 1 changes in the 
vertebrae adjacent to a previously 
herniated disc
• Investigate whether a dose-response 
relationship could be identified
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Inclusion criteria
• Between 18-65 years old
• MRI confirmed Lx disc herniation
• L3/L4 or L4/L5 or L5/S1
• Within preceding 6-24 months 
• LBP > 6/12
• Both conservative and surgically treated 
patients included
• Repeat MRI showed MC type 1 adjacent 
to the previously herniated disc
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Exclusion criteria
• Allergy to antibiotics
• Current pregnancy or lactation
• Kidney disease
• Pending litigation
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Treatment protocol
• Amoxicillin-Clavulanate (500mg/125mg) 
(Bioclavid®)
• 3 x daily
• 8 hr intervals
• 100 days
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
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ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Randomization (Computer-
generated)
• A (n=45)
• 1 Bioclavid tablet
• B (n=36)
• 1 placebo tablet
• C (n=45)
• 2 Bioclavid tablet
• D (n=36)
• 2 placebo tablet
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Primary outcome measures
• Roland Morris Disability Questionnaire 
(RMDQ)
• LBP Pain Rating Scale
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Secondary outcome measures
• Global perceived effect
• Leg pain
• Hours with LBP during the last 4/52
• EQ-5D Thermometer
• Day with sick leave
• Bothersomeness
• Constant pain
• MRI Modic grading
• Serum analysis
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Results
• Antibiotic group
• Placebo group
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
Baseline 100 days 1 Year 
RMDQ 15.0 11.5 7.0
Back pain 6.7 5.0 3.7
Leg pain 5.3 3.0 1.7
Baseline 100 days 1 Year 
RMDQ 15.0 14.0 14.0
Back pain 6.3 6.3 6.3
Leg pain 4.0 4.3 4.3
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Results
• Antibiotic group
• Placebo group
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
Baseline 100 days 1 Year 
Back pain (Hrs) 448 180 64
Sick days 51.0 - 18.9
EQ-5D 59 65 75
Baseline 100 days 1 Year 
Back pain (Hrs) 448 200 448
Sick days 42.0 - 45.4
EQ-5D 60 60 60
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ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Discussion
• Statistically & clinically significant 
improvement in all outcome measures
• Improvement seen at 1 year compared to 
at end of treatment 
• Propionic acid
• Reduction of leg pain
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Discussion
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
ANTIBIOTIC RX IN PATIENTS 
WITH MC TYPE 1
• Conclusion
• Antibiotics as a treatment option:
• LBP > 6/12
• MC type 1 in the adjacent vertebrae 
following a previous disc herniation
• Up to 2 years
• All other treatment options has 
failed
Albert et al. (2013) Antibiotic treatment in patients with chronic low back 
pain and vertebral bone edema (Modic type 1 changes): a double-blind 
randomized clinical controlled trial of efficacy  Eur Spine J, 22, 697-707
THOUGHTS/QUERIES/CONCERNS 
• Difference between single dose and
double dose antibiotics
• Conflict of interest
• MAST (Modic Antibiotic Spine Therapy) 
Medical™
• Other tests to determine bacterial
infection
• Duration of antibiotic therapy
TAKE HOME MESSAGE
• Antibiotic Rx may be highly effective
treatment in a specific sub group of
patients with LBP
• Study needs to replicated and further
tested
Questions?
Thank you for your time 
and attention
16
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1.4.2 Seminar Presentation 
INTERPRETATION 
OF MRI FOR 
LUMBAR SPINE
PHILIP CHEONG, APAM, FAMEI
APA MUSCULOSKELETAL PHYSIOTHERAPIST
CLINICAL DOCTORATE CANDIDATE (CURTIN)
OBJECTIVES
• Know the indications for when to order
MRI investigations for low back pain
• Knowledge of the current evidence for
lumbar spine MRIs
• Interpret MRI of the lumbar spine relevant
to physiotherapy practice
• Determine if the results of the MRI fits the
patient’s clinical picture
OUTLINE
• MRI basics
• Indications for use of MRI
• Summary of current evidence
• MRI costs
• MRI & reporting epidemiology
• Iatrogenic effects of early MRI
• Common sequences for musculoskeletal
MRI
• MRI images
• Case studies
MAGNETIC RESONANCE 
IMAGING (MRI)
• 3 planes of imaging
• Axial, Coronal, Sagittal
• Optimal for soft tissue
• Disc, muscle, ligament and spinal
cord/nerve roots
• Variable Sequences
• No ionizing radiation
WHEN IS IT INDICATED?
Imaging Action Rationale
• Risk factors for spinal infection
• Risk factors for/or signs of cauda
equina syndrome
• Severe neurologic deficits
• Signs & Symptoms of radiculopathy 
• Risk factors for/or symptoms of 
spinal stenosis
• No criteria for immediate imaging
• Back pain improved or resolved 
after a 1/12 trial of therapy
• Previous spinal imaging with no 
change in clinical status
Chou et al. (2011) Diagnostic imaging for LBP: Advice for High-Value Health Care from the American College of Physicians. Ann Intern Med, 154, 181-189
SUMMARY OF CURRENT 
EVIDENCE
• Abnormal findings common in asymptomatic 
population (Boden et al., 1990)
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SUMMARY OF CURRENT 
EVIDENCE
• Abnormal findings common in asymptomatic 
population (Jensen et al., 1994)
SUMMARY OF CURRENT 
EVIDENCE
• Abnormal findings common in asymptomatic 
population (Jarvick et al., 2001)
• The degree of abnormal findings in
MRI ≠ pain and/or disability (Berg et al., 2013)
• Not predictive of development or
duration of pain (Borenstein et al., 2001)
• Interpretation of MRI varies between
readers (Boden et al., 1990)
SUMMARY OF CURRENT 
EVIDENCE
• Strong association between rates of
advanced spinal imaging and spinal
surgery (Verrilli & Welch, 1996; Lurie et al. 2003; Jarvik et al., 2003;
Webster et al., 2013)
• Rates of interventional procedures (i.e.
epidural steroid, facet joint injections)
increased >3x (Friedly et al., 2007)
SUMMARY OF CURRENT 
EVIDENCE
Deyo et al. (2009) Overtreating chronic back pain: Time to back off? . J Am Board Fam Med, 22, 62-68
629%
307% 423%
220%
MRI COSTS
• USA Medicare population (Parker et al., 2008)
• MSK imaging increased 25.7% from
1996 to 2005
• MSK MRI has increased 353.5%
from 1996 to 2005
• Projected MSK imaging costs in
2020 - $3.6 billion
• MSK MRI - $2.0 billion
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MRI COSTS
• Appropriateness of MRI requests (Emery et
al., 2013)
MRI & REPORTING EPIDEMIOLOGY
McCullogh et al., 2012
MRI & REPORTING EPIDEMIOLOGY
• 237 Lx MRI reports
• 71 (30%) included the statement 
• 166 (70%) did not include the statement 
• Statement group
• Less likely to receive prescription for narcotics
• Repeat cross-sectional imaging and physio referral
also less common
• Similar rates of steroid injections,
surgical consultations and surgeries
between groups
McCullogh et al., 2012 
IATROGENIC EFFECTS OF 
EARLY MRI
• More likely to have surgery compared
to those who had x-rays with no
difference in outcomes (Jarvik et al., 2003)
• Longer disability duration (Graves et al., 2012)
• Webster et al. (2013) reported:
Radiculopathy Non-specific LBP
No-MRI
(n=45)
Early-MRI
(n=178)
No-MRI
(n=209)
Early-MRI
(n=123)
Disability 
(Days)
50 184 44.4 165
Total medical 
costs (US $)
4,100 22,339 2,306 17,028
MAGNETIC RESONANCE 
IMAGING (MRI)
Common Sequences
• T1 - weighted
• T2 - weighted
• STIR
http://www.neuroradiologycases.com/2011/08/post-radiotherapy-
marrow-changes.html
20
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MAGNETIC RESONANCE 
IMAGING (MRI)
T1 (BRIGHT)
• Fat
• Marrow
• Slow-flowing 
blood
• Proteinaceous 
tissue
• Paramagnetic 
contrast agents
T1 (DARK)
• Air
• Bone
• Fast-flowing blood
• Water
MAGNETIC RESONANCE 
IMAGING (MRI)
T2 (BRIGHT)
• Fat
• Marrow
• CSF
• Water
• IVD
• Proteinaceous 
tissue
T2 (DARK)
• Air
• Bone
• Fast-flowing blood
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Patient details
Referring Dr
Date/Time of scan Patient details
Referring Dr
Date/Time of scan
LUMBAR SPINE DISC MORPHOLOGY
Roudsari & Jarvik (2010) Lumbar spine MRI for low back pain: Indications and Yield. Am J Roent, 195, 550-559
NERVE ROOT IMPINGEMENT
http://www.orthopaedicsone.com/display/MSKMed/Lumbar+Disc+Herniations
LUMBAR DISC EXTRUSION
http://radiopaedia.org/cases/l5s1-disc-extrusion
22
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SPINAL STENOSIS
http://www.physiologie.uni-mainz.de/physio/mittmann/ThalFallZ2.pdf
SPINAL INSTRUMENTATION
SPINAL INSTRUMENTATION SPINAL INSTRUMENTATION (X-RAY)
SCOLIOSIS SCOLIOSIS
23
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MODIC CHANGES (TYPE 1)
Zhang et al. (2008). Modic changes: a systematic review. Eur Spine 
J, 17,1289-1299
LUMBAR DISCITIS
http://www.mghradrounds.org/index.php?s
rc=gendocs&link=nov_dec_2006
MODIC CHANGES (TYPE 2)
Zhang et al. (2008). Modic changes: a systematic review. Eur Spine 
J, 17,1289-1299
MODIC CHANGES (TYPE 3)
http://www.mastmedical.com/modic_en/what_are_modic_changes_en/
http://radiology.casereports.net/index.php/rcr/article/viewarticle/421/7
81
TUMOUR SPINAL METASTASIS
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CORD CHANGES
CASE STUDY 1
• 43 year old, male
• More than 18/12 history of low back
pain. Also c/o constant numbness in
right big toe for many years.
• Back pain started after doing heavy
lifting at work.
CASE STUDY 1
• Aggravating activities:
• Bending over, immediate pain, pain scale 7/10
• Lifting, immediate pain, pain scale 7/10
• Similar history of back pain 10 years
ago for which he received
physiotherapy treatment (Traction,
Electrical Stimulation, McKenzie
Extension exercises).
xxx
xxx
x
N N
Pback: 
Intermittent, 
Activity 
dependant
Numbness in right big toe: Constant
PHYSICAL 
EXAMINATION
• Lx Flexion: ½ ROM, pain reproduced
• Lx Extension: FROM
• No loss of strength
• Reflexes normal
• Slight loss of light touch sensation in
right big toe
• Motion palpation: L5/S1 hypo in flexion
PHYSICAL 
EXAMINATION
• Palpation: Increase tone in Lx
Extensors, and tender on palpation
• SIJ cleared
• Neurodynamics testing
• Slump test, L=R=üü
• SLR, L=R=üü
25
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MRI
• Indication for MRI?
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MRI
• What are the main findings on the
MRI?
• Do the MRI findings correlate to the
clinical assessment?
TREATMENT
• Dx: NSCLBP, Movt impairment
disorder – flexion pattern
• Education
• Home Exercise Program
• Knee to chest, Posterior pelvic tilts, Seated Lx 
flexion
• Soft tissue release for Lx Extensors.
• Had 5 sessions of therapy, and no
longer has back pain.
CASE STUDY 2
• 19 year old, male
• 2/52 history of worsening severe left
sided buttock, posterolateral thigh,
lateral shin pain with numbness
• Recently enlisted into armed forces,
and has been doing a lot of running
when the pain started
Courtesy of Ms Liang Zhiqi
Senior Physiotherapist, SGH
CASE STUDY 2
• Presented into ED, unable to FWB on
left leg
• Aggravating activities:
• FWB on left leg, pain scale 9/10 & numbness 
worsened
• Lx AROM, pain scale 9/10
27
1.4.2 Seminar Presentation 
xx
xx
xx
n
n
Pback: 
Intermittent
Pshin: Intermittent, numbness
x
x
x
x
x
x
xn
Pthigh: 
Intermittent
x x
xx
x
x
PHYSICAL 
EXAMINATION
• Lx AROM: ¼ ROM, pain and
numbness reproduced
• No loss of strength
• Reflexes normal
• Decreased sensation in left lateral
lower leg
• Neurodynamics testing
• SLR, L= 30 deg, reproduced leg symptoms,
SLR, R=üü
MRI
• Indication for MRI?
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MRI
• What are the main findings on the
MRI?
• Do the MRI findings correlate to the
clinical assessment?
CASE STUDY 3
• 38 year old, female
• 8/52 post partum.
• 3-4 year history of right sided low back,
buttock, posterior thigh and calf pain.
• Pain has worsened since giving birth
Courtesy of Ms Irene Toh
Principal Physiotherapist, SGH
CASE STUDY 3
• Aggravating activities:
• Lx Flexion, pain scale 8/10
• Sustained sitting for >10 mins, pain scale 8/10
• Relieving factors:
• Lying supine, eases completely in 5 mins
• Standing, eases to 2/10 
xx
xx
xx
Pback: 
Intermittent
x
x
x
x
x
Pthigh: 
Intermittent
x
x
x
x
x
x
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PHYSICAL 
EXAMINATION
• Lx flexion: ½ ROM, pain reproduced
• Myotomes
• L4
• L= 5/5, R= 4/5
• L5
• L=5/5, R= 4/5
• Reflexes
• Knee
• L=R= diminished
• Achilles
• L=R= diminished
PHYSICAL 
EXAMINATION
• Sensation intact
• Neurodynamics testing
• SLR
• L= üü, R= 30 deg, reproduced leg symptoms
• Slump
• L= üü, R= +ve
MRI
• Indication for MRI?
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MRI
• What are the main findings on the
MRI?
• Do the MRI findings correlate to the
clinical assessment?
CASE STUDY 4
• 86 year old, male
• Bilateral decompression laminectomy
in 2012 – No improvement
• Bilateral calves numbness with walking
for 3-4 mins
• Has difficulty with urination
Courtesy of Ms Irene Toh
Principal Physiotherapist, SGH
CASE STUDY 4
• Aggravating activities:
• Walking for 3-4 mins, bilateral leg numbness
• Relieving factors:
• Lying supine
n
n
Bilateral 
calves 
numbness
n
n
n
nn n
PHYSICAL EXAMINATION
• Lx flexion: FROM
• No loss of strength
• Sensation intact
• Reflexes
• Knee
• L=R= diminished
• Achilles
• L=R= diminished
31
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MRI
• Indication for MRI?
MRI
• What are the main findings on the
MRI?
• Do the MRI findings correlate to the
clinical assessment?
CASE STUDY 5
• 79 year old, male
• c/o bilateral leg weakness following a
fall x 2/7 ago
• Slipped and landed on bottom
• Slight pain in bottom and lower back
x   x
Pback/butto
ck: Constant
x   x
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PHYSICAL EXAMINATION
• Lx flexion: FROM
• No loss of strength
• Sensation intact
• Reflexes
• Knee
• L=R= üü
• Achilles
• L=R= üü
MRI
• Indication for MRI?
MRI
• What are the main findings on the
MRI?
• Do the MRI findings correlate to the
clinical assessment?
TAKE HOME MESSAGE
• A diagnosis that is based on magnetic
resonance imaging, in the absence of
objective clinical findings, may not be
the cause of the patient’s pain, and an
attempt at operative correction could
be the first step towards disaster (Boden et
al., 1990) 
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1.4.2 Seminar Presentation 
Questions?
Thank you for your time 
and attention
Additional images
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1.4.2 Seminar Presentation 
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1.4.2 Seminar Presentation 
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1.4.3 Specialist Topic Paper
Persistent pain post-total knee replacement: Still an enigma. 
“Introline” 
20% of post-TKR patients report severe chronic pain. How much do we 
actually know about this condition? 
Osteoarthritis 
The 2011-2012 Australian Health Survey showed that 14.8% (around 3.3 
million) of Australians suffer from arthritis, with a higher prevalence in 
females (17.7%) compared to males (11.8%).1 55.9% of Australians who 
had arthritis reported that they suffered from osteoarthritis (OA).1 
In the past, OA pain was attributed only to joint damage (nociceptive pain 
mechanism), and the resulting inflammatory response (neuroplastic pain 
mechanism) in the OA damaged joint. However, recent advances in pain 
sciences research have shown that OA pain is much more complex. 
Nociceptive, neuroplastic and neuropathic pain mechanisms, in 
combination with psychological and social factors (e.g. pain 
catastrophising, depression, anxiety, lack of social support, lower 
socioeconomic status) have been shown to contribute to the generation of 
OA pain.2 
The knee joint is commonly affected by OA, and the presentation of pain in 
knee OA sufferers varies greatly; from localised activity-related pain to 
referred or even widespread pain at sites distant from the knee.3,4   
Due to this variability in pain presentation, it has been hypothesized that 
both peripheral and central pain processes may be active to varying 
degrees in patients with knee OA.3 Peripheral and central sensitisation of 
the pain pathways usually results in normal stimuli becoming painful. 
Peripheral sensitization is likely to be driven by inflammation of the 
damaged structures in the OA joint, whereas central sensitization may be 
driven by the continuous intense nociceptive input from the OA joint.3 
38 
However, removal of the nociceptive input does not mean that central 
sensitisation is eliminated.4  
Even with recent advances that have led to improved understanding of OA 
pain, its pathophysiology is complex and still not fully understood. In 
summary, there are multiple mechanisms (nociceptive pain, neuroplastic 
pain and neuropathic pain), pain processes (peripheral sensitization, 
central sensitization), and psychological/social factors that contribute to 
the generation of OA pain.2,4 To further complicate the nature of OA pain; 
the mechanisms, pain processes and factors that mediate OA pain vary 
among individuals.2,4 
Management of knee OA is generally based on symptom severity and 
range from:  
(i) Non-pharmacological interventions (e.g. Weight reduction,
Lifestyle modification, Exercise rehabilitation)
(ii) Pharmacological interventions (e.g. NSAIDS, Analgesics –
Opioid / Non-opioid, Viscosupplements)
(iii) Surgical interventions (e.g. Arthroscopy, Total knee
replacement) when both non-pharmacological and
pharmacological interventions have failed.
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Total knee replacement 
Total knee replacement (TKR) is a surgical procedure commonly used to 
manage chronic knee pain and improve physical function in those with 
advanced knee OA. Knee OA is the most common diagnosis for TKR 
surgery, accounting for 97.4% of all TKR surgeries in Australia.5  
In 2012, a total of 41,810 TKR surgeries were performed in Australia,5 at a 
cost ranging from $18,874 to $23,702 per surgery in a public hospital.6 
Similar to other developed nations, TKR surgery is on the rise in Australia. 
From 2003 to 2012, the numbers of TKR surgery have increased by a 
staggering 92.4%.5  
 
Although many patients report good outcomes (reduced pain and 
increased function) a proportion of patients continue to report significant 
and persistent pain following TKR. A recent systematic review on the 
prevalence of persistent pain post-TKR have reported that about 20% of 
patients continue to report severe chronic pain after a technically 
successful and uncomplicated TKR.7 
 
Persistent post-surgical pain 
Persistent post-surgical pain has been defined by the International 
Association for the Study of Pain to be pain that has developed after 
surgery, has been present for at least 3 months, and is independent of any 
pre-existing pain condition.8  
 
Current belief of persistent post-surgical pain: ‘New’ pain after TKR 
The current belief is that persistent post-surgical pain is the consequence 
of ongoing inflammation (from intra-operative damage), or a manifestation 
of neuropathic pain resulting from the surgical intervention (due to surgical 
damage to nerves).9  
 
Risk Factors 
The risk factors for development of persistent pain post-TKR are well 
documented in the research literature.9 The table below summarizes the 
main proposed factors. 
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Table 1: Risk factors for persistent post-surgical pain after TKR.9  
Risk factors for persistent post-surgical pain after TKR 
Pre-Operative Intra-Operative Post-Operative 
 Genetic 
predisposition 
 Female gender 
 Depression 
 Anxiety 
 Pain catastrophising 
 High levels of pain 
 Long history of pain 
 Excessive tissue 
damage (e.g. 
Nerves, muscles, 
soft tissues)  
 Surgical approach 
(e.g. Posterior 
cruciate ligament 
sacrifice + lateral 
release) 
 Ongoing 
inflammatory 
response 
 High levels of acute 
post-operative pain 
 Anxiety 
 Depression 
 Pain catastrophising 
 
Even though the risk factors are well documented, there is currently no 
way of discerning which individuals are genetically predisposed to 
developing persistent post-TKR pain. It is also not possible to refuse TKR 
surgery to patients just because of their gender; and as TKR surgery is 
advocated only for end stage knee OA, most patients will have a relatively 
long history of pain with high pain levels.  
 
Hence, the knowledge of these factors has yet to mitigate the risk of TKR 
patients developing persistent pain post-surgery.  
 
Causes of persistent pain post-TKR 
From a structural point of view, it has been proposed that the causes of 
pain after TKR fit into 3 categories: intra-articular biomechanical, intra-
articular biological and extra-articular; however, the occurrence rates of 
these causes of pain after TKR are very low.10 Hence, it appears that for a 
substantial number of TKR patients there is no clear, structural cause for 
their persistent post-surgical pain. 
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Several groups have attempted to categorize persistent post-TKR pain in 
order to better manage poor outcomes. The UK-based Support and 
Treatment After Replacement (STAR) Expert Group 
(http://www.bristol.ac.uk/clinical-
sciences/research/musculoskeletal/orthopaedic/research/star), based at 
the University of Bristol involves pain researchers from across Europe, 
Canada and Australia, has proposed 5 relatively distinct post-operative 
presentations (personal communication from Prof Anthony Wright, 
member of STAR Expert Group). These are neuropathic pain, painful 
instability, proximal tibial tenderness, patellofemoral pain and chronic pain 
syndromes (i.e. widespread pain sensitisation and complex regional pain 
syndrome).  
 
The premise of TKR surgery is to remove the damaged joint and replace it 
with artificial components; however, this only removes the nociceptive and 
inflammatory pain mechanisms (stemming from the damaged OA joint) 
that drive OA pain. 
 
Due to the complexities of OA pain, treatments for OA (such as TKR) that 
target only one specific mechanism will not be effective for patients whose 
pain is largely mediated by other mechanisms.4 This could explain the 
seemingly high rates of persistent pain post-TKR.  
 
Widespread pain sensitivity before TKR: Pre-existing pain conditions 
Recent research (using quantitative sensory testing techniques) on knee 
OA patients without any other diagnosed pre-existing chronic pain 
conditions have found that a proportion of these patients have widespread 
pain sensitization.11 This finding is of interest, as widespread pain 
sensitisation has been associated with the development of persistent pain 
post-TKR.11 However, there is a possibility that the widespread pain 
sensitization is due to central sensitivity as a result of OA pain.  
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Further research needs to be done on this area in order for us to gain 
more understanding on the nature of the widespread pain sensitivity and 
its contribution to the development of persistent pain post-TKR. 
 
Persistent pain post-TKR: Pre-existing pain versus ‘new’ pain  
When looking at all the available literature on persistent pain post-TKR, it 
is possible that persistent pain post-TKR may reflect ‘new’ pain resulting 
from the surgical intervention, or may reflect lack of success in the 
detection/resolution of pre-existing pain conditions.  
 
In order to better understand the nature of persistent pain post-TKR and to 
differentiate between unresolved pre-operative pain and newly-developed 
post-operative pain, it has been suggested that an ideal future study would 
therefore need to include pre- and post-operative psychological and 
neurophysiological assessment, detailed intra-operative data and detailed 
post-operative pain data.9 There is currently no study of this quality 
available. 
Greater clarity is needed about the relative roles of:  
(i) Pre-existing pain conditions and  
(ii) Newly acquired pain post-surgery, in persistent pain post-TKR. 
 
Moving forwards 
Based on the number of TKR operations in 2012, and the reported rates of 
persistent pain post-TKR, it can be postulated that the cost of the failed 
surgery alone ranged from $157.8 million to $198.1 million in 2012. There 
is an urgent need to conduct more research on persistent pain post-TKR 
just on the basis of the above financial figures.  
 
Physiotherapists are perfectly placed to lead the research push towards 
increasing understanding of persistent pain post-TKR. This is due to their 
training and advanced knowledge of pain sciences and anatomy, as well 
as their roles in conservative treatment of patients with knee OA, pre-
operative assessment and post-operative rehabilitation of TKR patients. 
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The main focus of future research should be on the development of a 
screening protocol that will identify patients who are likely to experience 
this debilitating condition. The screening protocol should look at using an 
algorithm based on quantifiable clinical measures (i.e. quantitative sensory 
testing) rather than just risk factors. 
 
The ideal screening protocol will enable clinicians to predict the likelihood 
of patients developing persistent pain post-TKR and:  
(i) Use suitable interventions to resolve the pre-existing pain 
conditions before TKR, hence reducing the likelihood of 
developing persistent pain post-TKR; or  
(ii) Try a different approach to conservative management in lieu of 
TKR surgery. 
 
Competing Interests: No relevant disclosures. 
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Chapter 2: Management of Pain Disorders 
652 
2.1 Introduction 
This unit presents current pain knowledge and skills that will be applicable 
to students in the area of musculoskeletal physiotherapy and related 
interdisciplinary areas. This unit aligns with the International Association 
with the Study of Pain Curriculum on Pain for Physical Therapists (2012): 
http://www.iasppain.org/Content/NavigationMenu/GeneralResourceLinks/
Curricula/Therapy/default.htm. 
The unit takes a patient-centered interdisciplinary approach to translate 
pain science knowledge into clinical practice and better integrate low 
technology approaches (empathy, narrative) with clinical evidence and 
current neurobiology. The aim is to help clinicians deliver 'the right care to 
the right patient at the right time with the right team', 'to improve quality of 
life for people with pain and their families, and to minimise the burden of 
pain on individuals and the community'. 
This unit will address the key clinical roles and responsibilities a 
physiotherapist is likely to undertake in working with pain patients. 
These include: 
1. Assessment of pathophysiological processes (infection/inflammation), 
biomechanical factors (stress/strain), motor control strategies (adaptive 
and maladaptive) and cognitive and behavioural factors that contribute 
to a patient's pain, physical dysfunction and disability. 
2. In collaboration with the patient, development of a management 
program directed at modifying the effect of physical and behavioural 
contributors to a patient's pain and disability and reduction of the 
factors that may lead to the recurrence of pain and disability. 
Interventions discussed will focus on appropriate patient education, the 
appropriate use of paced exercise and activity, appropriate use of 
manual therapy and the importance of engaging empathetically with 
the patient to facilitate early, focused and appropriate sensory-motor 
strategies as appropriate to their pain disorder. 
3. Liaison and referral within an interdisciplinary team approach. 
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Physiotherapists need to recognise when additional or alternate 
interdisciplinary help is required in order to assist the patient in pain. 
Psychological and behavioural factors can impact significantly on a 
patient's pain experience and disability and may predict chronicity. Pain 
responses which impact on a patient's behaviour, symptom management 
and mood will be discussed and issues which indicate referral to a 
behavioural medicine psychologist highlighted. Sufficient knowledge about 
pharmacological agents and their side effects will be presented as a 
means to support proper usage of medication by clients/patients and to 
optimise the 'therapeutic window' 
offered to encourage the use of active physical and behavioural 
management as appropriate for each individual patient. 
The contact time for this unit was 36 hours.  
 
2.2 Syllabus 
 An interdisciplinary approach to the management of pain disorders 
aimed at encouraging professional collaboration.  
 The focus of the unit is the pain experience of patients and the 
physiological, psychosocial, and environmental components of that 
experience, with an application of profession-specific theoretical 
frameworks to assess and manage pain and disability. 
 
2.3 Learning Outcomes 
1. Recognise and analyse pain mechanisms and apply current theories 
on related clinical manifestations of pain relevant to highly skilled 
practice. 
2. Evaluate the social, cultural and environmental implications associated 
with the experience, assessment and management, of musculoskeletal 
pain. 
3. Differentiate between acute and chronic musculoskeletal pain and 
evaluate the implications for assessment and management of people in 
pain. 
4. Critically appraise assessment and intervention strategies and 
outcome measures for pain management. 
 48 
5. Formulate collaborative interdisciplinary intervention strategies 
consistent with a high level of practice. 
 
2.4 Assessments 
The work handed in for assessment in this unit were: 
2.4.1 Written Exam  
 This assessment comprised of short answer questions based on 
the first 4 weeks of lecture materials. 
2.4.2 Clinical Case Study 
 This assignment required presentation of one of my patients 
with persistent complex, musculoskeletal pain as a case study. 
This should not be a person with low back pain as this has been 
covered extensively in class. 
 The aim of the assignment is to demonstrate my ability to 
integrate basic and clinical pain science into a framework that 
can be used to help better manage patients with 
musculoskeletal pain. 
2.4.3 Medical Communication  
 The aim of this assessment is to demonstrate integration of the 
basic and clinical pain science into a framework that can be 
used to help better communicate with doctors and other health 
professionals involved with the clinical management of people 
with musculoskeletal pain. This assessment links with and 
extends the clinical case study presented above.  
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2.4.1 Written Exam 
Question 1 
Using your knowledge and understanding of the differences between 
human nociception and pain: 
(i) Briefly and clearly expand on this difference with reference to acute 
and chronic musculoskeletal pain.  
(ii) What are the implications of this difference in term of clinical 
management? 
 
Answer 
(i) Nociception is an input into the system, and pain is an output (final 
expression of all the filtering and processing). Nociception is the 
specialized apparatus that takes the stimulus that's of sufficient 
magnitude or duration to excite the nociceptive apparatus. Whether or 
not that's expressed as pain is what the brain decides to do with it. 
Pain is the final product of activity in distributed networks (interaction of 
multiple cortical and subcortical areas). Perception of pain depends on 
the nature of the pain and the context of each individual’s experience. 
Actual tissue damage is not needed to experience pain. 
Acute pain implies actual (or potential) tissue damage/injury with 
duration of less than 3 months. If there is an injury or insult, and if the 
noxious stimulus is of significant magnitude or duration, there is an 
activation of nociceptors. The impulse is then transmitted to the 1st 
order neurons along the primary afferents into the spinal cord and up to 
the 2nd and 3rd order neurons. Whether this input results in an 
expression of pain depends on the brain. 
Chronic pain is due to the neuroplastic changes in the central nervous 
system with duration of more than 3 months. It may be from 
nociceptive pain initially that transition into chronic pain. However, 
chronic pain does not always need acute pain as a precedent. 
(ii) Pain is individual and as clinicians it is important that we see the whole 
person (as it affects the biology of the whole person). An individual’s 
expression of pain is tied to the context of their sensory and emotional 
experience. We have to understand the type of questions that we need 
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to ask the patients, as purely asking about the nature of pain can be 
meaningless as opposed to finding out the context of their pain 
experience. Actual tissue damage is not needed for an expression of 
pain. It's the potential tissue damage that the brain decides on that 
might express pain, not just actual tissue injury. 
 
Question 2 
Current best practice pharmacologic management of acute 
musculoskeletal pain (nociceptive, inflammatory; non-cancer) 
recommends the use of non-opioid analgesia including paracetamol +/- 
NSAIDS (non-selective or coxibs). 
 
(i) Explain why you might combine these agents  
 
(ii) Indicate which NSAIDs would be most appropriate given the current 
evidence (risk/benefit for non-selective versus COX-2) 
 
(iii) Specify the proposed mechanism(s) of action for paracetamol and 
NSAIDS (non-selective and coxibs) 
 
Answer 
(i) Combination of paracetamol with NSAIDs results in better analgesia 
with fewer side effects. The improved anti-nociception is due to 
synergistic/additive effects. Lower dose of each drug is needed; hence 
there is decreased severity of side effects from each drug.  
(ii) COX-2 selective NSAIDs are the most appropriate given the current 
evidence. COX-2 selective NSAIDs have been shown to have: 
a. Rate of ulcers comparable to placebo 
b. Less blood loss as compared to Non-selective NSAIDs 
c. Less (negative) effect on bone healing as compared to Non-
selective NSAIDs 
COX-2 selective NSAIDs are advantageous (as compared to Non-
selective NSAIDs) in: 
a. Patients at increased risk of GI ulcers 
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b. Patients with a past history of aspirin-induced asthma 
In randomized control trials, there have been no differences between Non-
selective NSAIDs and COX-2 selective NSAIDS in renal and 
cardiovascular adverse events. However, epidemiological studies have 
shown the COX-2 selective NSAIDs are better for the kidney and 
celecoxib is better for the heart. 
(iii) The mechanism of action for paracetamol is unclear. The current 
proposed mechanisms of action for paracetamol are: 
a. Interaction with radical prostanoid intermediate 
b. Inhibition of COX-3 in the brain, without COX-1 or 2 effects 
c. Interaction with serotonin pathway 
d. Interaction with NMDA receptor/NO synthetase 
NSAIDs (non-selective and coxibs) work by inhibiting cyclogenase, which 
convert arachidonic acid to prostaglandins. Non-selective NSAIDs block 
both COX-1 and COX-2. Whereas coxibs work by only inhibiting COX-2. 
 
Question 3 
Manipulation-induced analgesia associated with manual therapy 
treatments (i.e. mobilisation/manipulation) is proposed to involve various 
interacting biological mechanisms  
 
(i) Describe the mechanisms, pathways and neurotransmitters proposed to 
be associated with manipulation-induced analgesia  
 
(ii) Describe what the specific therapeutic effect(s) might be  
 
Answer 
(i) The basic model of the mechanisms of manipulation-induced analgesia 
(MIA) is multifactorial and encompasses segmental inhibition, 
psychological effects, joint repair, influence of the chemical 
environment in the joint that reduces nociceptive input and descending 
inhibition. Most of the research has focused on the pain response 
immediately after treatment, and whether that is predominantly due to 
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segmental inhibition or descending inhibition. Further research has 
shown that descending inhibition is the most likely mechanism of MIA.  
Descending systems project down from the brain into the spinal cord and 
starts in areas like the frontal cortex, amygdala and hypothalamus. This 
then projects down into the periaqueductal grey and down into various 
nuclei in the medulla (i.e. nucleus raphe magnus) that then send neurons 
down to the spinal cord, and those neurons can then act to modulate pain 
by (1) kick-starting the inhibitory interneurons, (2) presynaptic inhibition, or 
by (3) directly inhibiting the pain projection neurons.  
The study by Skyba et al. (2003) shows that the key neurotransmitters 
associated with MIA are serotonin (5-HT) and noraderanaline (NA). The 
activation of 5-HT and NA descending neurons coming down from the 
brain and down to the spinal cord, synapses (5-HT1A and α2A receptors) 
with pain projection neurons in the dorsal horn (that are going up to part of 
spinothalamic tract and spinomesencephalic tract) and is having a direct 
inhibitory effect on those neurons.  
(ii) The specific therapeutic effects of manipulation-induced analgesia are: 
a. Rapid onset analgesia that happens within seconds to minutes 
after treatment 
b. Modality specific effect (no influence on thermal pain) mainly to 
mechanical pain 
c. Cumulative analgesic effect (stepwise improvement with fairly 
closely spaced treatment sessions) 
d. Crudely somatotopically organized analgesic effect 
e. Relationship between hypoalgesia and sympathoexcitation 
f. Non-opioid (serotonin mediated) analgesia 
 
Question 4 
Mechanical hyperalgesia and allodynia are clinical correlates commonly 
associated with acute and chronic musculoskeletal pain. These clinical 
correlates are proposed to reflect peripheral and central sensitisation 
processes. 
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(i) Explain the neuronal and non-neuronal mechanisms proposed to 
underlie these clinical correlates as they relate to acute and chronic 
musculoskeletal pain 
 
Answer 
(i) Peripheral sensitization is a physiological event where there is 
increased responsiveness and reduced threshold of nociceptors to 
stimulation of their receptive fields. The clinical correlates of peripheral 
sensitization are localised pain and sensitivity, spontaneous pain, 
hypersensitivity, allodynia and hyperalgesia. In acute musculoskeletal 
pain, injury and inflammation of the damaged tissues leads to profound 
changes in chemical milieu of nociceptors.  Which leads to a decrease 
in nociceptors threshold and increased responsiveness to subsequent 
stimuli. Phosphorylation dramatically alters activity of receptors and ion 
channels. In summary, the physiologic principles of peripheral 
sensitization are changes in nociceptor properties, altered receptor-ion 
channels, increased membrane excitability, activation signalling 
cascades (phosphorylation proteins; gene transcription) and 
phenotypic switch (where the way the nerve fibres (C, Aβ, Aδ) function 
changes as it relates to light touch driving sensitivity).  
Central sensitization is a physiological event where there is increased 
responsiveness of nociceptive neurons in the central nervous system 
to their normal or sub-threshold input. This phenomenon is activity-
independent (does not require ongoing nociceptive input). The clinical 
correlates of central sensitization are widespread pain, spontaneous 
pain, hypersensitivity, allodynia, primary and secondary hyperalgesia, 
visceral sensitivity and referred pain. The physiologic principles of 
central sensitization are similar to that of peripheral sensitization. The 
main difference is that the processes occur in the central nociceptors 
transmission neurons in the dorsal horn or in the spinal nucleus of the 
trigeminal. There is also phenotypic switch of nociceptor specific 
neurons to WDR. The 3 key phases which increases sensitivity of the 
central nervous system are phosphorylation, trafficking and 
transcription.  
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An example is an acutely sprained ankle where there is initially a 
stimulus-response couple (putting weight on the ankle is painful, taking 
weight off reduces/stops the pain), and an area of hyperalgesia where 
the damaged tissues are. If this pain becomes chronic and we know 
that the damaged tissues have healed, but the patient has no stimulus-
response coupling (ankle is painful regardless of whether weight is put 
on it), and widespread hyperalgesia (not just at site of previous injury at 
the ankle). 
 
Question 5 
You are considered an expert in musculoskeletal pain. You are 
interviewed on national radio about “nerve-related” pain. The phone 
lines are opened for callers: Roger, a 34 years old male building labourer, 
phones in to the radio station. He thinks he might have “nerve” pain (i.e. 
neuropathic pain) in his right leg.  
 
Using simple, non-jargonistic language, that is appropriate for a radio 
audience and is neurobiologically plausible (i.e.; accurate), address 
Roger’s query by: 
 
(i) Indicating what specific questions you would ask to help sort out if he 
has neuropathic pain. Note: also indicate the answers that would suggest 
neuropathic pain 
 
(ii) Indicating to him what pharmacologic options might be appropriate to 
discuss with his doctor given he is also anxious and that NSAIDS have not 
helped 
 
Answer 
(i) Hi Roger, thank you for calling. In order for me to help you, I would 
need to ask you a few questions. The questions are: 
a. Question: Can you describe the pain that you are experiencing? 
Burning, shooting, electrical shocks and/or stabbing sensations 
add credence to the theory that he might be experiencing 
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neuropathic pain. 
b. Question: Do you experience any tingling, pins and needles, 
numbness or ants crawling sensation in or near your area of 
pain? 
Presence of the above sensations might suggest neuropathic 
pain. 
c. Question: Does the presence of clothes or a blanket that is in 
contact with the affected area cause you pain? 
A positive response indicates that he is suffering from allodynia, 
which suggests the presence of neuropathic pain. 
d. Question: Is the affected area painful if you have a hot or cold 
shower? 
A positive response indicates that he is suffering from thermal 
hyperalgesia, which suggests presence of neuropathic pain. 
e. Question: If you apply light pressure to the area of pain, does 
your pain get worse? 
A positive response indicates that he is suffering from 
mechanical hyperalgesia, which suggests presence of 
neuropathic pain. 
(ii) In your case, I would advise discussing with your doctor about the use 
of pregabalin for your pain. The other benefits of taking pregabalin are 
that it has been shown to reduce pain-related sleep interference and 
also helps with reducing anxiety. Combination therapy (combination of 
2 or more drugs) is often helpful in managing nerve pain. Medicines 
like tramadol, tapentadol and/or topical lidocaine patches can be used 
in combination with pregabalin to optimise your pain relief. As I do not 
have your complete medical history, the medications that I am 
suggesting may or may not be suitable for your condition. I strongly 
recommend having a proper discussion with your doctor about this 
issue. 
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2.4.2 Clinical Case Study 
1. Clinical Summary 
Current History: 
S.J. presented to the clinic in a wheelchair, and was accompanied by his 
wife. He is a 68 year-old cattle station owner who was diagnosed as 
having severe osteoarthritis (OA) of both knees in 2006. He states that he 
was coping well with his condition until 3 years ago, when he started to 
feel that the pain in his right knee started to worsen. He states that his 
pain has started to worsen even more over the last 6 months. He 
complains of pain from his right knee going down to his right shin (refer to 
body chart). S.J. states that he can walk a short distance (approximately 
10 minutes) but he prefers not to use his knees too much as he does not 
want to “wear them out further”. He has a BMI of 30. S.J. was screened 
and cleared of any red flags. 
Body Chart: 
 
 
Constant pain 
in right knee 
and shin. 
Occasional 
sharp, 
shooting pain. 
/////
/////
/////
/////
/////
///// 
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Pain History: 
S.J. reports that he is in constant pain. 3 years ago before the pain 
worsened, he stated that his pain was 5/10 on average then. Since 6 
months ago, his pain is 7/10 on average (With pain medication. Pain is 
10/10 unmedicated). He states that pain shoots down from the right knee 
to the right shin, and he often feels a strange sensation (sometimes 
numbness, other times it feels like someone is sticking pins in) in that 
same area. His pain worsens when he has a cold shower. He is unable to 
wear jeans as the weight of the jeans resting/rubbing on his right knee and 
shin gives him pain. He is unable to do the physical work at the cattle 
station due to his pain. His functional limitations are squatting (unable to 
do at all), climbing up and down stairs (able to go up 2-3 steps but has to 
stop and rest for a couple of minutes due to pain), walking for 10 minutes 
and mustering cattle. S. J. reports that he is often unable to sleep for more 
than 2 hours at a time due to the pain in his right knee. He also has 
complains of morning stiffness in both his knees lasting about 15-20 
minutes. 
 
Social History: 
S.J. does not smoke or drink, and has no other medical conditions. He 
lives on the cattle station, which is about a 4 hour drive from the nearest 
town (Newman, Western Australia), with his wife and 2 sons (35 and 38 
years old). His youngest son had a spinal cord injury 3 years ago when he 
fell off his horse and is a paraplegic. As he is unable to do anything 
physical, his eldest son has taken over all of the physical tasks involved in 
the running of the cattle station. He has put on about 20-25 kg over the 
last 3 years. He states that this is due to the lack of physical activity 
(because of fear of further damage to his knees) and also his eating habits 
(frequent snacking of sweets and having big meals everyday). His wife 
was diagnosed with breast cancer 4 years ago, she received treatment 
and the cancer went into remission. However, during a follow up screening 
6 months ago, the oncologist discovered that the cancer has relapsed and 
has spread into her lymph nodes. He accompanies his wife to Perth for 
her treatment fortnightly.  
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Medication: 
S. J. is currently on Etoricoxib (60mg, once daily) and Tramadol ER 
(100mg, thrice daily). He has been on these medications and dosage for 
the last 2 years.  
 
Investigations: 
Radiographs of both knees show severe joint space narrowing and 
presence of multiple osteophytes. 
 
Screening Tools and Outcome Measures: 
The Patient-Specific Functional Scale (PSFS), PainDETECT, Pain 
Catastrophizing Scale (PCS), Tampa Scale for Kinesiophobia (TSK) and 
DASS 21 questionnaires were administered. 
Based on the PSFS, S. J. listed the following 4 activities: 
 Mustering cattle – 0/10 (Unable to perform activity) 
 Walking for 10 minutes – 2/10 (Severe impairment in performing 
activity) 
 Walking up and down stairs – 2/10 (Severe impairment in 
performing activity) 
 Squatting – 0/10 (Unable to perform activity) 
S.J. scored 30/38 for the PainDETECT questionnaire. Due to the high 
score on the PainDETECT, it is likely that a neuropathic pain component is 
present. A score of >19 indicates that a neuropathic pain component is 
likely. 
He scored 45/52 for the PCS (Rumination: 15, Magnification: 10, 
Helplessness: 27); this indicates that he demonstrates catastrophic 
thinking, which plays a role in heightening his pain intensity and 
magnification of his pain. A score of 30 represents a clinically relevant 
level of catastrophizing.  
S.J. scored 65/68 for the TSK; this means that he has a high degree of 
kinesiophobia (irrational fear of movement due to vulnerability of re/injury). 
A score of 37 differentiates between high and low scores of kinesiophobia. 
For the DASS 21 questionnaire, his scores were: 21 (Depression Score); 6 
(Anxiety Score); 20 (Stress Score). Based on the DASS 21 scores, S. J. 
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has extremely severe depression scores, moderate anxiety scores and 
extremely severe stress scores. 
 
Pain Management: 
Due to the remote location of the cattle station, S. J. has limited access to 
health care. He is currently only under the care of the general practitioner 
(GP) in Newman, which he sees infrequently.  
 
Patient Perspective: 
S.J. expressed anger, anxiety and feeling very stressed over several 
issues (e.g. future of the cattle station, difficulty with caring for his 
paraplegic son, wife’s cancer relapse). He would like to be able to get 
back to doing some physical work around the cattle station, however he 
tries not to move around much as he is worried about causing more 
damage to his knees. His GP has mentioned that a total knee replacement 
(TKR) might be a good solution for his knee pain, but S.J. is not keen as 
he has a few friends that have had bad experiences after having had a 
TKR (worse pain after TKR, infection and no change in pain). He states 
that the only activity that he finds enjoyable now is eating. He feels like 
there is no joy in life anymore, and the thought of losing his wife is too 
much to bear. S.J. also mentioned that he has 2 shotguns at home and he 
has thought that there is no point in living at times. 
 
Physical Examination Findings: 
 Knee Flexion:  
o Right: 90 degrees, P1 R2, 8/10 pain. 120 degrees, P2, 10/10 
pain. 
o Left: 120 degrees, P1 R2, 6/10 pain. 
 Functional: 
o Squat: ¼ squat, 9/10 pain. ½ squat, 10/10 pain. Unable to 
squat fully. 
o Stairs: Up – Leads with left leg, and moves up step one at a 
time. Able to go up a maximum of 3 steps before needing to 
rest due to 10/10 pain. Down – Leads with right leg, and 
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moves down step one at a time. Able to go down a maximum 
of 3 steps before needing to rest due to 10/10 pain. 
o Sit to stand = Uses arms to push up when standing. No 
eccentric control of knees when sitting down. Drops straight 
into chair when sitting. 
 Sensory testing: 
o Light touch with brush = 10/10 pain reproduced at right knee 
and shin. 
o Light pressure = 10/10 pain reproduced at multiple sites 
(bilateral thighs, knees, shins and elbows). 
o Cold (using test tube filled with ice water) = 10/10 pain 
reproduced at right knee, shin and elbow. 
 
Summary: 
It is clearly evident that S. J. has both nociceptive and neuropathic pain, 
as well as features of peripheral and central sensitization. This is 
compounded by psychological factors (kinesiophobia, catastrophic 
thinking, and high DASS 21 scores - extremely severe depression scores, 
moderate anxiety scores and extremely severe stress scores) and his 
passive pain coping mechanisms. It is important to note that the timing of 
his worsening pain coincides with major negative events that have 
happened to his family.  
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2. Case Interpretation 
OA Background 
OA pain is complex; nociceptive, neuroplastic and neuropathic pain 
mechanisms, in combination with psychological and social factors (e.g. 
pain catastrophising, depression, anxiety, lack of social support, lower 
socioeconomic status) have been shown to contribute to the generation of 
OA pain(1). The presentation of pain in knee osteoarthritis sufferers varies 
greatly, from localised activity-related pain to referred or even widespread 
pain at sites distant from the knee(1-4). 
There are multiple mechanisms (nociceptive pain, neuroplastic pain and 
neuropathic pain), pain processes (peripheral sensitization, central 
sensitization), and psychological/social factors that contribute to the 
generation of OA pain(1, 5). To further complicate the nature of OA pain; the 
mechanisms, pain processes and factors that mediate OA pain vary 
among individuals(1, 5). 
Management of knee OA is generally based on symptom severity and 
range from:  
(iv) Non-pharmacological interventions  (e.g. Weight reduction, 
Lifestyle modification, Exercise rehabilitation)  
(v) Pharmacological interventions (e.g. NSAIDS, Analgesics)  
(vi) Surgical interventions (e.g. Arthroscopy, Total knee 
replacement) when both non-pharmacological and 
pharmacological interventions have failed 
 
Current Neurobiology Pain Perspective: 
Based on the clinical findings, S.J.’s pain profile comprises of nociceptive, 
inflammatory and neuropathic pain 
The evidence that supports the presence of nociceptive pain are:  
 Knee range-of-motion 
 Functional tasks (limitations)   
The evidence that supports the presence of inflammatory pain are:  
 Morning stiffness in knees 
 Allodynia in affected area (as evidenced by light touch with brush) 
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 Mechanical hyperalgesia in affected area (as evidenced by light 
pressure) 
The evidence that supports the presence of neuropathic pain are:  
 High PainDETECT questionnaire score (30/38) 
 Shooting pain from right knee to shin 
 Pins and needles and numbness in the affected area 
 Pain in the affected area if he has a cold shower 
 Weight of jeans on his right knee and shin gives him pain 
 Cold hyperalgesia in affected area  
 Allodynia in affected area  
 Mechanical hyperalgesia in affected area  
S.J. also appears to have features of peripheral sensitization (localised 
pain and sensitivity) and central sensitization (widespread sensitivity to 
light pressure and cold). Injury and inflammation results in profound 
changes in the chemical milieu of the nociceptors. This leads to increased 
responsiveness and reduced threshold of nociceptors to stimulation of 
their receptive fields. Post-translational processing (phosphorylation) and 
altered gene expression are the main mechanisms of peripheral 
sensitisation(6). Spontaneous ectopic activity and the constant barrage of 
nociceptive input from the osteoarthritic knee most likely initiated the 
central sensitization(6, 7).  
His pain is also compounded by the presence of psychological distress 
(i.e. depression, anxiety, stress) and his belief systems (i.e. passive pain 
management mentality, kinesiophobia, pain catastrophising). Stress 
causes the hypothalamus to secrete CRH, which stimulates the pituitary to 
secrete ACTH, which then stimulates the synthesis of cortisol. 
Simultaneously, the adrenal glands are stimulated and secrete adrenalin. 
Uncontrolled stress leads to the impaired regulation of the immune and 
stress systems which have been found to have links between mood 
disorders and inflammatory disease(8). Catastrophising, anxiety, fear of 
movement and individual’s experiences and belief systems can act to 
increase the perception of OA pain(9). 
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Current Clinical Guidelines: 
Based on the current guidelines for conservative management of patients 
with knee OA(10), there are a number of gaps in the management of S.J.’s 
condition. The gaps that need to be addressed are: 
1. Education of his condition 
a. S.J. was never educated on his condition and has no clear 
understanding of the pathophysiology of OA and the current 
clinical best practice guidelines on the treatment of OA. 
b. There is a pressing need to change his current belief system 
on the management of his condition, this will help to change 
his passive approach to pain management to a more active 
one. 
2. Prescription of an appropriate exercise program 
a. The success of an appropriate exercise program for him will 
depend on his understanding of his condition, as well as 
changing his belief system to be in line with an active pain 
management approach. 
b. Low impact exercises and strength training will make up the 
basis of his exercise program. 
3. Weight management plan 
a. S.J.’s BMI is 30, which puts him in the obese range. As per 
current best practice guidelines(10), reduction in weight has 
been shown to reduce pain levels. 
4. Pharmacological management plan 
a. He is currently on the maximum dosage of Etoricoxib and 
Tramadol ER. But his pain levels are still not well controlled. 
Current guidelines(10) recommend the use of NSAIDs as 
being appropriate for chronic knee OA pain, however, the 
efficacy of opioids are uncertain. Duloxetine has been 
flagged as being appropriate for use in chronic knee OA 
pain, and hence might be suitable for use in S.J.’s case.  
However, it is important to note that based on his DASS 21 
scores, there is a strong likelihood that S.J. might be 
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diagnosed as having depression. Pharmacological 
treatment for depression includes use of tricyclic 
antidepressants (TCAs) and selective serotonin reuptake 
inhibitors (SSNRIs). Hence it is important that he is not 
prescribed high dose TCAs or SSNRIs if he is on duloxetine 
for the knee pain, as that could lead to serotonin syndrome. 
Use of tramadol is not suitable for S.J., as there is a 
precaution for use of tramadol on individuals that have a 
suicide risk. Furthermore, if he is diagnosed as being 
clinically depressed, tramadol has a precaution for use for 
individuals that are on TCAs and SSNRIs.    
b. As S.J.’s pain has a neuropathic component, it is important 
that he is treated pharmacologically for it. Current 
evidence(7) recommends treating neuropathic pain with low 
dose TCAs, SSNRIs, calcium channel α2-δ ligands, topical 
lidocaine or opioid agonists. Opioid agonists like tramadol 
may not be suitable for S.J. due to his suicide ideation, and 
if he is prescribed any type of SSNRIs (e.g. duloxetine). The 
use of TCAs and SSNRIs for the treatment of his 
neuropathic pain might not be suitable, pending his 
diagnosis of depression and pharmacological treatment. 
The most logical pharmacological treatment for S.J.’s 
neuropathic pain is a combination of pregabalin and 
lidocaine patch. A benefit of pregabalin is the improvement 
of sleep disturbances and reduction in anxiety (which are 2 
issues that S.J. has highlighted).  
 
Gaps In Clinical Practice: 
The current guidelines for conservative management of patients with knee 
OA are focused on treatment of nociceptive pain.  However, 2 recent 
studies have found that close to 20% of knee OA sufferers reported 
components of neuropathic pain, using the PainDETECT questionnaire(11, 
12). The issue of neuropathic pain in knee OA sufferers is something that 
needs to be addressed.  
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Interdisciplinary Approach: 
The utmost priority for S.J. is an urgent referral for him to be assessed by 
a mental health practitioner (e.g. psychiatrist, psychologist) due to his 
suicide ideation/risk. Due to the complexity of this case, a referral to a 
tertiary multi-disciplinary pain management clinic will be ideal.  
S.J. will need to be reviewed by:  
 Psychiatrist 
o To assess his psychological distress and suicide ideation 
 Pain management doctor  
o To review, recommend and titrate medications that will suit 
his condition. 
 Clinical/Behavioral psychologist  
o To change current belief system 
o Teach coping strategies 
o Help organize a better sleep pattern  
 Physiotherapist (who specializes in managing chronic pain)  
o Educate S.J. on his condition 
o Change current belief system 
o Exercise prescription  
o Weight management 
 Dietitian 
o Review and set a nutrition plan for weight control 
 
3. Patient Management Plan 
Refer to Appendix 1.  
Please note that mustering of cattle is not in the current goals as it is 
complex activity that will require intensive rehabilitation (looking at a time 
frame of 3 to 6 months) before the possibility of it happening. 
 
4. Summary (For Patient) 
Refer to Appendix 2.
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Appendix 1        Patient Management Plan 
Management 
Options 
Details Goals Screening 
Tools/Outcome 
Measures 
Education/Advice 
-Good quality of 
evidence for 
education and self 
management(10)  
-Educated S.J. on his condition.  
-Explained that pain does not necessarily 
mean damage/harm.  
-Explained that normal movement will not 
damage his knees further and will in fact 
help with the pain.  
-Education on the effects of stress and 
belief systems on perceived pain. 
-Gave S.J. some resources (Explain Pain 
book and painHEALTH website) for him to 
have a look at. 
STG: Changing his 
current belief 
systems and 
increasing 
knowledge of pain. 
Encourage 
movement and 
positive thinking. 
MTG/LTG: 
Reduction of TSK 
to <37, PCS to <30 
and global 
reduction of DASS 
21 scores.  
Tampa Scale for 
Kinesiophobia 
Pain Catastrophizing 
Scale 
DASS 21 
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Exercise Plan 
-Good quality of 
evidence for 
incorporation of 
strength/exercise 
program(10)  
-Reinforced that movement is not harmful 
and that an increase in physical activity will 
help with his condition. 
-Walking – start with short distances (8 
minutes) but do so frequently (3 times) 
throughout the day. 
-Home exercises – Straight leg raise in 
supine (3 sets of 5 repetitions with 5 
seconds hold), Bridging (3 sets of 5 
repetitions with 5 seconds hold), Knee 
extension in supine with rolled up towel 
under knee (3 sets of 5 repetitions with 
yellow theraband), Wall squats (3 sets of 5 
with 5 seconds hold). 
STG: Walking – 3 
x10 mins daily 
Home Ex – 3 sets 
of 8 repetitions with 
5 secs hold 
MTG: Walking – 2 
x15 mins daily 
Home Ex – 3 sets 
of 8 repetitions with 
8 secs hold 
LTG: Walking – 30 
mins daily 
Home Ex – 3 sets 
of 10 repetitions 
with 10 secs hold 
 
Patient-Specific 
Functional Scale 
STG: Walking for 10 
mins, 4/10 
Stairs (Up/Down – 5 
steps), 4/10 
¼ squat, 2/10 
MTG: Walking for 15 
mins, 5/10 
Stairs (Up/Down – 8 
steps), 5/10 
½ squat, 3/10 
LTG: Walking for 30 
mins, 7/10 
Stairs (Up/Down – 10 
steps), 7/10 
½ squat, 5/10 
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Weight Management 
-Good quality of 
evidence for weight 
management(10) 
-Look at current diet, and reduce portion 
size. 
-Reduce consumption of soft drinks and 
sweets. 
-Increase daily activity 
STG: Reduce soft 
drink and sweets 
intake by 50%. 
Drop 4 kgs 
MTG: Drop 8 kgs 
LTG: Drop 12 kgs 
 
Return To Work -To start with light physical work such as 
walking for short distances along the 
boundary of the cattle station to check for 
damaged fences and pumps for the 
watering holes 
-Mustering cattle on horseback is an 
activity that will be looked at in future  
STG: Driving out to 
check on fences 
and watering holes 
and walking for 
short distances (5 
mins) 
MTG: Climbing up 
a flight of steps to 
check on water 
tanks 
LTG: ½ squat to 
check on power 
generator 
Patient-Specific Functional 
Scale 
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Medication 
-Good quality of 
evidence for use of 
COX-2 inhibitors(10) 
-Lidocaine patch 
and pregabalin is 
recommended for 
use as a first-line 
treatment for 
neuropathic pain(7) 
-Continue with Etoricoxib, advised that 
tramadol might not be suitable for him. 
-To explore use of pregabalin and 
lidocaine patch with GP/Pain Management 
doctor. 
STG: Review of 
medication with 
GP/Pain Specialist 
MTG/LTG: 
Effective use of 
medication 
PainDETECT 
STG/MTG/LTG: Reduction 
of PainDETECT scores to 
indicate control of 
neuropathic pain 
component 
 
Referral To Others  -Spoke at length about the findings of 
DASS 21 questionnaire. Arranged for S.J. 
to see a GP in Perth on the same day.  
-GP to do an assessment of his mental 
state and arrange for referral to see 
psychiatrist. 
-Arranged an appointment for S.J. to be 
seen at a pain management clinic, where a 
pain management doctor and 
STG: Review by 
GP on same day to 
assess mental 
state and arrange 
referral to 
psychiatrist. 
Assessment by 
pain management 
clinic and dietitian 
Tampa Scale for 
Kinesiophobia 
Pain Catastrophizing Scale 
DASS 21 
-Reduction in the scores of 
the above instruments  
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clinical/behavioral psychologist will see 
him. 
-Arranged an appointment for him to be 
seen by a dietitian. 
MTG/LTG: Review 
with the pain 
management clinic 
and dietitian as 
needed 
Review In 2 weeks when he returns for his dietitian 
and pain management appointment 
Subsequent appointments will be every 
fortnight (tagged to wife’s appointments in 
Perth), and as required. 
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Appendix 2       Summary (For Patient) 
Management 
Options 
Comments 
Education/Advice Explanation about knee OA and how normal movement will help your condition. Pain does 
not necessarily mean damage/harm. Stress and your current beliefs about pain are 
aggravating your condition. I am going to loan you a book titled “Explain Pain” which will 
give you more insight into your pain. You can also have a look at this website 
(http://painhealth.csse.uwa.edu.au/pain-management-making-sense-of-pain.html). Stay 
positive and find ways to incorporate more movement into your daily routine. Goal: Start to 
be more physically active as that can help with your stress levels. Keep a positive outlook.  
Exercise Plan Your path to recovery begins with being regular with your exercise and physical activity. 
Goal: Start with walking short distances (8 minutes) but do so frequently (3 times) daily. 
Home exercises – Straight leg raise in lying, Bridging, Wall squats (3 sets of 5 repetitions 
with 5 seconds hold), Knee extension in lying with rolled up towel under knee (3 sets of 5 
repetitions with yellow theraband). I will progress your exercises as we go along.  
Weight Management Based on your BMI, you are in the obese range. Reduction of weight has been shown to be 
beneficial to reducing your pain levels. Goal: Reduce portion size. Reduce consumption of 
soft drinks and sweets by 50%. Increase daily activity. Aim to lose a 1 kg of weight per 
week. 
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Medication There is a need to review your pain medication. You should continue with Etoricoxib, 
however tramadol might not be suitable for you. As your pain has a neuropathic 
component, there is a need to explore use of pregabalin and lidocaine patch with the 
GP/Pain Management doctor. Goal: The right medication will play a role in controlling your 
pain levels. The pain specialist will come up with a medication plan for you. This will 
typically involve quick acting and sustained pain-relieving medication. It is important that 
you know what medication is for which type of pain. Once you have worked out a “rescue 
plan”, remember to share this with your family and let them know what it is.  
Referral to others  See the GP next door for an assessment on your mental health and also to discuss 
medications. The GP will arrange for referral to see psychiatrist if needed. I have arranged 
an appointment at the pain management clinic, where a pain management doctor and 
clinical/behavioral psychologist will assess you. The psychologist can help you with coping 
strategies and managing your mood. I have also arranged an appointment for you to see a 
dietitian who will work out a nutrition plan for you. 
Review I will see you in 2 weeks when you come back to Perth for your dietitian and pain 
management appointments. During that appointment I will review your progress and go 
through the mid term goals and long term goals again. I will give you a phone call in a 
week’s time to see how you are faring. 
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2.4.3 Medical Communication  
 
Dr Glenn Liew              29th September 2014 
St Francis Medical 
11/29 Station Street 
Subiaco, WA 6008 
RE: Mr S.J. (DOB: 01/01/1946) 
Dear Glenn, 
 
Thank you for agreeing to review S.J. at such short notice. 
 
Presenting disorder: S.J. is a 68-year-old male, who presented to the 
clinic today due to right knee pain. He was diagnosed with severe 
osteoarthritis (OA) of both knees in 2006. He states that he was coping 
well with his condition until 3 years ago, when he started to feel that the 
his right knee pain worsened. His pain has increased even more over the 
last 6 months 
 
Brief subjective pain history and behavior: S.J. reports that he is in 
constant pain. 3 years ago before the pain worsened, he stated that his 
pain was 5/10 on average then. Since 6 months ago, his pain is 7/10 on 
average (with pain medication. Pain is 10/10 un-medicated). He states that 
pain shoots down from the right knee to the right shin, and he often feels 
numbness/pins and needles in that same area. His pain worsens when he 
has a cold shower. He is unable to wear jeans as the weight of the jeans 
on his right knee/shin gives him pain. S.J. reports that he is often unable to 
sleep for more than 2 hours at a time due to pain. He also has complains 
of morning stiffness in both his knees lasting about 15-20 minutes. 
 
Behavioral responses to pain: S.J. turned up for his appointment with 
me today in a wheelchair, as he prefers not to use his knees too much as 
he does not “wear them out further”. He has also stopped all physical work 
at the cattle station due to this belief.  
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Social history: S.J. does not smoke, drink or have any history of drug 
abuse. He lives on the cattle station (4 hours drive from Newman), with his 
wife and 2 sons (35 and 38 years old). His youngest son fell off his horse 3 
years and is now a paraplegic. S.J.’s eldest son has taken over all of the 
physical tasks involved in the running of the cattle station. He has put on 
about 20-25 kg over the last 3 years (due to the lack of physical activity 
and eating habits). His wife recently (6 months ago) had a relapse of 
breast cancer. S.J. feels like there is no joy in life anymore, and the 
thought of losing his wife is too much to bear. He also mentioned that he 
has 2 shotguns at home and he has thought that there is no point in living 
at times. 
 
Medical non-pain and pain co-morbidities: S.J. has no other medical 
conditions. He was screened and cleared of any red flags. 
 
Screening Tools and Outcome Measures: S.J. scored 30/38 for the 
PainDETECT questionnaire. A score of >19 indicate that a neuropathic 
pain component is likely. 
S.J. listed the following 4 activities on the Patient-Specific Functional 
Scale: 
 Mustering cattle – Unable to perform activity 
 Walking for 10 minutes – Severe impairment in performing activity 
 Walking up and down stairs – Severe impairment in performing 
activity 
 Squatting – Unable to perform activity 
He scored 45/52 for the Pain Catastrophizing Scale; this indicates that he 
demonstrates catastrophic thinking, which plays a role in heightening his 
pain intensity and magnification of his pain.  
S.J. scored 65/68 for the Tampa Scale for Kinesiophobia; this means that 
he has a high degree of kinesiophobia (irrational fear of movement due to 
vulnerability of re/injury). 
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For the DASS 21 questionnaire, his scores were: 21 (Depression Score); 6 
(Anxiety Score); 20 (Stress Score); indicating that he has extremely 
severe depression scores, moderate anxiety scores and extremely severe 
stress scores. 
 
Pain mechanisms: S.J. has nociceptive, inflammatory and neuropathic 
pain, as well as features of peripheral and central sensitization. This is 
compounded by psychological factors (kinesiophobia, catastrophic 
thinking, and extremely severe depression scores, moderate anxiety 
scores and extremely severe stress scores on the DASS 21) and his 
passive pain coping mechanisms. It is important to note that the timing of 
his worsening pain coincides with major negative events that have 
happened to his family.  
 
Pain management strategies to date and outcome: Due to the remote 
location of the cattle station, S.J. has limited access to health care. He is 
currently only under the care of the general practitioner (GP) in Newman, 
which he sees infrequently. S.J. has been on Etoricoxib (60mg, once daily) 
and Tramadol ER (100mg, thrice daily) for the last 2 years.  
 
Physical examination findings and interpretation:  
 Knee flexion ranges were restricted and painful which are consistent 
with degenerative OA changes. Right knee flexion was more restricted 
and painful compared to the left. 
 Functionally, S.J. was unable to do a full squat due to pain (able to do 
½ squat with 10/10 pain); Up/Down stairs only a maximum of 3 steps at 
a time (due to pain); needed to use arms to push up with standing and 
was unable to control descent when sitting down. 
 Generalised mechanical and cold sensitivity: sensitivity to light touch at 
right knee and shin; sensitivity to light pressure at bilateral thighs, 
knees, shins and elbows; sensitivity to cold at right knee, shin and 
elbow.  
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Management plan: Based on the current guidelines(1) for conservative 
management of patients with knee OA, please refer to Appendix 1 for the 
management plan for S.J.  
 
Recommendations: Following my assessment of S.J., I make the 
following recommendations. 
1. Review of mental state: Apart from the results of the DASS 21 
questionnaire, I am also concerned that S.J. has showed signs of 
suicide ideation. Would you be able to do an assessment on his 
mental state and arrange any appropriate referrals? 
2. Medications: S.J. will need to have his current pain medications 
reviewed. I would suggest continuing with Etoricoxib. However, 
tramadol might not be suitable for him. Kindly explore the use of 
pregabalin and lidocaine patch for his neuropathic pain. 
3. Pain management: I have made arrangements for S.J. to be seen 
at PainCare in Fremantle on the 13th October 2014. 
4. Nutrition: I have made arrangements for S.J. to be seen by a 
dietitian (Kate Fleming) on the 13th October 2014. 
5. I will review S.J. after his pain management and dietitian 
appointments.  
 
 
Regards, 
 
Philip Cheong 
APA Musculoskeletal Physiotherapist
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Chapter 3: Pharmacology for Health 
Professionals 
3.1 Introduction 
Pharmacology is the study of drugs, including their actions and effects in 
living systems. Knowledge acquired from this unit will provide health 
professionals with a sound understanding of pharmacological principles. 
As well as learning about the pharmacology of drugs acting on major body 
systems, including the cardiovascular, respiratory, endocrine and 
central nervous systems, health professionals will also learn about the 
mechanism of drug absorption, distribution, biotransformation and renal 
elimination. The contact time for this unit was 48 hours.  
 
3.2 Syllabus 
 Pharmacological principles.  
 Mechanisms of drug absorption, distribution, metabolism and renal 
elimination.  
 Half-life, clearance, drug concentration and effect.  
 Relationship between rate of drug dosing and plasma concentrations.  
 Bioavailability and bioequivalence. 
 Renal disease and drug dosing - serum creatinine and creatinine 
clearance.  
 Mechanisms of drug toxicity, adverse reactions, interactions.  
 Meaning of information in drug monographs.  
 Autonomic Nervous System pharmacology.  
 Pharmacology of drugs acting on respiratory, gastrointestinal, 
cardiovascular, central nervous, endocrine and musculoskeletal 
systems.  
 Drugs for pain, allergy and mental illness.  
 Antimicrobial, antifungal and antiviral agents. 
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3.3  Learning Outcomes 
1. Apply the pharmacological and pharmacokinetic principles of drugs 
affecting the major systems of the body. 
2. Interpret and calculate the pharmacokinetic parameters of a drug and 
its use in designing drug dosage regimens. 
3. Critically appraise literature relating to pharmacological and 
pharmacokinetic principles in the advancement in drug treatment/s. 
 
3.4 Assessments 
Assessment for this unit comprised of 3 online tests, a literature review 
essay and a final written examination. The completed examination scripts 
for the online tests and final written examination were not returned to 
students. Hence only the literature review essay is available: 
3.4.1  Literature Review Essay 
 For this assignment, I had to submit a literature review essay on 
a topic of my interest. 
 The topic I had chosen was, “Examine the relevant literature 
and review advances in the understanding and management of 
neuropathic pain”. 
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3.4.1 Literature Review Essay 
 
Title:  
Examine the relevant literature and review advances in the understanding 
and management of neuropathic pain 
 
Abstract: 
Neuropathic pain arises as a direct consequence of a lesion or disease 
affecting the somatosensory system. This review focuses on the current 
understanding, clinical assessment and pharmalogical management of 
neuropathic pain. 
 
Introduction 
In 1994, the International Association for the Study of Pain (IASP) defined 
neuropathic pain as, “Pain initiated or caused by a primary lesion or 
dysfunction in the nervous system.”(1) This definition has been useful in 
differentiating neuropathic pain from other types of pain, but it is neither 
precise nor specific.  
The IASP subsequently reviewed the definition of neuropathic pain in 2008 
to be: “Pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system.”(2) This revised definition of 
neuropathic pain emphasizes on the concept of aberrant somatosensory 
processing (far in excess of normal plasticity of the undamaged 
nociceptive system) which is the hallmark of neuropathic pain.  
Neuropathic pain can be classified into either central (spinal, brainstem, 
thalamus or cortex) or peripheral (nerve, plexus, dorsal root ganglion or 
root), depending on the anatomic location of the lesion or disease.  
 
Epidemiology 
In France, neuropathic pain has been approximated to affect 6.9% of the 
French general population.(3) In the United States of America, an 
estimated 35% of USA general population suffer from chronic pain, and 
17.9% of those chronic pain sufferers have neuropathic pain.(4)  
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Due to the complex nature of neuropathic pain, it is often under 
diagnosed(5) and not treated appropriately. To add to the complexity of 
neuropathic pain, sufferers of chronic/neuropathic pain also tend to have 
higher depression and anxiety scores and more sleep disturbances.(6, 7) 
 
Pathophysiology 
Most of our understanding on the pathophysiology of neuropathic pain is 
based on animal studies. 
The general mechanisms of neuropathic pain are peripheral and central 
sensitisation. The specific mechanisms are ectopic nerve activity, 
structural re-organization and loss of inhibitory interneurons 
Following axonal injury (nerve lesion), a cascade of events takes place. 
There is an upregulation in the α2δ Ca2+ subunits in the dorsal root 
ganglion neurons, which causes prolonged membrane depolarization of 
the calcium channels.(8) A downregulation in μ opioid receptors has also 
been observed in animal studies of neuropathic pain states.(9, 10) The 
nerve lesion causes upregulation of nerve growth factor (NGF), tumour 
necrosis factor α (TNFα), transient receptor potential vanilloid type 1 
(TRPV1) and pro-inflammatory cytokines.(11-13) The release of these 
products trigger the expression of sodium channels and sensitisation of 
the TRPV1 receptors in the nearby healthy nerve fibres. 
Peripheral sensitisation sets in following a nerve lesion. Peripheral 
sensitization is a physiological event where there is increased 
responsiveness and reduced threshold of nociceptors to stimulation of 
their receptive fields. Injury and inflammation of the damaged tissues 
leads to profound changes in chemical milieu of nociceptors, which leads 
to a decrease in nociceptors threshold and increased responsiveness to 
subsequent stimuli. Phosphorylation dramatically alters activity of 
receptors and ion channels. Changes in nociceptor properties, altered 
receptor-ion channels, increased membrane excitability, activation 
signalling cascades (phosphorylation proteins; gene transcription) and 
phenotypic switch (where the way the nerve fibres (C, Aβ, Aδ) function 
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changes as it relates to light touch driving sensitivity) are the hallmarks of 
peripheral sensitization.(14) 
Alterations in sodium channels (increased expression) and potassium 
channels (inhibition) occur following nerve lesion.(15-19) This alteration in 
sodium and potassium channels, coupled with peripheral sensitization, 
causes ectopic nerve activity to occur. 
The ectopic nerve activity is the primary driver of central sensitization in 
neuropathic pain. Central sensitization is a physiological event where 
there is increased responsiveness of nociceptive neurons in the central 
nervous system to their normal or sub-threshold input.(20) This 
phenomenon is activity-independent (does not require ongoing nociceptive 
input). Phosphorylation of the NMDA and AMPA receptors dramatically 
increases their sensitivity. Phosphorylation of the NMDA receptor 
increases its distribution to the synaptic membrane and its responsiveness 
to glutamate, which causes increased excitability to the cell membrane.(14) 
The physiologic principles of central sensitization are similar to that of 
peripheral sensitization. The main difference is that the processes occur in 
the central nociceptors transmission neurons in the dorsal horn or in the 
spinal nucleus of the trigeminal. There is also phenotypic switch of 
nociceptor specific neurons to wide dynamic range neurons. The low 
threshold Aβ and Aδ fibres are then able to activate the second order 
nociceptive neurons in the dorsal root ganglion. 
Selective loss of inhibitory GABAergic interneurons has been shown to 
occur in an animal model.(21) Some animal studies have also shown a 
decrease in efficacy of descending inhibitory pathways and the 
endogenous endorphin system in neuropathic pain conditions.(22, 23) The 
loss of inhibitory interneurons, decrease in efficacy of the descending 
inhibitory pathways and endogenous endorphin system, contributes to the 
complexity of managing neuropathic pain. 
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Clinical Assessment of Neuropathic Pain 
Even though neuropathic pain is very heterogeneous, the clinical signs 
and symptoms are similar across the various neuropathic pain 
conditions/syndromes. Sufferers of neuropathic pain frequently exhibit 
paroxysmal, persistent and paradoxical pain that can be stimulus 
independent or stimulus evoked. 
 
Sensory Testing 
Neuropathic pain patients tend to present with both negative 
(Hypoaesthesia, Pall-hypoaesthesia, Hypoalgesia and Thermal 
hypoaesthesia) and positive (Spontaneous: Paraesthesia, Superficial 
burning pain, Paroxysmal Pain; Evoked: Allodynia, Static hyperalgesia, 
Punctuate hyperalgesia, Heat/Cold hyperalgesia, etc) sensory signs and 
symptoms.(24) 
The area of sensory abnormality must be compatible with the lesion site.  
Sensory testing (thermal-cold/heat, touch, vibration, pressure and pin 
prick) plays an important role in the clinical assessment. Sensory testing in 
the clinical environment can be assessed easily with common items. 
Thermal (cold/heat) testing can be accomplished by using a test tube filled 
with water at 20°C for cold testing, and water at 40-45°C for heat testing; 
touch can be assessed by response to gentle application of a piece of 
cotton wool; vibration by tuning fork placed at strategic bony landmarks; 
pressure by gentle pressure exerted by the healthcare practitioner’s finger, 
and pin prick by response to a toothpick or sharp stimuli.(24) 
 
Screening Tools 
Screening tools based on verbal pain descriptions can be used to help 
determine the presence of neuropathic pain. Several screening tools like 
the painDETECT, Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS) and Self-Administered Leeds Assessment of Neuropathic 
Symptoms and Signs (S-LANSS) have been developed for neuropathic 
pain screening.  
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The painDETECT was developed to detect neuropathic pain components 
in chronic low back pain patients, however it has been validated for use 
across musculoskeletal pain conditions.(5, 7) The painDETECT has a 
sensitivity of 85%, specificity of 80% and positive predictive accuracy of 
83%.(7) 
The LANSS has shown sensitivity of 85% and specificity of 80% in 
detecting neuropathic pain.(25) The S-LANSS is a validated self-report 
version of the LANSS and has been shown to have sensitivity ranging 
from 74-78% and specificity ranging from 68-83% depending on cut-off 
score.(26) Positive scores on either questionnaire identify neuropathic pain 
mechanisms being present in the patient. 
 
Management of Neuropathic Pain 
For the purposes of this review, only pharmacological management of 
neuropathic pain will be discussed.  
Based on our understanding of the pathophysiological processes in 
neuropathic pain, the general concept for treatment of neuropathic pain 
focuses on  
i. Reduction of peripheral sensitisation 
ii. Reduction of central sensitisation, and  
iii. Enhancement of the descending inhibitory pathways. 
 
i. Reduction of peripheral sensitisation 
 Sodium channel blockade  
o Tricyclic antidepressants (Amitriptyline, Nortriptyline and 
Desipramine) have several modes of action: 
 Inhibition of reuptake of serotonin and/or 
norepinephrine 
 Block sodium channels 
 Modulates mood 
And have been shown to be effective in treating neuropathic 
pain conditions such as diabetic neuropathy, post herpetic 
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neuralgia, chronic radiculopathy and neuropathic pain post 
breast cancer treatment.(27-31) 
o Lidocaine (topical) works by blocking sodium channels and 
has been shown to be effective in the treatment of peripheral 
neuropathic pain syndromes.(32) 
 
ii. Reduction of central sensitisation 
 NMDA antagonists (Ketamine, Methadone) 
o Ketamine is an NMDA receptor antagonist which works by 
inhibiting “the progressive increase in action potential 
discharge (wind-up) and neuronal hyperexcitability produced 
by repeated stimulation of small-diameter primary 
afferents.”(33) A small pilot study on the use of intraoperative 
ketamine during knee arthroplasty has indicated that when 
used in conjunction with spinal anaesthesia, it may be able 
to influence the reduction of persistent post total knee 
arthroplasty pain.(34) The normal route of ketamine 
administration is either via intravenous or subcutaneous 
infusions. However, an oral/sublingual route of administration 
has been developed with good results.(35)  
 Calcium channel blockers  
o Pregabalin and Gabapentin are calcium channel α2-δ 
ligands that reduce the release of excitatory 
neurotransmitters. Multiple studies have shown the 
effectiveness of both pregabalin and gabapentin in the 
management of neuropathic pain.(36-40)  
o Pregabalin has been shown to be effective for use in 
diabetic neuropathy, post herpetic neuralgia and central pain 
after spinal cord injury.(41) 
o Gabapentin has been shown to be effective for use in 
diabetic neuropathy, post herpetic neuralgia and cancer 
associated neuropathic pain.(41) 
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iii. Enhancement of the descending inhibitory pathways 
 Tricyclic antidepressants (TCA), Serotonin Norepinephrine 
Reuptake Inhibitors (SNRIs) and opioids all work to enhance the 
descending inhibitory pathways via inhibition of norepinephrine and 
serotonin reuptake. 
 SNRI  
o Duloxetine is a Serotonin Norepinephrine Reuptake Inhibitor 
(SNRI), which works by inhibiting reuptake, thus increasing 
the levels of serotonin and norepinephrine in the CNS. 
Multiple studies have shown Duloxetine to be an effective 
pain relief for patients suffering from diabetic neuropathy.(42-
45) 
 Opioids  
o Tramadol is a centrally acting drug that has a μ-opioid effect 
and also inhibits norepinephrine and serotonin reuptake. It 
has been shown to be effective in the treatment of diabetic 
neuropathy and polyneuropathy.(46, 47) 
o Tapentadol is a newer drug that has a μ-opioid receptor 
agonism effect and also inhibits noradrenaline reuptake.  
 Tapentadol has been shown to be more effective than 
morphine in the treatment of diabetic neuropathy in 
the animal model.(48) In a human trial, Tapentadol 
demonstrated a 30% improvement in pain intensity for 
60.5% of research participants with diabetic 
neuropathy.(49)  
 Tapentadol has demonstrated effectiveness in the 
treatment of chronic low back pain with/without 
neuropathic pain component(50), and also was 
associated with a lower incidence of adverse events 
as compared to oxycodone in the treatment of chronic 
low back pain.(51)  
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Combination therapy 
Combination therapy in the treatment of neuropathic pain is promising. 
Typically, with combination therapy the individual doses of each drug is 
much lower as compared to single drug therapy.  
A study which looked at combination of oxycodone with gabapentin found 
better results in patients with diabetic neuropathy as compared to mono 
therapy.(52) Combination of morphine with gabapentin,(53) nortriptyline and 
gabapentin,(54)  and topical lidocaine with pregabalin,(55) also demonstrated 
better results than mono therapy in patients suffering from diabetic 
neuropathy and post herpetic neuralgia. Combination therapy of 
oxycodone and pregabalin was administered to patients diagnosed with 
neuropathic pain of various etiologies (due to either Lumbar stenosis, 
Failed Back Surgery Syndrome, Post herpetic neuralgia, Diabetic 
neuropathy or Radiculopathy), the group that received combination 
therapy fared significantly better compared to the mono therapy group.(56) 
 
Current Pharmacological Guidelines for the Treatment of Neuropathic Pain 
The recommended first line pharmacological treatment of neuropathic pain 
are calcium channel blockers (gabapentin/pregabalin), TCA/SNRI or 
sodium channel blockers (topical lidocaine).(41, 57, 58) 
 
Conclusion 
Neuropathic pain is complex and extremely challenging for healthcare 
professionals to handle. Due to the multiple mechanisms and the 
variability of these mechanisms, each individual with neuropathic pain is 
unique and different. Pharmacological management of the neuropathic 
pain patient must be targeted to their specific pain pathways. In addition, 
neuropathic pain sufferers also tend to be more depressed, have higher 
anxiety levels and disturbances to sleep, these factors all need to be 
addressed in their individual treatment plan.
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Chapter 4: Specialised Physiotherapy 
Clinics 
4.1 Introduction 
In this unit, students undertake an advanced clinical placement intended to 
improve their knowledge and skills in a specialised area of clinical 
practice. The placement may involve advanced physiotherapy practice or 
extended scope practice in an area relevant to the personal development 
of the student. It is envisaged that supervision will be provided by a 
physiotherapist with specialist knowledge and skills or by a medical 
practitioner with specialist knowledge and skills. 
The placement will be structured to provide specific learning opportunities 
for the student. This is a Doctoral level placement and will involve a high 
level of self-directed learning leading to the development of specific 
expertise. It is envisaged that the placement will involve evidence based 
practice and will include a specific emphasis on utilizing and 
understanding specific outcome measures as a means to evaluate 
practice.  
The contact time for this unit was 96 hours.  
 
4.2 Syllabus 
 Supervised clinical practice with an emphasis on development of 
advanced competencies in a specific area of physiotherapy practice.  
 Emphasis on advanced skills in patient/client communication, physical 
examination, interpretation of clinical information and development of 
evidence-based physiotherapy treatment plans.  
 Evaluation of response to treatment and modification of treatment at an 
advanced level.  
 Understanding of the indications for inter-professional patient/client 
referral and inter-professional management consistent with advanced 
practice in physiotherapy. 
 
 
 
 
 
98 
4.3 Learning Contract 
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4.4 Supervisor Evaluation Form 
 
 
 
 
101  
 
 
 
 
102 
4.5 Overview of Placement 
Pain Medicine is recognized as a medical specialty that uses a 
multidisciplinary approach in the reduction/management of pain and 
improving quality of life. The areas of pain medicine include acute pain, 
chronic pain and cancer pain.  
At Royal Perth Hospital, Pain Medicine is divided into 2 branches: Acute 
Pain Service (APS) and Pain clinic (dealing with chronic pain issues).  
 
Acute Pain Service 
The role of the APS is to:  
 Provide/improve post-operative analgesia 
 Conduct daily rounds to ensure that all post-operative patients 
have adequate pain relief 
 Educate ward staff in the current clinical guidelines in acute pain 
management 
The APS team members include Pain Medicine Specialists, Nurse 
Practitioners and Clinical Nurses.    
 
Pain Clinic 
The role of the pain clinic is to: 
 Provide a multidisciplinary approach to the diagnosis and 
management of chronic pain conditions in an outpatient setting 
 Tailor a management plan to each patient’s specific needs 
The Pain Clinic team members include Pain Medicine Specialists, Nurse 
Practitioners, Clinical Nurses, Psychiatrist, Clinical Psychologists and 
Physiotherapists. 
During the placement at RPH Pain Medicine, I had the unique opportunity 
to experience and take part in all aspects of pain medicine.  
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4.6 Placement Goals and Objectives 
1. Develop an increased understanding of the roles of each of the 
multidisciplinary team members in the Pain Medicine clinic by the 
end of the placement 
a. Pain Medicine Specialist 
i. Observed and participated in clinic sessions with 
various Pain Medicine Consultants 
ii. Gained knowledge on the pharmacological and 
interventional approaches for chronic pain 
b. Nursing 
i. Observed and participated in patient education 
sessions on chronic pain management 
ii. Observed the scope of nursing practice in pre and 
post procedures/interventions 
c. Psychiatry 
i. Was not able to observe due to patient confidentiality 
issues 
d. Clinical Psychology 
i. Observed an initial assessment session, but not able 
to join in during treatment sessions due to patient 
confidentiality issues 
ii. Gained knowledge on the use of different 
psychological approaches (Cognitive Behavioral 
Therapy (CBT) and Acceptance & Commitment 
Therapy (ACT)) 
e. Physiotherapy 
i. Observed and participated in triage clinic sessions 
with the extended scope physiotherapist 
ii. Participated in joint clinic sessions with the Pain 
Medicine Consultants  
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2. Develop understanding of different types of pain syndromes seen at 
the Pain Medicine clinic 
a. Developed deeper understanding in the presentation and 
management of the following conditions: 
i. Fibromyalgia 
ii. Osteoarthritis 
iii. Phantom Limb Pain 
iv. Non-specific Chronic Low Back Pain 
v. Cervicogenic Headaches 
vi. Neck Pain  
 
3. Acquire knowledge on the procedures/interventions used by the 
Pain Medicine physicians on patients with acute and chronic pain 
a. Acute Pain 
i. Developed deeper understanding on the different 
medications (and mode of administration) used on the 
Analgesic Ladder. 
ii. Learnt about the following analgesic infusions and 
their uses 
1. Patient Controlled Analgesia 
2. Opioid Infusion 
3. Epidural Infusion 
4. Regional Infusion 
5. Ketamine Intravenous Infusion 
b. Chronic Pain 
i. Observed the following procedures and developed 
deeper understanding of the purpose of the procedure 
and the structures affected 
1. Medial Branch Block 
2. Lateral Femoral Cutaneous Nerve Block 
ii. Due to funding cuts, the number of interventional 
procedures has dropped significantly. Therefore I was 
only able to observe 2 interventions.  
 
 
 
 
105 
4. Identify areas where physiotherapy can play a part in the 
management of pain disorders 
a. Physiotherapists can play a number of roles in the spectrum 
of pain management 
i. Triage clinics 
1. No specific additional training is needed, as the 
role of the triage clinic is to determine which 
health professional that the patient needs to be 
seen by. 
ii. Extended/Advanced scope practice  
1. Specific training needed on  
a. Pharmacology 
b. Training program on management of 
pain disorders 
c. Psychological approaches (CBT and 
ACT) 
2. With the additional training, physiotherapists 
can offer medication counseling and simple 
psychological intervention 
 
5. Help with the administration of LEAP (Lifestyle Education & 
Activation Program) for chronic pain sufferers 
a. Multidisciplinary pain management program that 
incorporates pain medicine, clinical psychology, occupational 
therapy, physiotherapy and dietitian input. 
b. Observed and participated in the administration of the LEAP 
program 
i. Assisted in the physiotherapy-led exercise classes 
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4.7 Outcome Measure 
A standardised assessment form for LEAP was developed and 
implemented for use for assessment of future LEAP participants. Refer to 
Appendix 1 for assessment form. 
 
Functional Outcome Measure 
1. The Aggregated Locomotor Function Score (ALF) has been 
incorporated as the functional outcome measure for the 
assessment form. The ALF is a measure of observed locomotor 
function. It consists of 3 components: 8 metres walk time, stair 
ascent and descent time and transferring time(1).  
The ALF has been shown to have excellent intra-tester reliability (ICC2,k: 
0.99; 95% CI: 0.98-0.99), low standard error of measurement (0.86 s) and 
smallest detectable difference (9.5%) values(1). The ALF was chosen as it 
featured 3 functional movements that all LEAP participants experience in 
their daily activities.  
 
Questionnaires 
1. The Pain Catastrophising Scale (PCS) is a self-report questionnaire 
describing thoughts and feelings that individuals might experience 
when in pain. It has 13 items over 3 subscales: rumination, 
magnification and helplessness(2). The PCS demonstrated 
adequate reliability (Cronbach’s Alpha: 0.87)(2); (Cronbach’s Alpha: 
0.91 for rumination subscale; 0.75 for magnification subscale; 0.87 
for helplessness subscale; 0.93 for total PCS)(3), and good criterion-
related, concurrent and discriminant validity(4). 
2. The Tampa Scale of Kinesiophobia (TSK) assesses fear of 
movement/physical activity and/or (re)injury in individuals with 
pain(5, 6). The TSK demonstrates adequate reliability (Cronbach’s 
Alpha: 0.77)(5). 
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4.8 Case Studies 
4.8.1 Case Study 1 
Current History: 
B.N. is a 65 year-old male who was diagnosed as having severe 
osteoarthritis (OA) of both knees in 2010. He states that he was coping 
well with his condition until 2 years ago, when he started to feel that the 
pain in his left knee started to worsen. He states that his pain has started 
to worsen even more over the last 6 months. He complains of pain from 
his left knee going down to his shin (refer to body chart). He states that he 
can walk a short distance (approximately 200 metres) but he prefers not to 
use his knees too much as he does not want to “wear them out further”. 
He has a BMI of 35. B.N. was screened and cleared of any red flags. 
Body Chart: 
 
 
Constant pain 
in left knee and 
shin. Frequent 
sharp, shooting 
pain and pins 
& needles. 
/////
/////
/////
/////
/////
///// 
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Pain History: 
B.N. reports that he is in constant pain. 2 years ago before the pain 
worsened, he stated that his pain was 4/10 on average then. Since 6 
months ago, his pain is 12/10 on average. He states that pain shoots 
down from the left knee to the shin, and he often feels pins and needles 
and an electrical shooting pain in the same area. His pain worsens when 
the weather is hot. He is unable to wear jeans as the weight of the jeans 
resting/rubbing on his right knee and shin gives him pain. He is unable to 
work due to his pain (he used to work as a sheep shearer). His functional 
limitations are squatting (unable to do at all), climbing up and down stairs 
(only able to go up 2-3 steps), walking for 200 metres. He also reports that 
he is often unable to sleep for more than 2 to 3 hours at a time due to the 
pain. He complains of stiffness in both his knees (particularly in the 
morning that lasts about 10-15 minutes, and after sustained sitting). 
 
Social History: 
B.N. is a heavy smoker and averages about 20 cigarettes daily; he also 
drinks about 4 cans of beer daily. He lives on a sheep station, which is 
about a 4 hour drive on unpaved roads from the Kalgoorlie, with his wife. 
B.N. states that he has put on about 30 kg over the last 2 years. He states 
that this is due to the lack of physical activity (because of fear of further 
damage to his knees) and also his eating habits (frequent snacking of 
sweets and having big meals everyday). His wife was diagnosed with 
breast cancer 4 years ago, she received treatment and the cancer went 
into remission. However, during a follow up screening 3 months ago, the 
oncologist discovered that the cancer has relapsed and spread into her 
lymph nodes.  
 
Medication: 
B.N. is currently on Celecoxib (100mg, once daily) and Panadol Osteo (2 
caplets, thrice daily). He has been on these medications and dosage for 
the last 2 years.  
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Investigations: 
Radiographs of both knees show severe joint space narrowing and 
presence of multiple osteophytes. 
 
Screening Tools and Outcome Measures: 
The Western Ontario and McMaster Universities Arthritis Index (WOMAC), 
PainDETECT, Pain Catastrophizing Scale (PCS), Tampa Scale for 
Kinesiophobia (TSK) and Depression Anxiety Stress Scales (DASS 21) 
questionnaires were administered. 
B.N. scored 73/96 for the WOMAC (Pain: 14/20, Stiffness: 5/8, Function: 
54/68); this indicates that he has significant issues with pain, stiffness and 
performing daily activities. 
B.N. scored 31/38 for the PainDETECT questionnaire. Due to the high 
score on the PainDETECT, it is likely that a neuropathic pain component is 
present. A score of >19 indicate that a neuropathic pain component is 
likely. 
He scored 45/52 for the PCS (Rumination: 15/16, Magnification: 10/12, 
Helplessness: 20/24); this indicates that he demonstrates catastrophic 
thinking, which plays a role in heightening his pain intensity and 
magnification of his pain. A score of 30 represents a clinically relevant 
level of catastrophizing.  
B.N. scored 65/68 for the TSK; this means that he has a high degree of 
kinesiophobia (irrational fear of movement due to vulnerability of re/injury). 
A score of 37 differentiates between high and low scores of kinesiophobia. 
For the DASS 21 questionnaire, his scores were: 28 (Depression Score); 
14 (Anxiety Score); 34 (Stress Score). Based on the DASS 21 scores, 
B.N. has extremely severe depression scores, moderate anxiety scores 
and extremely severe stress scores. 
 
Pain Management: 
B.N. is currently only under the care of the general practitioner (GP) in 
Kalgoorlie, which he sees infrequently.  
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Patient Perspective: 
B.N. expressed anger, anxiety and feeling very stressed over several 
issues (e.g. Loss of financial stability due to unemployment, severity of 
pain in his knee, wife’s cancer relapse). He would like to be able to get 
back to doing some physical work around the house, however he tries not 
to move around much as he is worried about causing more damage to his 
knees. His GP has mentioned that a total knee replacement (TKR) might 
be a good solution for his knee pain, but he is not keen as he has a few 
friends that have had bad experiences after having had a TKR (worse pain 
after TKR, infection and no change in pain). He states that the only activity 
that he finds enjoyable now is eating. He feels like there is no joy in life 
anymore, and the thought of losing his wife is too much to bear. B.N. also 
mentioned that he has access to firearms and plenty of rope at home and 
he has thought that there is no point in living at times. 
 
Physical Examination Findings: 
 Knee Flexion:  
o Right: 120 degrees, P1 R2, 6/10 pain. 
o Left: 80 degrees, P2, 12/10 pain. 
 Functional: 
o Squat: ¼ squat, 12/10 pain. Unable to squat lower. 
o Stairs: Up – Leads with right leg, and moves up step one at a 
time. Able to go up a maximum of 3 steps before needing to 
rest due to 12/10 pain. Down – Leads with left leg, and 
moves down step one at a time. Able to go down a maximum 
of 3 steps before needing to rest due to 12/10 pain. 
o Sit to stand = Uses arms to push up when standing. No 
eccentric control of knees when sitting down. Drops straight 
into chair when sitting. 
 Sensory testing: 
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o Light touch with brush = 8/10 pain reproduced at left knee 
and shin. 
o Light pressure = 7/10 pain reproduced at multiple sites 
(bilateral thighs, knees and shins). 
o Cold (using test tube filled with ice water) = 7/10 pain 
reproduced at left knee and shin. 
o Heat (using test tube filled with warm water) = 7/10 pain 
reproduced at left knee and shin. 
 
Summary: 
It is clearly evident that B.N. has both nociceptive and neuropathic pain, as 
well as features of peripheral and central sensitization. This is 
compounded by psychological factors (kinesiophobia, catastrophic 
thinking, and high DASS 21 scores - extremely severe depression scores, 
moderate anxiety scores and extremely severe stress scores) and his 
passive pain coping mechanisms.  
 
Case Interpretation 
OA Background 
OA pain is complex; nociceptive, neuroplastic and neuropathic pain 
mechanisms, in combination with psychological and social factors (e.g. 
pain catastrophising, depression, anxiety, lack of social support, lower 
socioeconomic status) have been shown to contribute to the generation of 
OA pain(7). The presentation of pain in knee osteoarthritis sufferers varies 
greatly, from localised activity-related pain to referred or even widespread 
pain at sites distant from the knee(7-10). 
There are multiple mechanisms (nociceptive pain, neuroplastic pain and 
neuropathic pain), pain processes (peripheral sensitization, central 
sensitization), and psychological/social factors that contribute to the 
generation of OA pain(7, 11). To further complicate the nature of OA pain; 
the mechanisms, pain processes and factors that mediate OA pain vary 
among individuals(7, 11). 
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Current Neurobiology Pain Perspective: 
Based on the clinical findings, B.N’s pain profile comprises of nociceptive, 
inflammatory and neuropathic pain 
The evidence that supports the presence of nociceptive pain are:  
 Knee range-of-motion 
 Functional tasks (limitations)   
The evidence that supports the presence of inflammatory pain are:  
 Morning stiffness in knees 
 Allodynia in affected area (as evidenced by light touch with brush) 
 Mechanical hyperalgesia in affected area (as evidenced by light 
pressure) 
The evidence that supports the presence of neuropathic pain are:  
 High PainDETECT questionnaire score (31/38) 
 Shooting pain from left knee to shin 
 Pins and needles and numbness in the affected area 
 Pain in the affected area if the weather is hot 
 Weight of jeans on his left knee gives him pain 
 Cold/Heat hyperalgesia in affected area  
 Allodynia in affected area  
 Mechanical hyperalgesia in affected area  
B.N. also appears to have features of peripheral sensitization (localised 
pain and sensitivity) and central sensitization (widespread sensitivity to 
light pressure and cold). Injury and inflammation results in profound 
changes in the chemical milieu of the nociceptors. This leads to increased 
responsiveness and reduced threshold of nociceptors to stimulation of 
their receptive fields. Post-translational processing (phosphorylation) and 
altered gene expression are the main mechanisms of peripheral 
sensitisation(12). Spontaneous ectopic activity and the constant barrage of 
nociceptive input from the osteoarthritic knee most likely initiated the 
central sensitization(12, 13).  
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His pain is also compounded by the presence of psychological distress 
(i.e. depression, anxiety, stress) and his belief systems (i.e. passive pain 
management mentality, kinesiophobia, pain catastrophising). Stress 
causes the hypothalamus to secrete CRH, which stimulates the pituitary to 
secrete ACTH, which then stimulates the synthesis of cortisol. 
Simultaneously, the adrenal glands are stimulated and secrete adrenalin. 
Uncontrolled stress leads to the impaired regulation of the immune and 
stress systems which have been found to have links between mood 
disorders and inflammatory disease(14). Catastrophising, anxiety, fear of 
movement and individual’s experiences and belief systems can act to 
increase the perception of OA pain(15). 
 
Current Clinical Guidelines: 
Based on the current guidelines for conservative management of patients 
with knee OA(16), there are a number of gaps in the management of B.N.’s 
condition. The gaps that need to be addressed are: 
1. Education of his condition 
a. He was never educated on his condition and has no clear 
understanding of the pathophysiology of OA and the current 
clinical best practice guidelines on the treatment of OA. 
b. There is a pressing need to change his current belief system 
on the management of his condition, this will help to change 
his passive approach to pain management to a more active 
one. 
2. Prescription of an appropriate exercise program 
a. The success of an appropriate exercise program for him will 
depend on his understanding of his condition, as well as 
changing his belief system to be in line with an active pain 
management approach. 
b. Low impact exercises and strength training will make up the 
basis of his exercise program. 
3. Weight management plan 
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a. His BMI is 35, which puts him in the obese range. As per 
current best practice guidelines(16), reduction in weight has 
been shown to reduce pain levels. 
4. Pharmacological management plan 
a. He is currently on Celecoxib (100mg, once daily) and 
Panadol Osteo (2 caplets, thrice daily). But his pain levels 
are still not well controlled. Current guidelines(16) 
recommend the use of NSAIDs as being appropriate for 
chronic knee OA pain. Use of tramadol is not suitable, as 
there is a precaution for use of tramadol on individuals that 
have a suicide risk. Furthermore, if he is diagnosed as being 
clinically depressed, tramadol has a precaution for use for 
individuals that are on TCAs and SSNRIs. Tapentadol has 
been shown to be effective for the management of mixed 
pain (nociceptive and neuropathic), hence it might be a 
suitable analgesic for B.N.   
b. It is important that he is treated pharmacologically for the 
neuropathic pain. Current evidence(13) recommends treating 
neuropathic pain with low dose TCAs, SSNRIs, calcium 
channel α2-δ ligands, topical lidocaine or opioid agonists. 
The use of TCAs and SSNRIs for the treatment of his 
neuropathic pain might not be suitable, pending his 
diagnosis of depression and pharmacological treatment. 
The most logical pharmacological treatment for B.N.’s 
neuropathic pain is to start a course of pregabalin. A benefit 
of pregabalin is the improvement of sleep disturbances and 
reduction in anxiety.  
 
Treatment: 
1. Education of condition 
a. Educated B.N. on OA 
b. Explained that pain does not necessarily equate to damage 
or harm. 
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c. Encouraged normal movement. 
d. Resources on OA from WA Arthritis Foundation given to 
B.N. 
2. Exercise program 
a. Reinforced that normal movement is the first step to getting 
better. 
b. Stationary bicycle (he has access to a stationary bicycle at 
home that his wife uses for exercise) 
i. Start with minimal resistance, 5 minutes, thrice daily, 
for the first 2-3 weeks. 
ii. To increase duration by 3 minutes every week after 
the third week. 
c. Strengthening exercises, 3 times daily 
i. Straight leg raise 
1. 3 sets of 5 repetitions with 5 seconds hold 
ii. Bridging 
1. 3 sets of 5 repetitions with 5 seconds hold 
iii. Sit to stand 
1. Start with 1 set of 5 repetitions 
2. No use of arm rests allowed 
3. To control descend from standing to sitting 
4. Progress to 3 sets of 5 repetitions in 8 weeks 
time 
3. Weight management plan 
a. Reviewed current diet 
i. Substitute consumption of soft drinks and sweets with 
fresh fruits 
ii. Referral to dietitian 
b. Increase daily activity via exercise program 
4. Medications 
a. Referral to pain medicine physician  
b. Wrote a note to his GP to review B.N.’s pain medications 
i. Recommendations 
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1. Increase Celecoxib to 100mg, twice daily 
2. Start Pregabalin 75mg, twice daily. Titrate as 
needed 
3. Explore use of Tapentadol. 
5. Interdisciplinary referrals 
a. Psychiatrist (Urgent referral) 
i. To assess his psychological distress and suicide 
ideation 
b. GP/Pain management doctor  
i. To review, recommend and titrate medications that 
will suit his condition. 
c. Clinical psychologist  
i. To change current belief system 
ii. Teach coping strategies 
iii. Help organize a better sleep pattern  
d. Dietitian 
i. Review and set a nutrition plan for weight control 
 
Learning achieved 
1. Chronic pain is multi-dimensional and it is important to integrate its 
different aspects (physical presentation, physiological and 
psychological) in order to ensure that the patient is managed 
appropriately.  
2. Knowing when to appropriately refer out to other health care 
professionals is critical.  
3. Clear communication is very important 
a. To patient 
b. To other health care professionals 
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4.8.2 Case Study 2 
Current History: 
C.J. is a 30 year-old male who was diagnosed as having post-herpetic 
neuralgia (PHN) (affecting the right arm – C5/6, C6/7 and C7/8 
dermatomes) in November 2015. C.J. has a classical case of PHN as his 
symptoms appeared a year after he had recovered from right-sided 
shingles. He has a BMI of 30, and he has been screened and cleared of 
any red flags. Other than his weight, C.J. does not have any medical 
conditions. 
Body Chart: 
 
 
Constant pain in 
affected area. 
Burning shooting 
pain, pins & 
needles and 
numbness. Also 
c/o sensitivity to 
touch and pressure 
//
//
//
//
//
//
//
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//
//
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//
//
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Pain History: 
C.J. reports that he has constant pain and sensitivity in his right arm. He 
rates that pain as 5/10 on average, but whenever it flares up, it can go up 
to 10/10. Flare-ups can be caused by changes in temperature (weather, 
hot/cold shower) and if he uses his arms excessively. He is unable to wear 
any type of long sleeved clothing as the rubbing of the clothing on his right 
arm increases his pain. However, he states that having a compression 
bandage over the right arm helps to keep his pan manageable. The 
compression bandage is kept on most of the time. He only takes it off 
when he needs to shower. He was previously working in retail, but is 
currently unemployed due to his condition. His functional limitations are 
lifting/carrying anything more than 2kg. 
 
Social History: 
C.J. does not smoke and only drinks alcohol occasionally. He is currently 
staying in shared accommodation. He has been unemployed since 
January 2016, and spends most of his time at home. He will go over to his 
grandmother’s place once a week to help her out with some simple 
maintenance tasks. He used to exercise regularly (walking for 1 hour 4-5 
times weekly), but has stopped ever since he started getting the pain in his 
right arm. Due to the cessation of his walks and his unemployment, he has 
put on about 5-10 kgs over the last few months. C.J. furthered revealed 
that he really enjoyed his walking, but his pain got too unbearable after 
doing half the distance of his normal walks.    
 
Medication: 
C.J. is currently on Pregabalin (75mg, twice daily), Amitriptyline (10mg, 
nocte) and Tramadol (50mg, up to four times daily). He has been on these 
medications and dosage since November 2015.  
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Screening Tools and Outcome Measures: 
The Brief Pain Inventory (BPI) Short form, Pain Catastrophizing Scale 
(PCS), Tampa Scale for Kinesiophobia (TSK) and Depression Anxiety 
Stress Scales (DASS 21) questionnaires were administered. 
For the BPI, C.J. scored 8/10 for the Pain Severity Score and 5/10 for the 
Pain Interference Score. (Note: he scored 5/10 for interference with 
walking ability) 
C.J. scored 33/38 for the PainDETECT questionnaire. Due to the high 
score on the PainDETECT, it is likely that a neuropathic pain component is 
present. A score of >19 indicate that a neuropathic pain component is 
likely. 
He scored 11/52 for the PCS (Rumination: 2/16, Magnification: 3/12, 
Helplessness: 6/24); this indicates that he does not catastrophise. A score 
of 30 represents a clinically relevant level of catastrophizing.  
B.N. scored 26/68 for the TSK; this means that he has a low degree of 
kinesiophobia. A score of 37 differentiates between high and low scores of 
kinesiophobia. 
For the DASS 21 questionnaire, his scores were: 10 (Depression Score); 
12 (Anxiety Score); 19 (Stress Score). Based on the DASS 21 scores, he 
has mild depression scores, moderate anxiety scores and moderate stress 
scores. 
 
Pain Management: 
C.J. is currently under the care of his general practitioner (GP) in 
Booragoon. He just had a review with the GP a fortnight ago. 
 
Patient Perspective: 
He has expressed frustration at the pain levels and his inability to hold on 
to a job due to his pain. He would like to find some part-time work once he 
is able to gain some control over his pain levels. He is trying to remain 
active but is hesitant to start with his walking routine, as he does not want 
to aggravate his condition. 
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Physical Examination Findings: 
 Upper limb AROM:  
o FROM with shoulders, elbows and wrists. 
o Pain levels in right arm remained stable at 5-6/10. 
 Sensory testing: 
o Light touch with brush = 10/10 pain reproduced at right C5/6, 
C6/7 and C/78 dermatomes. 
o Light pressure = 10/10 pain reproduced at right C5/6, C6/7 
and C/78 dermatomes. 
o Cold (using test tube filled with ice water) = 10/10 pain 
reproduced at right C5/6, C6/7 and C/78 dermatomes. 
o Heat (using test tube filled with warm water) = 8/10 pain 
reproduced at right C5/6, C6/7 and C/78 dermatomes. 
 
Summary: 
It is clear that C.J. has neuropathic pain. He has fairly low levels of 
psychological distressed as evidenced by the questionnaires. However, 
the levels of psychological distress have a high chance of increasing, if his 
pain levels are not brought under better control. 
 
Case Interpretation 
PHN Background 
PHN is the most common complication that comes on after an episode of 
herpes zoster(17). The exact pathophysiological mechanisms of PHN pain 
are poorly understood. PHN may be caused by the damage to the primary 
afferent neuron or dorsal root ganglion during the initial acute episode of 
herpes zoster; this can lead to sensitisation of these structures that lead to 
spontaneous activity causing pain(17, 18). Peripheral and central 
mechanisms have been shown to have a likely role in the maintenance of 
PHN pain(18, 19). 
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Current Neurobiology Pain Perspective: 
Based on the clinical findings, C.J.’s pain profile comprises mainly of 
neuropathic pain 
The evidence that supports the presence of neuropathic pain are:  
 High PainDETECT questionnaire score (33/38) 
 Burning, shooting pain in the affected area 
 Pins and needles and numbness in the affected area 
 Cold/Heat hyperalgesia in affected area  
 Allodynia in affected area  
 Mechanical hyperalgesia in affected area  
 
Current Clinical Guidelines: 
Based on the current guidelines for conservative management of patients 
with PHN, treatment is based on symptom control(20, 21). 
1. Psychological interventions 
a. PHN has been shown to have adverse affects on quality of 
life, and psychological interventions need to be given if 
indicated(17, 22). 
b. However, C.J. shows minimal levels of psychological 
distress, therefore psychological intervention is not needed 
at this time. 
2. Pharmacological management plan 
a. He is currently on Pregabalin (75mg, twice daily), 
Amitriptyline (10mg, nocte) and Tramadol (50mg, up to four 
times daily).  
b. Current evidence(13, 20, 21) recommends treating PHN pain 
with low dose TCAs, calcium channel α2-δ ligands, topical 
treatments (lidocaine patch, capsaicin cream or patch) and 
opioids.  
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Treatment: 
1. Education  
a. C.J. has good knowledge and understanding of his 
condition. Hence, no further education on his condition is 
warranted. 
b. Educated on the need to remain physically active to get 
good outcome 
2. Exercise program 
a. Exercise is not in the list of recommended treatments in the 
clinical guidelines for PHN. However, exercise has been 
frequently cited as a key factor in the management of 
chronic pain. Hence an exercise program was prescribed to 
C.J. 
b. Walking  
i. Start with 15 minute walks, three times a week. 
ii. To increase duration by 5 minutes every week after 
the third week. 
c. Strengthening exercises (with a 500ml water bottle), 3 times 
daily 
i. Shoulder flexion 
1. 3 sets of 10 repetitions 
ii. Shoulder abduction 
1. 3 sets of 10 repetitions  
iii. Bicep curls 
1. 3 sets of 10 repetitions  
3. Desensitization protocol 
a. Advised C.J. to take off compression bandage as often as 
possible 
b. To lightly stroke his right arm with a cotton swab at least 3 to 
5 times a day  
4. Weight management plan 
a. Increase daily activity via exercise program 
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5. Medications 
a. C.J. was seen in a joint consultation with the pain medicine 
consultant; hence the pain medicine consultant adjusted the 
medication as below. 
1. Increased Pregabalin to 150mg, twice daily.  
2. Increase Amitriptyline to 25mg, nocte. 
3. Discontinued Tramadol. 
4. Started Tapentadol 100mg, twice daily. 
 
Learning achieved 
1. Titration of medication is essential to ensure that the patient has 
adequate pain cover. In this case, the choice of medications 
prescribed to the patient by his GP is mostly correct. However, the 
level of each medication is too low to be of effective use. 
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4.9 Problems with the placement 
There were no problems/issues faced during the placement. However, 
sourcing for a suitable placement proved to be a major difficulty for myself 
as I have not worked in Australia for a number of years and hence did not 
have the contacts needed to acquire and confirm a placement until 2016. 
The change in funding model for public healthcare provision in Western 
Australia also proved to be a big hurdle for me to secure a placement. 
Previous arrangements to secure a clinical placement in Pain Medicine at 
Sir Charles Gairdner Hospital fell through due to the funding cuts. 
 
4.10 Changes that could have improved the original placement plan 
I feel that no changes are needed. I would have preferred to have more 
time at the placement, 96 hours is considerably short for an advanced 
level placement. 
 
4.11 Contribution of placement to professional and personal 
development 
I have derived a considerable sum of benefit from this placement. The 
knowledge gained from this placement has increased my understanding of 
pain and its management. 
 
4.12 Conclusion 
This placement has been immensely beneficial to my learning and 
continuing development. Physiotherapists deal with pain everyday and it is 
pertinent that we are familiar with all aspects of pain management in order 
for us to provide proper care for our patients. Higher emphasis on pain 
education (which should include physiology of pain, pain pharmacology 
and pain psychology units) is needed at both undergraduate and 
postgraduate physiotherapy degree courses.
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Appendix 1 (LEAP Assessment Form) 
 
 
  
    
 
 
Height:____________ Weight: ____________ 
 
BMI:____________ 
 
Subjective Hx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mark painful areas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pain Levels 
At Best: 
 
At Worst: 
 
 
DATE:______________ 
 
 
Royal Perth Hospital 
 
LEAP Assessment Form 
(Physiotherapy)  
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Co-Morbidities 
 
 
 
 
 
 
 
 
 
 
 
 
Current Medications 
 
 
 
Previous Rx Attendance Hx (Last 5 sessions) 
 
 
 
Objective Examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aggravating Activities and Pain Levels 
(1) 
 
(2) 
 
(3) 
 
 
ALF 
8 metre walk Stairs ascent and descent Transfer 
 
 
 
Walking aid 
 
 
Alternate legs  
Always lead with 1 leg 
Used railings 
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Objectives of LEAP explained to 
patient  
 
YES                           NO 
 
Patient agreeable to take part in LEAP 
 
YES                           NO 
 
Is patient suitable for LEAP?  
 
YES                           NO 
 
 
TSK Scores: 
 
PCS Scores: 
 
If not suitable, please explain why and state further management plan 
 
 
 
 
 
 
 
Physiotherapist:_________________         
Signature:______________________ 
 
